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Abstract 
 Insulin resistance and androgen excess are the cardinal phenotypic features of 
polycystic ovary syndrome (PCOS). The severity of hyperandrogenism and metabolic 
dysfunction in PCOS are closely correlated. Aldoketoreductase type 1C3 (AKR1C3) is an 
important source of androgen generation in human adipose tissue, and may represent a link 
between androgen metabolism and metabolic disease in PCOS. We performed integrated in 
vitro studies using a human preadipocyte cell line and primary cultures of human adipocytes, 
coupled with in vivo deep phenotyping of PCOS women and age- and BMI-matched controls. 
 
 We have shown that insulin upregulates AKR1C3 activity in primary female 
subcutaneous adipocytes. AKR1C3 mRNA expression increased with obesity. Androgens 
were found to increase lipid accumulation in human adipocytes. In clinical studies, androgen 
exposure induced relative suppression of adipose lipolysis in PCOS women, supporting a role 
for androgens in lipid accumulation. Androgens were detectable in adipose fluid from PCOS 
women, and correlated with systemic markers of androgen metabolism.  
 
 Using comprehensive in vivo, ex vivo, and in vitro techniques, we have shown 
regulation of adipose androgen generation through AKR1C3, with evidence of a vicious circle 
of hyperinsulinaemia, adipose androgen generation and lipid accumulation. These data 
identify AKR1C3 as a promising therapeutic target in PCOS. 
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1.1 Introduction 
 Polycystic ovary syndrome (PCOS) is a clinical triad of anovulation, insulin resistance 
(IR) and androgen excess, with an estimated prevalence of 5-10% in women of reproductive 
age (Franks, 1995, Dunaif, 1997). Androgen excess (or hyperandrogenism), defined as 
clinical or biochemical evidence of elevated androgens in females, generally presents 
clinically with male-pattern hair growth (hirsutism) or acne (Housman and Reynolds, 2014), 
Figure 1-1.  
 
Figure 1-1 Clinical hyperandrogenism: hirsutism and acne in a woman with PCOS 
(Housman and Reynolds, 2014). Reproduced with permission from Elsevier. 
 
 Women with PCOS are predisposed to glucose intolerance and metabolic syndrome 
(Taponen et al., 2004), with associated risk factors for cardiovascular disease and a likely 
increased risk in future cardiovascular events in the postmenopausal period (Mani et al., 
2013) (Figure 1-2). Anovulatory infertility secondary to PCOS is the most common cause of 
subfertility in the developed world, and consumes the majority of healthcare budgets allocated 
to assisted conception (Fauser et al., 2012). Insulin resistance and androgen excess are the 
cardinal features driving the clinical phenotype in PCOS, but the precise interplay between 
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androgen metabolism and insulin sensitivity is poorly understood; hyperinsulinaemia leads to 
androgen excess in females of reproductive age, while women with monogenic disorders of 
androgen excess develop a PCOS-like phenotype with polycystic ovaries and insulin 
resistance. 
 
 
Figure 1-2 Odds ratio of cardiovascular events and T2DM in POCS vs local or national 
female population. Age-specific prevalence of MI, angina and composite CV outcome was 
significantly higher in PCOS women over 45 years old compared to the local female 
population (Mani et al., 2013). Reproduced with permission from Wiley and Sons. 
 
 PCOS has traditionally been regarded as a disorder of primary ovarian, and to a lesser 
extent, adrenal, origin (Franks et al., 1999). However, this dogma has recently been 
challenged, leading to a paradigm shift in our understanding of the origins of androgen excess 
and metabolic dysfunction in PCOS. Increased focus on extra-ovarian and extra-adrenal 
androgen activation has highlighted the role of peripheral tissues such as adipose in local 
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androgen generation (Fassnacht et al., 2003, Quinkler et al., 2004). Recent studies have 
explored how systemic upregulation of crucial androgen-activating enzymes such as 5α-
reductase (5αR) and aldoketoreductase type 1 C3 (AKR1C3) may contribute to androgen 
excess in PCOS (Stewart et al., 1990), and how this process may be driven by insulin 
(Vassiliadi et al., 2009).  Our understanding of the role of androgens in adipose tissue is also 
evolving; adipose tissue is capable of local androgen activation and inactivation (Blouin et al., 
2009a), while androgens themselves modulate adipose tissue function, lipid metabolism and 
insulin sensitivity (Corbould, 2007). Similar to effects observed with glucocorticoids, 
regulation by androgens of the balance between lipid accumulation and lipid breakdown 
(‘lipid flux’) in adipose tissue may crucially orchestrate adverse androgen-mediated effects on 
metabolism and insulin sensitivity (Gathercole et al., 2011).  
 
1.2 An introduction to polycystic ovary syndrome (PCOS) 
 PCOS is the most common endocrine disorder, affecting up to 10% of women of 
reproductive age. The clinical syndrome was initially described by Stein and Leventhal in 
1935, although polycystic ovaries (cystic oophoritis, sclerocystic ovaries) associated with 
androgen excess and infertility were noted as far back as 1721. Diagnosing a ‘syndrome’, 
traditionally defined by a collection of signs, symptoms and clinical features, has proven 
exceptionally difficult, however.  
 
1.2.1 Diagnostic criteria 
There have been numerous attempts over the last two decades to reach consensus on 
diagnostic criteria for PCOS (Table 1-1) (Fauser et al., 2012, Rotterdam, 2004b, Chang and 
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Katz, 1999). Chronic anovulation and clinical and/or biochemical hyperandrogenism remain 
the key clinical components of all proposed diagnostic criteria. The addition of sonographic 
features of polycystic ovaries (PCO) to the broadened 2003 Rotterdam criteria (sponsored by 
the European Society for Human Reproduction and Embryology and the American Society 
for Reproductive Medicine) encompasses those patients who may have PCO on ultrasound 
with co-existent androgen excess but without ovulatory dysfunction, or anovulation without 
hyperandrogenism. It was increasingly recognized that this subgroup of women, who did not 
meet diagnostic criteria for PCOS according to the initial 1990 National Institute of Health 
(NIH) guidelines, had convincing clinical evidence of the disorder and should be classified as 
such accordingly (Carmina and Lobo, 2001).   
 
Table 1-1 1990 (NIH) and 2003 (Rotterdam) criteria for diagnosis of PCOS 
Revised diagnostic criteria of polycystic ovary syndrome 
1990 Criteria (both criteria required) 
• Chronic anovulation and 
• Clinical and/or biochemical signs of hyperandrogenism and exclusion of other 
aetiologies 
Revised 2003 criteria (2 out of 3 required) (Rotterdam, 2004a, Rotterdam, 
2004b) 
• Oligo- or anovulation 
• Clinical and/or biochemical signs of hyperandrogenism  
• Polycystic ovaries on ultrasound  
 
and exclusion of other aetiologies (congenital adrenal hyperplasia, androgen-secreting 
tumours, primary disorders of insulin resistance, Cushing’s syndrome) 
 
Application of the Rotterdam criteria has been controversial, and resulted in a 
significant increase in the population deemed to be affected (Goodarzi and Azziz, 2006, 
Barber et al., 2007). Four phenotypic subgroups may now be defined by the presence of the 
following: 1) androgen excess, anovulation and PCO (AE, Anov + PCO), 2) Anov + PCO, 3) 
AE + Anov and 4) AE + PCO. The majority of women with PCOS appear to fall into the first 
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diagnostic category (Welt et al., 2006). It has been suggested that women with non-
hyperandrogenic PCOS have a metabolic profile similar to that of healthy controls (Barber et 
al., 2007). This assumption has recently been disputed (O'Reilly et al., 2014b), with 
biochemical evidence of insulin resistance found even in non-hyperandrogenic women in one 
study. However, the same study showed lower insulin sensitivity in those women with 
androgen excess than without, and it is increasingly clear that circulating androgen burden 
correlates inversely with insulin sensitivity in PCOS (Pugeat et al., 2000, Legro et al., 2002). 
A third task force attempted to further explore the diagnostic conundrum of PCOS. 
The Androgen Excess Society (AES) recognized four cardinal features of PCOS: 1) ovulatory 
and menstrual dysfunction, 2) biochemical hyperandrogenaemia, 3) clinical 
hyperandrogenism and 4) polycystic ovaries (Azziz et al., 2006). Similar to previously 
published criteria, the contributors concluded that insulin resistance and metabolic 
derangements, whilst prevalent in a significant proportion of patients, were not an essential 
component for diagnosis of the syndrome. However, hyperandrogenism was considered a 
mandatory component of the syndrome, and women with ovulatory dysfunction and PCOS 
(Anov + PCO) without androgen excess were therefore not considered to have PCOS 
according to this categorization. 
 
1. Hyperandrogenism: hirsutism and/or hyperandrogenaemia 
   and 
2. Ovarian dysfunction: Oligo-ovulation and/or polycystic ovaries 
   and 
3. Exclusion of other androgen excess or related disorders. 
 
Chapter 1               General Introduction 
 7 
A recent publication has reported that the prevalence rates of PCOS in a large predominantly 
Caucasian population according to NIH, Rotterdam and AE-PCOS Society criteria are 6.1, 
19.9 and 15.3%, respectively (Yildiz et al., 2012). 
  
1.2.2 Clinical features 
It is important to recognize that no single diagnostic criterion is sufficient for a 
diagnosis of PCOS. The presence of insulin resistance, metabolic dysfunction or obesity is not 
required to diagnose PCOS according to currently accepted criteria. This notwithstanding, 
insulin resistance in women with PCOS is present in 50-65% of cases, in both obese and 
nonobese subjects (Dunaif et al., 1989). As is clear from long-standing debate on diagnostic 
criteria, PCOS has a distinctly heterogeneous clinical phenotype, leading many authors to 
speculate that it may represent the common clinical consequence of a large range of diverse 
disorders of androgen metabolism and insulin sensitivity, the so-called ‘fruit bowl’ concept. 
PCOS is associated clinically with anovulatory infertility, dysfunctional bleeding, androgen 
excess, insulin resistance, obesity and metabolic syndrome (Dunaif, 1997). Direct longitudinal 
associations with cardiovascular disease, sleep apnoea and endometrial carcinoma have also 
been elucidated (Azziz et al., 2005, Morton, 2013, Barry et al., 2014, Mani et al., 2013). 
However, the vast majority of women with PCOS will present with clinical signs of 
hyperandrogenism, or anovulation manifest by primary subfertility or oligomenorrhoea 
(Legro et al., 2014).  
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1.2.2.1 Anovulation 
Polycystic ovary syndrome is the most common cause of anovulatory infertility 
(Rotterdam, 2004b). Anovulation presents clinically as menstrual irregularity, with either 
infrequent menses (oligomenorrhoea) or frequent, excessive and painful menstrual bleeding 
(dysfunctional uterine bleeding) (Franks, 1995). Polycystic ovaries (PCO) are present in most 
patients with PCOS, although their presence alone is not diagnostic of the clinical and 
biochemical syndrome. PCO may be detected ultrasonographically in up to 22% of the 
normal, non-hyperandrogenic population with regular menses (Polson et al., 1988), but the 
prevalence is much higher in women with hyperandrogenism (Franks, 1989). Increased 
numbers of antral follicles are characteristic of PCOS; even women with ovulatory PCOS 
have an increased proportion of follicles arrested in early stages of development (Webber et 
al., 2003). This finding suggests that abnormal follicle development in PCOS is independent 
of ovulatory status. The same study found that the density of pre-antral and small antral 
follicles in the polycystic ovary is six times that of the normal ovary.  
Accelerated follicle development with subsequent arrest at the antral or pre-antral 
stage may be mediated via androgens (Vendola et al., 1999). Numerous pathways have been 
elucidated, with intra-ovarian androgen excess promoting primordial follicle activation, with 
subsequent inhibition of early-stage follicle transition leading to follicle arrest (Yang et al., 
2010). Increased folliculogenesis in PCOS may lead to suppression of serum follicle-
stimulating hormone (FSH), although levels are invariably within the normal range (Laven et 
al., 2004). Insulin has also been implicated in this process. Severity of anovulation was 
correlated with insulin resistance and adiposity in a recent study (Androulakis et al., 2014). At 
a molecular level, insulin has gonadotrophic actions, and may exert synergistic effects with 
androgens and LH in contributing to arrest of folliculogenesis (Poretsky et al., 1999).  
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Treatment options for ovulatory dysfunction in PCOS are determined by whether 
fertility is desirable. In anovulatory women with primary or secondary subfertility who are 
seeking to conceive, clomiphene citrate is usually first-line therapy when other causes of 
infertility have been excluded (Legro et al., 2014). This compound is a selective oestrogen 
receptor modulator (SERM), which antagonizes the negative feedback effect of oestrogen at 
the level of the hypothalamus, resulting in increased gonadotrophin pulses and increased 
ovarian stimulation (Thessaloniki, 2008). Metformin may also be used alone or in 
combination with clomiphene, although there is no evidence that the combination is superior 
to clomiphene alone (Legro et al., 2007). For oligo- or amenorrhoeic women not seeking 
fertility, cyclical progestins may be used, for example medroxyprogesterone acetate 10mg 
daily for 7 days to induce withdrawal bleeding (Rotterdam, 2004b). This can be repeated 
every three months to prevent endometrial hyperplasia due to amenorrhoea and unopposed 
oestrogen exposure (Conway et al., 2014). Combined oral contraceptives (COCs) also play a 
key role in the treatment of menstrual disturbances in PCOS. Typical formulations contain 20-
35 µg of ethinylestradiol, with an antiandrogenic progestin such as drospirenone, although 
concern exists about the adverse cardiovascular and metabolic risk profile of COCs with 
higher oestrogen doses (Bird et al., 2013, Lidegaard et al., 2011).  
 
1.2.2.2 Hyperandrogenism 
Androgen excess may manifest clinically in PCOS women with male-pattern hair 
growth (hirsutism), acne or frontal alopecia (Franks, 1995). Overt virilisation is rarely 
associated with the degree of hyperandrogenaemia observed in PCOS. The presence of the 
latter often suggests underlying severe insulin resistance or androgen-secreting pelvic 
neoplasms (Azziz et al., 2009). In a large cohort of 950 patients presenting with signs of 
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clinical hyperandrogenism, over 72% were diagnosed with underlying PCOS (Carmina et al., 
2006). Clinical or biochemical hyperandrogenism are crucial diagnostic criteria according to 
all currently accepted international standards for the diagnosis of PCOS (section 1.2.1). 
Hirsutism severity is graded clinically according to the modified Ferriman-Gallwey 
index (Azziz et al., 1995), whereby 9 areas of the body are assigned a score of 0-4 depending 
on the density of terminal-end hairs, giving a final score out of 36. Cut-off values are 
somewhat arbitrary, with wide inter-racial variability, but a value ≥ 8 is generally considered 
pathological. Hirsutism is found in up to 75% of women with PCOS (DeUgarte et al., 2006). 
The prevalence of acne in selected cohorts of PCOS women ranges from 12-14% depending 
on the population studied (Wijeyaratne et al., 2002, Falsetti et al., 2002), while that of 
androgenic alopecia varies widely between studies, from 5-50%.  
Definition of biochemical hyperandrogenism has been controversial. Little consensus 
has been reached on which androgens should be measured, what constitutes normal reference 
ranges and which analytical techniques should be employed (O'Reilly et al., 2014b).  Serum 
testosterone (T) measurement has traditionally been the tool-of-choice for assessment of 
hyperandrogenaemia in PCOS. However, its use is blighted by inaccuracy; T circulates in the 
low-nanomolar range in females. Equally, circulating testosterone is bound to sex-hormone 
binding globulin (SHBG), albumin and other proteins, such that measured T is an inaccurate 
reflection of tissue exposure. SHBG levels fluctuate in the setting of metabolic disturbance, 
with suppression of hepatic SHBG output by insulin in the setting of hyperinsulinaemia. 
Measurement of free (unbound) T with equilibrium dialysis or direct radioimmunoassay 
(RIA) is inaccurate, unreliable and rarely available (Vermeulen et al., 1999). 
Dehydroepiandrosterone sulphate (DHEAS) circulates in the micromolar range in serum, but 
unfortunately is elevated in only approximately 25% of patients with PCOS (Orio et al., 
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2003). Androstenedione (A) measured by liquid-chromatography tandem mass spectrometry 
(LC-MS/MS) may be a more reliable marker of PCOS-related androgen excess, circulating at 
higher concentrations and not influenced by variables such as SHBG (O'Reilly et al., 2014b). 
Cosmetic approaches for hirsutism include waxing, threading, shaving, electrolysis 
and laser therapy. Eflornithine cream inhibits hair growth by irreversibly blocking ornithine 
decarboxylase, but it typically takes 8 weeks to demonstrate clinical benefit, and should be 
combined with laser therapy to achieve maximal effect (Ganger and Hamzavi, 2006). COCs 
may be useful in the treatment of androgen excess, with a suppressive effect on LH-mediated 
ovarian androgen generation (Conway et al., 2014). Oestrogen-containing preparations have 
the added bonus of increasing hepatic SHBG production, thereby reducing free (and 
physiologically active) testosterone levels. Combined preparations containing ethinyoestradiol 
20-35 µg and an anti-androgenic progestin such as drospirenone or cyprotereone acetate are 
used most frequently. Higher oestrogen doses are associated with increased metabolic risk 
and unfavourable body composition changes (Nader and Diamanti-Kandarakis, 2007, Merz et 
al., 2006), as well as increasing thromboembolic risk, particularly in formulations containing 
anti-androgen progestins (Bird et al., 2013). Oral anti-androgen pharmacotherapy can be 
effective, but the attraction of using such products should be tempered by an awareness of 
side effect profiles and teratogenic potential. Anti-androgens should only be used with 
concomitant contraception. Cyproterone acetate may be given in isolation at a dose of 50-
100mg day but, like drospirenone, is often combined at lower doses with ethinyloestradiol in 
an oral contraceptive formulation (Swiglo et al., 2008). Spironolactone, traditionally used as 
an aldosterone receptor antagonist, may antagonize the androgen receptor, and is effective for 
hirsutism at doses of 50-200mg/day. Other oral antiandrogen treatments such as the AR 
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antagonist flutamide (Paradisi and Venturoli, 2010) and the 5αR type 2 inhibitor finasteride 
(Moghetti et al., 2000) appear to be safe when used with concomitant contraception. 
 
1.2.2.3 Metabolic dysfunction, insulin resistance and cardiovascular disease 
Relatively few patients with PCOS present with clinical or biochemical signs of overt 
metabolic disease such as dyslipidaemia, insulin resistance or type 2 diabetes mellitus 
(T2DM) as their primary complaint. Nonetheless, the prevalence of insulin resistance is 
estimated at between 50% and 70% in women with PCOS (Azziz et al., 2009). Dyslipidaemia, 
usually in the form of low circulating high-density lipoprotein (HDL) cholesterol and elevated 
triglycerides, as typically found in insulin resistant states, is observed in as many as 70% of 
patients (Sverrisdottir et al., 2008). Obesity is highly prevalent in PCOS, and appears a crucial 
regulator of the reduced central and peripheral insulin sensitivity observed in the condition 
(Escobar-Morreale et al., 2012). Observed metabolic derangements are worse in obese 
patients, and the progression from insulin resistance to overt T2DM over time is observed 
predominantly in significantly obese patients (Legro et al., 1999). Obesity therefore appears 
to be the critical determinant of metabolic disturbance in PCOS, but it is important to 
emphasise that the degree of insulin resistance is more profound than that observed in body 
mass index (BMI)-matched obese women without PCOS (Vassiliadi et al., 2009). This 
suggests a role for other complex and poorly-understood phenomena, including circulating 
androgen burden, in PCOS-related metabolic disease. 
 PCOS is associated with a constellation of classic and non-classic 
cardiovascular risk factors. In addition to an adverse risk profile, young women with PCOS 
have increased carotid intima-media thickness in multiple studies (Bajuk Studen et al., 2013, 
Ketel et al., 2010). Hyperandrogenic PCOS women are more likely to develop hepatic 
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steatosis, another non-classic marker of endogenous cardiovascular risk, independent of BMI 
or the presence of insulin resistance (Jones et al., 2012). Whether the clustering of risk factors 
for cardiovascular disease (CVD) observed in PCOS truly translates into increased incidence 
of or mortality from CVD is contentious, and results between studies have varied widely. One 
large study found increased cardiovascular mortality in postmenopausal women was 
associated with longer duration of anovulatory cycles during reproductive years (Shaw et al., 
2008). These findings were not replicated in a prospective study over 21 years (Schmidt et al., 
2011), but a recent meta-analysis identified women with PCOS at a two-fold increased 
relative risk for future cardiovascular events and arterial disease, an association not affected 
after adjustment for BMI (de Groot et al., 2011). 
 
1.3 Physiology of insulin action and insulin resistance 
1.3.1 Insulin structure and secretion 
 Insulin is a crucial regulator of carbohydrate and lipid metabolism in vertebrates, as 
well as playing a key role in growth and development. It was the first protein to undergo 
amino acid sequencing, in 1955 by Fred Sanger. The 6000 dalton insulin molecule consists of 
two polypeptide chains; in humans chain A contains 21 amino acids and chain B has 30 
amino acids (Figure 1-3). The chains are tethered by covalent disulfide bonds, while chain A 
also contains an internal covalent bond between residues A6 to A11 (Yamamoto et al., 2012).  
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Figure 1-3 Amino acid structure of the human insulin molecule. Chain A contains 21 amino 
acids; chain B has 30 amino acids. The chains are linked by covalent disulfide bonds. Chain 
A also has an internal covalent bond between residues A6 and A11 (Yamamoto et al., 2012). 
Reprinted with kind permission from Yamamoto et al. Copyright 2015 American Chemical 
Society.  
  
The initial translational product of the insulin gene is preproinsulin, a ‘prepeptide’ of 24 
amino acids which is synthesized in the pancreatic β-cells, located within cellular clusters 
known as the islets of Langerhans (Chan et al., 1976). Preproinsulin is cleaved to proinsulin, 
which consists of B and A chains linked to a connecting peptide called C-peptide, in the 
endoplasmic reticulum. Proinsulin is then packaged in storage granules alongside converting 
proteases (Steiner et al., 1985). These storage granules mature to form secretory granules, 
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with cleavage of proinsulin to release insulin and C-peptide. Insulin is secreted in response to 
various physiological and electrophysiological stimuli (Figure 1-4).  
   
 
Figure 1-4 Regulation of insulin secretion (Reproduced with kind permission from 
medicinehack.com) 
 
 Briefly, β-cells sense glucose via the transmembrane Glucose Transporter-2 (GLUT-
2), leading to ATP production via glucokinase and subsequent closure of ATP-sensitive 
potassium channels (Ashcroft and Rorsman, 2012). This drives calcium influx into the β-cell 
via voltage-gated calcium channels, which then triggers exocytosis of insulin-containing 
secretory granules to the cell membrane, followed by insulin release. Insulin secretion in 
response to rise in serum glucose after eating exhibits a biphasic response, with a rapid initial 
peak (first phase of insulin secretion) within 3-10 minutes, followed by a more indolent 
second secretory phase until normoglycaemia is restored (Zou et al., 2014). In addition to 
glucose, insulin release is triggered by a variety of other physiological stimuli, including 
gastrointestinally-derived incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP), parasympathetic release of acetylcholine, various amino acids 
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such as arginine and leucine, cholecystokinin (CCK), and drugs such as sulfonyulureas 
(Layden et al., 2010). 
 
1.3.2 Insulin signaling  
 The metabolic effects of insulin are mediated via the insulin receptor (INSR), which is 
ubiquitously expressed in humans. The INSR is a member of the ligand-activated receptor and 
tyrosine kinase family of transmembrane signaling proteins, and is encoded by the INSR gene 
on Chromosome 19 (Lee and Pilch, 1994). The insulin receptor is a tetramer, consisting of 
two α- and two β-subunits. The α-subunits are allosteric inhibitors of β-subunit activity; once 
insulin binds to the former, allosteric inhibition is removed, enabling the β-subunits to 
autophosphorylate within the cytosol by means of intrinsic tyrosine kinase activity (Menting 
et al., 2014) (Figure 1-5). Insulin signal transduction is mediated via insulin receptor substrate 
(IRS) proteins, of which four have been identified (Rhodes and White, 2002). These IRS 
proteins contain a large number of tyrosine and serine phosphorylation sites. IRS activity is 
positively regulated by the degree of tyrosine phosphorylation, and can be negatively 
regulated by tyrosine phosphatases (Knobler and Elson, 2014). Most serine phosphorylation 
also results in negative regulation of IRS function. Tyrosine phosphorylation at residues 612 
and 632 in humans is required for activation of phospho-inositide 3 kinase (PI3K).  
 In addition to the IRS pathway, insulin signaling also proceeds through Grb2/SHC and 
ras, leading to activation of the mitogen-activated protein (MAP) kinase isoforms ERK1 and 
ERK2 (Cheatham et al., 1994). Activation of this pathway mediates the effects of insulin on 
differentiation, mitogenesis, cell growth and survival.  
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Figure 1-5 Metabolic actions of insulin signalling mediated via the INSR and PI3K pathway 
activation. 
 
 Once activated by IRS, PI3K mediates most of the key metabolic effects of insulin. 
After activation, PI3K generates phosphatidylinositol-3,4,5-triphosphate (PIP3) from 
phosphatidylinositol-3,4 bisphospate (PIP2). PIP3 is a secondary messenger, and is capable of 
activating various dependent kinases, one of the most crucial of which is protein kinase 
B/(PKB/akt) (Schultze et al., 2011) (Figure 1-5), of which there are three isoforms. Once 
phosphorylated (in the catalytic domain at Thr308 and in the hydrophobic motif at Ser473), 
PKB/akt is an important mediator of insulin action (Sarbassov et al., 2005), including roles in 
glucose uptake, transcriptional regulation, secondary messenger systems and enzymatic 
activation (Dummler and Hemmings, 2007). PKB/akt also phosphorylates Foxo1, inhibiting 
its transcriptional activity; this results in suppression of hepatic gluconeogenesis and 
increased cardiac myocyte survival (Battiprolu et al., 2012). 
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1.3.3 Metabolic actions of insulin 
 Insulin is released in response to a variety of stimuli, the most potent of which is 
plasma glucose as described above. It plays a crucial role in carbohydrate and fat metabolism, 
and its most important target organs are the liver, muscle and adipose tissue. As an anabolic 
hormone, insulin promotes fuel storage and decreases fuel mobilization. Key metabolic 
effects on target organs are summarized below. 
 
1.3.3.1 Carbohydrate and glucose metabolism 
 The liver is an important organ of glucose generation in times of fasting. Key 
processes such as glycogenolysis, which is the breakdown of glycogen to release glucose, and 
gluconeogenesis, which involves de novo glucose synthesis from amino acids, glycerol, 
lactate and other precursors, help to maintain plasma glucose in the normal range and ensure 
that the body has sufficient fuel supplies in the fasted state (Rui, 2014). Insulin secretion in 
response to a glucose load after eating (‘fed state’) suppresses hepatic glycogenolysis and 
gluconeogenesis, thereby preventing development of hyperglycaemia. Glycogen storage is 
promoted in the liver and also muscle. Insulin also directly lowers serum and extracellular 
glucose levels by increasing cellular glucose uptake in adipose tissue and muscle. This 
process crucially depends on PKB/akt activation, which results in translocation of Glucose 
Transporter-4 (GLUT-4) to the transmembrane region of the cell, leading to glucose uptake in 
fat or muscle.  GLUT-4 is localised to cytoplasmic vesicles; after insulin binds to the INSR, 
PKB/akt is phosphorylated, which in turn phosphorylates AS160 (Castorena et al., 2014). 
AS160 phosphorylation then allows vesicle translocation to the cell membrane, where GLUT-
4 facilitates increased glucose uptake. 
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1.3.3.2 Insulin and lipid metabolism 
 Insulin is a crucial mediator of the balance between lipid accumulation and 
breakdown, or so called ‘lipid flux’ (Gathercole et al., 2011). In general, insulin promotes 
lipid accumulation by increasing lipogenesis and reducing lipid mobilization. Specifically, 
insulin (i) increases de novo synthesis of triacylglycerol (TAG), (ii) increases free fatty acid 
(FFA) uptake from dietary lipid and (iii) drives re-esterification of FFAs with glycerol to 
produce TAG, while at the same time suppressing lipolysis, which is the breakdown of TAG 
into FFAs and glycerol. Insulin also suppresses β-oxidation, another key process in lipid 
mobilization whereby FFA molecules are degraded in the mitochondria to generate acetyl-
coA (Koliaki and Roden, 2013).  
 As discussed in section 1.3.3.1, insulin stimulates glycogen production in the liver. 
However, at high levels of glycogen accumulation, further glycogenesis is suppressed; at this 
point, additional hepatic glucose is converted into fatty acids, which are exported from the 
liver as lipoproteins.  
 
1.3.3.3 Other insulin-mediated effects 
 In its role as an anabolic hormone, insulin stimulates amino acid synthesis and uptake 
into cells in the fed state. In the fasted state when insulin levels are low, the balance is tipped 
in favour of protein degradation (Perry et al., 2014). Insulin also exerts crucial roles in cell 
survival and differentiation through the MAP kinase pathway, promoting growth and gene 
expression. 
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1.3.4 Molecular features of insulin resistance 
 Key roles for IRS-1 and IRS-2 in growth and nutrient homeostasis have been 
highlighted by tissue-specific gene knockout studies in mice (Biddinger and Kahn, 2006). 
Simultaneous knockout of IRS-1 and IRS-2 is embryonically lethal; systemic IRS-1 knockout 
results in growth retardation and peripheral insulin resistance with compensatory 
hyperinsulinaemia, while IRS-2-null mice develop severe insulin resistance followed by 
pancreatic β-cell failure and hyperglycaemia (Withers et al., 1998). Tyrosine phosphorylation 
of the INSR and IRS-1 is impaired or absent in muscle in obesity and T2DM (Cusi et al., 
2000).  
 Loss of IRS-1 and IRS-2 results in impaired PI3K and PKB/akt activation, leading to 
insulin resistance and hyperglycaemia. However MAP kinase pathway activation may be 
normal or even upregulated in this setting, promoting mitogenesis, overgrowth and obesity. 
These findings suggest differential regulation of PI3K and MAP kinase signaling pathways in 
the setting of insulin resistance, particularly in muscle and adipose tissue (Cusi et al., 2000). 
Inhibition of PI3K cascades in the liver in humans leads to hyperinsulinaemia, glucose 
intolerance and dyslipidaemia (Miyake et al., 2002).  
 Impaired PKB/akt phosphorylation also upregulates increased Foxo1 transcriptional 
activity, leading to increased hepatic glucose output and hyperglycaemia. In animal models, 
we know that hepatic knockout of Foxo1 may reverse established hyperglycaemia and heart 
failure in mice (Battiprolu et al., 2012). Once insulin resistance is established at a cellular 
level, compensatory hyperinsulinaemia may drive a sequence of molecular events with further 
adverse effects on insulin sensitivity.  Amongst other effects, hyperinsulinaemia may suppress 
IRS-2 gene transcription in the liver, impair GLUT-4 cellular trafficking and paradoxically 
increase Foxo1 transcription (Gonzalez et al., 2011, Qi et al., 2013).   
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1.3.5 Monogenic disorders of insulin resistance 
 Insulin resistance is generally clinically expressed only in the context of obesity. In a 
small proportion of patients, however, severe insulin resistance (SIR) develops independent of 
adiposity due to monogenic gene defects impacting on either insulin signaling or adipocyte 
biology (Semple et al., 2011). Clinical suspicion of monogenic disorders of insulin resistance 
or T2DM should always be raised in insulin resistant patients with normal body mass index 
(BMI) or with a strong family history of insulin resistance or diabetes in first-degree relatives. 
SIR should be particularly considered in patients with BMI <30kg/m2 in the setting of a 
fasting serum insulin >150pmol/l, and/or a peak insulin >1500pmol/l during OGTT. 
Symptomatic fasting or postprandial hypoglycaemia may precede onset of hyperglycaemia in 
severe monogenic insulin resistance by many years, with onset of the latter only after β-cell 
decompensation is complete.  In insulin-treated patients with a BMI <30kg/m2, a daily 
exogenous insulin requirement of >3 units/kg is also suggestive of SIR. 
 Other clinical indicators of monogenic SIR include the presence of acanthosis 
nigricans (dark, velvet-like thickening of the skin in the axilla, groin and skin folds 
characterised histologically by hyperkeratosis, papillomatosis and occasionally 
hyperpigmentation, Figure 1-6), or in young women by the presence of severe 
hyperandrogenism (Poretsky et al., 1999). Concomitant ovulatory dysfunction, androgen 
excess and severe PCO on ultrasound frequently results in a misdiagnosis of common PCOS 
in such patients. Androgen excess and PCO in patients with SIR has traditionally been 
interpreted as the result of synergy between insulin and gonadotrophin action at the level of 
the ovary, although we also know that insulin can exert direct effects on ovarian 
steroidogenesis (Nestler and Jakubowicz, 1996, Musso et al., 2005). However other pathways 
of androgen generation in these patients remain to be elucidated. 
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Figure 1-6 Axillary acanthosis nigricans in a patient with severe insulin resistance (SIR). 
(Reproduced with kind permission from WebMD UK. Copyright © 2009 Boots UK Limited 
and WebMD UK Limited All rights reserved). 
 
 The generic term HAIR-AN (hyperandrogenism-insulin resistance-acanthosis 
nigricans) is often used to describe the typical features of female patients with SIR; ‘type A 
insulin resistance syndrome’ also encompasses lean women with SIR, acanthosis, anovulation 
and severe androgen excess (Semple et al., 2010). A newer classification system for 
syndromes of SIR is proposed in Table 1-2. Monogenic insulin resistance may be categorized 
into disorders with primary defects in insulin signaling and abnormalities of adipose tissue 
development (Semple et al., 2011). Disorders of insulin signaling may be further subdivided 
into (i) those with defects at the level of the INSR (eg loss-of-function mutations of the INSR, 
so called ‘insulin receptoropathies) and (ii) disorders of postreceptor insulin signal 
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transduction. Disorders of adipose tissue development include generalized and partial 
lipodystrophy, and rare genetic causes of severe obesity with hyperphagia. The section below 
will focus on insulin receptoropathies and lipodystrophy. 
 
Table 1-2 Classification of syndromes of severe IR 
Syndromes Discriminant features 
1. Primary defects in insulin signaling 
 
 
(i) Generalised (eg. INSR mutations, anti-
INSR antibodies) 
Severe hyperinsulinaemia; normal lipid 
profile; absence of hepatic steatosis; 
normal or increased leptin, adiponectin, 
SHBG 
(ii) Partial (AKT2, AS160, TBC1D4) Variable according to precise signaling 
defect 
2. Secondary to adipose tissue 
abnormalities 
 
(i) Severe obesity (eg POMC, LEP, 
LEPR, MC4R) 
Severe hyperphagia, early onset obesity 
(ii) Lipodystrophy 
Generalised (eg AGPAT2, BSCL2, PTRF, 
CAV1) 
Partial (eg LMNA, PPARG) 
Congenital absence of adipose tissue, or 
regional abnormalities of fat distribution 
Severe dyslipidaemia and hepatic 
steatosis 
Low adiponectin, leptin and SHBG levels 
 
   
1.3.5.1 Insulin receptoropathies 
 Over 100 allelic variant defects in the INSR have been reported to date (Parker and 
Semple, 2013). INSR defects give rise to a heterogeneous clinical phenotype, with a spectrum 
of clinical and biochemical severity depending on the degree of INSR loss-of-function. 
Broadly speaking, insulin receptoropathies can be categorized as autosomal recessive or 
dominant. Recessive disorders are less common but more aggressive, generally presenting in 
the first decade clinically with linear growth retardation, soft tissue overgrowth and 
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hyperglycaemia (Musso et al., 2004). In the early stages of the disease, biochemical 
characteristics include fasting hypoglycaemia, postprandial hyperglycaemia and severe 
hyperinsulinaemia, with progression to frank hyperglycaemia often resistant to insulin 
treatment. Seminal clinical descriptions of such patients have lead to persistence of the older 
arbitrary divsion of these autosomal recessive conditions into Donohue syndrome (also 
termed ‘leprechaunism’) and Rabson Mendenhall syndrome (RMS) (Rabson and Mendenhall, 
1956, Donohue and Uchida, 1954). 
 Autosomal dominant loss-of-function of the INSR usually presents in early puberty in 
females, with menstrual disturbance, hyperandrogenism and acanthosis nigricans. Male 
patients are often not diagnosed until the development of frank hyperglycaemia in the 4th or 
5th decade of life; earlier diagnosis in males may be facilitated by targeted familial screening 
after the diagnosis of a first-degree relative. As summarized in Table 2, patients with receptor 
defects in insulin signaling are protected from the severe dyslipidaemia and fatty liver disease 
seen in patients with lipodystrophy or ‘post-receptor’ insulin signaling defects (Semple et al., 
2009).  
 
1.3.5.2 Lipodystrophy 
 Defects in adipose tissue development are considered a secondary cause of SIR. 
Lipodystrophy may be categorized as generalized or partial, inherited or acquired. Acquired 
partial lipodystrophies include HIV-associated lipodystrophy and C3 nephritic factor-
associated lipodystrophy (Grinspoon, 2005, Misra et al., 2004). Lipodystrophy is relatively 
easily identified clinically, and should be considered in all patients with SIR with 
derangements in lipid profile and biochemical or radiological evidence of non-alcoholic fatty 
liver disease (NAFLD).  
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 Congenital generalized lipodystrophies (CGL), such as Berardinelli-Seip congenital 
lipodystrophy (BSCL) are characterized by an almost complete lack of adipose tissue from 
birth, with early onset of insulin resistance in infancy, followed by overt hyperglycaemia in 
the 2nd or 3rd decade (Garg, 2011). CGL has a striking clinical phenotype and is usually 
apparent at birth. Partial lipodystrophies, such as familiar partial lipodystrophy, are 
characterized by adipose tissue atrophy in distinct depots, usually in the limbs, with variable 
truncal fat loss and often excess fat around the face or neck (Prieur et al., 2014). The 
phenotype in partial lipodystrophy may be more subtle, but should be considered in lean 
patients with hepatic steatosis, severe dyslipidaemia, acanthosis and, in women, severe 
hyperandrogenism and PCO. 
 
 
1.4 Physiology of androgen secretion and androgen excess in females 
1.4.1 Androgen biosynthesis 
 Androgen biosynthesis in females occurs predominantly in the adrenal glands and 
ovaries. In the adrenal glands, androgen generation in the zona reticularis of the adrenal 
cortex is driven by adrenocorticotrophic hormone (ACTH), while luteinizing hormone (LH) 
stimulates de novo androgen generation in ovarian thecal cells (Burger, 2002). Androgen 
activation from weak precursors to potent T and dihydrotesterone (DHT) in peripheral tissues 
is also increasingly recognized; peripheral androgen generation in adipose tissue, liver, skin 
and other ‘intracrine’ organs is now believed to play an important role in androgen 
metabolism in health and disease (Fassnacht et al., 2003, Quinkler et al., 2004).  Adrenal and 
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ovarian androgen synthesis will be discussed below. Adipose androgen metabolism is 
discussed in section 1.7. 
 
1.4.1.1 Adrenal androgen synthesis and metabolism 
 The adrenal glands are a crucial organ of androgen biosynthesis in humans. The 
adrenals are located bilaterally in the retroperitoneum, sitting just above the kidney on both 
sides; each gland weighs approximately 4 grams (McNicol, 2008). The adrenal gland is 
composed of an outer cortex and inner medulla; the latter is responsible for synthesizing and 
secreting catecholamines, such as adrenaline, noradrenaline and dopamine. The adrenal cortex 
is composed of three layers: the outermost zona glomerulosa is the site of mineralocorticoid 
synthesis; the middle layer, the zona fasciculata, synthesizes glucocorticoids such as cortisol; 
the innermost zona reticularis is responsible adrenal androgen synthesis and release (Idkowiak 
et al., 2011) (Figure 1-7).  
 The adrenal androgen precursors dehydroepiandrosterone (DHEA) and its sulfated 
ester DHEAS are secreted by the zona reticularis. DHEA is sulfated to inactive DHEAS by 
the action of cytosolic sulphotransferase (SULT2A1); conversely DHEAS can be hydrolysed 
to DHEA by microsomal steroid sulphatase (STS) (Oostdijk et al., 2015). Approximately 75% 
of circulating DHEA is derived from the adrenal gland (either directly synthesised or derived 
from circulating DHEAS); the remainder is produced in the gonads (Longcope, 1986). DHEA 
may be converted to androstenedione (A) by 3β-HSD2 (HSD3B2) in both the adrenal and 
ovary, and subsequently to more potent androgens such as T and DHT in peripheral target 
tissues (see below).  
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Figure 1-7 Adrenal steroidogenesis from cholesterol precursor. Mineralocorticoids are 
synthesized in the outermost zona glomerulosa (light green). Glucocorticoid synthesis occurs 
in the zona fasciculata (yellow), while the innermost zona reticularis (pale blue) synthesises 
and secretes the adrenal androgens DHEA and DHEAS. DHEA is metabolized to active 
androgens in peripheral target tissues. Androstenedione and testosterone may be also be 
peripherally aromatised to oestrogens by CYP19A1 (placental aromatase). 
 
 Circulating concentrations of DHEA and DHEAS exhibit a characteristic age-
associated pattern (Arlt, 2004) (Figure 1-8). High levels in the perinatal period reflect fetal 
adrenal androgen production, but levels decline rapidly after involution of the fetal zone of 
the adrenal cortex. Levels of DHEAS rise again between 6th and 10th year of life, reflecting a 
process of maturation of the zona reticularis known as adrenarche (Sklar et al., 1980), before 
peaking in the third decade. There is a steady decline in DHEAS thereafter, dropping to 10-
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20% of maximum levels by the eighth decade (Orentreich et al., 1992). This age-related drop 
in adrenal androgens has been termed the ‘adrenopause’, attributed to involution of the zona 
reticularis, and occurs in both men and women, independent of the menopause.  
 
 
Figure 1-8 Serum DHEAS levels in men and women throughout life (Arlt, 2004). Reproduced 
with permission from Elsevier. 
 
1.4.1.2 Ovarian androgen synthesis and metabolism 
 The ovary is another crucial site of androgen generation in women. Ovarian androgen 
generation takes place in the outer theca cells of the follicular unit, and is regulated by 
pituitary LH secretion. Each basic follicular unit contains a single oocyte and granulosa cells, 
which are separated from the outer theca cells by a basement membrane or basal lamina 
(Magoffin, 2005). Theca cells form a layer of cells adjacent to the basal lamina known as the 
theca interna; this area is highly vascularized and steroidogenic (Erickson et al., 1985) (Figure 
1-9). Primordial follicles do not contain theca cells, and the latter only begin to differentiate in 
the theca interna after a second layer of cuboidal granulosa cells develops in the second stage 
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of follicular development. Upon reaching steroidogenic potential, theca cells are responsive to 
LH stimulation. 
 
 
Figure 1-9 Theca and granulosa cell action under the influence of FSH and LH across 
follicular development in the human ovary (Reproduced with kind permission from 
ClinicalGate.com). 
  
 De novo thecal androgen generation is dependent upon expression of a number of key 
steroidogenic enzymes, a process driven by differentiation of the theca interna during 
folliculogenesis (Logan et al., 2002). LH receptor expression facilitates expression of 
CYP11A1, HSD3B2 and CYP17. CYP11A1 (cholesterol side-chain cleavage enzyme) is 
localized to the mitochondria, while CYP17 and HSD3B2 are found in the endoplasmic 
reticulum. LH drives thecal androgen generation through stimulation of the cAMP-signaling 
pathway, leading to expression and upregulation of CYP17 and HSD3B2. LH also upregulates 
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steroidogenic acute regulatory protein (StAR), a key protein involved in the transport of 
cholesterol to the inner leaflet of the mitochondria, where it acts as substrate for CYP11A1 
(Nelson et al., 2001). The stimulatory action of LH on ovarian steroidogenesis are modulated 
by a long list of growth and differentiation factors which may be derived from the ovary itself 
or from the peripheral circulation (Magoffin, 2002). Factors acting synergistically to augment 
LH activity include insulin, insulin-like growth factor-1 (IGF-1), inhibin and GDF-9; factors 
that inhibit LH action include activin and TGF-α. The role of insulin in this process will be 
discussed in more detail in section 1.5.  
 The principal androgen precursor product of thecal steroidogenesis is A. Androgens 
are important modulators of follicular function, exerting their effects via the androgen 
receptor (AR). The AR is expressed throughout the mature ovarian follicle, including oocyte, 
theca and granulosa cells (Lebbe and Woodruff, 2013). Once the follicular unit has 
transitioned from primordial to primary follicle, AR expression allows testosterone to 
stimulate further follicular maturation to the secondary follicle stage; this has been reported 
both in primate models and in ovaries from testosterone-treated transsexual women (Weil et 
al., 1998, Chadha et al., 1994). Whilst androgen action is crucial for follicular development, 
conditions of androgen excess such as PCOS are characterized by the accumulation of small 
antral follicles in the ovarian cortex. The obvious deduction from these findings is that 
supraphysiological androgen exposure may be detrimental in the early stages of follicular 
development, leading to disruption of dominant follicle selection and subsequent anovulatory 
fertility (Franks and Hardy, 2010). Theca cell hyperplasia is a common histological finding in 
ovarian tissue from women with PCOS. 
 The theca provides crucial androgen substrate for aromatization to oestrogens in the 
granulosa cells; human theca cells do not express CYP19A1. In order for aromatization to 
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proceed, A must therefore diffuse from the theca across the basal lamina to the granulosa 
cells, which express CYP19A1 from the small antral stage onwards. FSH, secreted from 
gonadotroph cells in the anterior pituitary, significantly upregulates granulosa aromatase 
activity. Interestingly, this induction of granulosa aromatase activity by FSH is itself 
positively regulated by androgens via the AR (Hillier and De Zwart, 1981). Therefore, in 
addition to providing substrate for aromatization, thecal androgens themselves induce 
granulosa aromatase activity, allowing granulosa cells in the selected dominant follicle to 
synthesise large quantities of oestrogen. This process of cross-talk between theca and 
granulosa cells, cumulating in oestrogen synthesis by the follicular unit, and initially proposed 
by Bjersing in 1967, is termed the two-cell, two gonadotrophin theory (Bjersing and 
Carstensen, 1967); thecal androgen generation under LH stimulation provides substrate for 
granulosa aromatase activity which is stimulated by FSH.  
  
1.4.2 Peripheral (pre-receptor) androgen metabolism  
 A large body of evidence supports activation of weaker androgen precursors in 
peripheral target tissues to more potent metabolites such as T and DHT. Although de novo 
androgen generation from cholesterol in the peripheral tissues is unlikely, secretion of large 
quantities of DHEA and DHEAS from the adrenal glands provides substrate for a complex 
process of peripheral androgen generation. The term ‘intracrinology’ has been coined in the 
last two decades to describe this process of local hormone synthesis in selected target tissues 
such as skin, liver, fat, muscle, cerebral cortex and breast (Labrie et al., 1997a); locally-
generated hormones may then exert their effects on the tissue of origin without being released 
systemically or into the extracellular tissues. After menopause and consequent cessation of 
ovarian oestradiol secretion, the vast majority of sex steroids are synthesized locally in 
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peripheral intracrine tissues. However, declining serum levels of DHEA and DHEAS with 
advancing age (‘adrenopause’) may lead to a global reduction in substrate available to 
peripheral tissues; decreased local androgen synthesis in target organs may play a role in age-
related diseases such as sarcopenia (Labrie et al., 2003).  
 Tissue-specific androgen generation is dependent upon local expression and activity of 
key steroidogenic enzymes. Peripheral metabolism of DHEA to more potent androgens 
requires 3β-HSD, 17β-HSD and 5αR enzymatic activity (Figure 1-10). Additionally, A and T 
may be further aromatized to oestrone and oestradiol, respectively, in the presence of 
placental aromatase (CYP19A1). DHT, however, is not susceptible to aromatization. 3β-HSD 
is responsible for conversion of DHEA to A. Type 2 3β-HSD (HSD3B2) is largely expressed 
in the adrenals and ovaries (Luu-The et al., 1991); the most important peripheral 3β-HSD 
isoform appears to be type 1 (HSD3B1), which is expressed in skin, adipose tissue, liver, 
brain and breast (Milewich et al., 1993). There are multiple isoforms of human 17β-HSD; 
types 3 and 5 are the most important for androgen activation, converting A to T (Dufort et al., 
1999). Type 3 17β-HSD is expressed predominantly in the Leydig cells of the testes, 
contributing to approximately 50% of total androgen load in men. It shares significant 
homology with type 5 17β-HSD, which catalyses the conversion of A to T in peripheral 
tissues. Type 5 17β-HSD is expressed in a variety of tissues, including adrenal, ovary, adipose 
and breast (Quinkler et al., 2004). It belongs to the aldoketoreductase family of enzymes, and 
is also called aldoketoreductase type 1C3 (AKR1C3).  The role of this enzyme in adipose 
androgen metabolism will be discussed in detail in Section 1.7. 
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Figure 1-10 Peripheral pre-receptor androgen metabolism. 3β-HSD type 1(HSD3B1) 
catalyses the peripheral conversion of DHEA to androstenedione (A), which in turn is 
converted by 17β-HSD5 (also called AKR1C3) to testosterone (T). T may bind to the 
androgen receptor directly or undergo conversion to potent dihydrotestosterone (DHT) by the 
action of 5α-reductase type 1 (SRD5A1) or type 2 (SRD5A2). A and T may be aromatized to 
oestrone (E1) and oestradiol (E2) respectively.  
 
 5αR catalyses the conversion of T to DHT, the most potent androgen, which binds to 
the AR with significantly greater affinity than T. The enzyme 5αR has three isoforms, with 
isoforms 1 and 2 sharing 47% homology. SRD5A1 is expressed predominantly in skin (in 
particular genital) and adipose tissue, and SRD5A2 in reproductive tissues such as the seminal 
vesicles, prostate and epididymis in men, and ovaries in women; both isoforms are expressed 
in the liver (Tomlinson et al., 2008b). 5αR2 is likely to be the most important contributor to 
androgen activation in humans, but the role of 5αR1 in diseases such as PCOS and obesity 
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remains to be elucidated. Increased expression of 5αR1 in the skin causes hirsutism (Dijkstra 
et al., 1987). The role of 5αR3 is poorly understood and it is unlikely to be a key player in 
systemic androgen or glucocorticoid metabolism. 
 In vivo evidence for peripheral androgen formation comes from studies examining 
dexamethasone-induced suppression of adrenal androgens in PCOS women compared to 
controls; androgens remain higher in the PCOS cohort despite administration of 
dexamethasone (Lachelin et al., 1982). Mirroring this, suppression of ovarian androgen 
production using long-acting gonadotrophin-releasing hormone (GnRH) agonists results in 
significant suppression of androgen levels in both groups; however post-treatment androgen 
levels remain persistently higher in PCOS patients (Rittmaster and Thompson, 1990). 
Peripheral androgen generation may make an important contribution to androgen excess in 
PCOS. Stewart et al identified evidence of systemically upregulated urinary excretion of 5α-
reduced androgen and glucocorticoid metabolites in women with PCOS (Stewart et al., 1990). 
This provides indirect evidence of increased peripheral 5α-reductase (5αR) activity in this 
disorder. Another key study showed that urinary excretion of the 5α-reduced metabolite 
androsterone (An) was significantly increased in PCOS compared to controls after 
administration of an oral androgen load with DHEA, mirrored in the serum by increased 
levels of DHT (Fassnacht et al., 2003). Interestingly, Vassiliadi and colleagues found that 
peripheral 5α-reductase activity, as measured indirectly using the same urinary ratios 
described in the Stewart paper, correlated closely with serum insulin levels and markers of 
insulin resistance (Vassiliadi et al., 2009). The androgen-activating and glucocorticoid-
inactivating roles of 5α-reductase are shown in Figure 1-11. 
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Figure 1-11 Androgen activation and glucocorticoid inactivation by 5α-reductase. Net 
systemic 5α-reductase activity is calculated in urinary steroid excretion profiles by the ratio 
of androsterone to etiocholanolone (An/Et) and 5α-THF/THF. 11β-HSD1 activity is estimated 
by the ratio of (5α-THF+THF)/THE. 
 
1.4.3 The role of androgens in female health and development 
1.4.3.1 Androgen receptor (AR) 
 The biological effects of androgens are mediated in both sexes via the androgen 
receptor (AR), a member of the nuclear receptor superfamily (subfamily 3) (Montgomery et 
al., 2001). Other members of this family include the mineralocorticoid, glucocorticoid, 
oestrogen and progesterone receptors. The AR gene is located on the X-chromosome (Xq11-
12). The AR (919 aa) consists of four domains: 1) a large N-terminal domain (NTD) with an 
activation function 1 (AF1), 2) a DNA-binding domain (DBD), 3) the hinge region (HR) 
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which contains a nuclear localization signal (NLS), and 4) a ligand-binding domain (LBD), 
containing the activation function 2 (AF2) (Figure 1-12).  
 
Figure 1-12 Protein structure and domains of the androgen receptor (AR) (Werner et al., 
2010). NTD: N-terminal domain; DBD, DNA-binding domain; HR, hinge region; LBD, 
ligand-binding domain; AF1/2, activation function 1 and 2; NLS, nuclear localization signal; 
Q(n), polymorphic glutamine repeat; G(n), polymorphic glycine repeat; FQNLF, peptide 
interacting with AF2. Reproduced with permission from Elsevier. 
 
  In the absence of ligand, the AR is largely confined to the cytoplasm. After binding of 
T or DHT, the AR undergoes conformational change, leading to dissociation of heat shock 
proteins (HSPs), which enables nuclear targeting of AR and subsequent nuclear dimerization 
(Bennett et al., 2010). Androgen response elements (AREs) promote recruitment of co-
activators, which facilitate subsequent gene transcription. Non-ligand bound AR is returned to 
the cytoplasm where it is either recycled in preparation for further ligand binding, or targeted 
for ubiquitin-mediated proteasomal degradation. 
  
1.4.3.2 Androgens and fetal sexual differentiation 
 Androgens exert multi-system biological actions in humans; these effects may be 
gender-specific. In embryogenesis, androgens play a key role in early development of external 
genitalia (sex differentiation). This is mechanistically distinct from the earlier phase of sexual 
determination, which is controlled by transcription factors and non-steroid regulators. Sexual 
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dimorphism occurs at about 6 weeks after conception, when androgens drive differentiation of 
the bipotential gonadal anlage into testes. Low levels of circulating androgens in the female 
fetus allow the development of the genital tubercle and urogenital swellings into clitoris and 
labia majora, respectively (Hiort, 2013). In complete androgen insensitivity syndrome 
(CAIS), affected 46,XY individuals have a deleterious loss-of-function mutation of the AR, 
which results in external genitalia with in utero resistance to the virilising effects of 
androgens (Werner et al., 2010). Such patients have phenotypically female external genitalia 
with clitoris and labia majora. Mirroring this, 46,XX individuals with disorders of adrenal 
steroidogenesis, such as congenital adrenal hyperplasia (CAH), may be exposed to excess 
adrenal androgens during crucial stages of embryogenesis, leading to virilisation of the 
external genitalia. Severe cases may result in complete masculinization, with clitoromegaly, 
scrotum formation from the urogenital swellings and even frank phallus development 
(Kamrath et al., 2013). 
 
1.4.3.3 Androgens, adrenarche, pubarche and gonadarche 
 As discussed in section 1.4.1.1, high circulating DHEAS levels in the early neonatal 
period decline rapidly in the first three months of life. Physiological increases in serum 
DHEAS levels occur in both sexes around 6-8 years of age, although recently more sensitive 
detection methods such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
and gas chromatography-tandem mass spectrometry suggest that secretion of adrenal 
androgens may begin as early as 3 years of age (Remer et al., 2005). This process is termed 
adrenarche, and, although its regulation is poorly understood, is likely to reflect maturation of 
the zona reticularis. DHEA secreted by the adrenal is then activated to more potent androgens 
in the adrenals and peripheral tissues, which leads to the development of pubic (‘pubarche’) 
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and axillary hair. This occurs physiologically from the age of 8 years onwards (Idkowiak et 
al., 2011). Adrenarche is also associated with development of a distinctive male body odour 
in both sexes, as well as greasy hair and skin (Voutilainen et al., 1983). Although definition 
consensus remains elusive, premature adrenarche (PA) is best defined by the presence of 
elevated adrenal androgen levels above age- and sex-matched reference interevals, with 
concurrent clinical evidence of increased androgen action (such as pubarche), below the age 
of 8 years in girls and 9 years in boys (Utriainen et al., 2007). Premature adrenarche is 
associated with a constellation of subsequent metabolic and reproductive abnormalities, 
which will be discussed further in section 1.5.  
 It is important to note that adrenarche appears to be a process largely independent 
from gonadarche, the term used to describe maturation of the gonads and onset of sex steroid 
production. This notwithstanding, adrenal androgens may indirectly modulate GnRH 
pulsatility, thereby kick-starting gonadarche. Gonadal androgen secretion manifests clinically 
with testicular and penile enlargement in boys, and breast development (also termed 
‘thelarche’) and menarche in girls. Onset of gonadarche is reliant upon maturation of the 
GnRH ‘pulse generator’; increasing GnRH amplitude stimulates LH pulsatility, which drives 
gonadal androgen secretion (Neely and Crossen, 2014). GnRH pulse amplitude and frequency 
increases to every 1-2 hours, particularly at night, in early puberty (Apter et al., 1993). 
Initiation of GnRH release from the hypothalamus is a complex process mediated by 
neuropeptides such as kisspeptin, leptin and neurokinin. When this process begins 
prematurely, manifesting clinically as thelarche and/or menarche in girls, and testicular and/or 
penile enlargement in boys, it is referred to as true central precocious puberty (Fuqua, 2013). 
However, like premature adrenarche, there is great controversy over the issue of timing of 
normal pubertal development. This is largely a reflection of an increased number of children 
Chapter 1               General Introduction 
 39 
entering puberty at younger ages, and therefore distinguishing pathological and physiological 
onset becomes much more difficult. A 1997 study found that the average age of thelarche in 
white and African-American girls was 10 years and 8.9 years, respectively (Herman-Giddens 
et al., 1997), but this remains controversial. Most commentators agree that precocious puberty 
implies the development of secondary sexual characteristics (testicular enlargement, breast 
development or menarche) before the age of 9 years in boys or 8 years in girls. 
  True central precocious puberty (CPP), often called GnRH-dependent precocious 
puberty, is the clinical and biochemical consequence of premature upregulation of the 
hypothalamic-pituitary-gonadal axis. Idiopathic CPP represents over 90% of cases and is 
more common in girls than boys. A variety of other subtypes of CPP exist, triggered by 
acquired CNS insults such as trauma, infection and neoplastic disease; it is also described in 
inherited or developmental CNS diseases such as Tuberous Sclerosis or Neurofibromatosis 
Type 1 (Fuqua, 2013). GnRH-independent precocious puberty (also termed precocious 
pseudopuberty) is much less common, observed in rare gonadal or adrenal androgen-secreting 
tumours, CAH and McCune-Albright syndrome. Differentiating CPP from PA may be 
difficult on clinical grounds alone, but generally girls with pubic and/or axillary hair without 
evidence of thelarche, or boys with pubic/axillary hair without testicular enlargement, are 
likely to have PA. Diagnosis may be further complicated by the existence in girls of the 
phenomenon of premature thelarche, in which modest early breast development is noted in the 
absence of menstruation and other pubertal findings. Clinical correlation with biochemical 
findings of pubertal range testosterone levels in boys and 17β-oestradiol in girls, as well as 
gonadotrophin response to GnRH stimulation, is usually sufficient to make the diagnosis. 
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1.4.3.4 Multi-system effects of androgens in females 
 Although their actions are classically associated with male sexual development, 
growth and general well-being, androgens also exert multi-system effects in females, and 
states of androgen excess or deficiency in women are associated with significant health 
consequences. The major physiological role played by androgens in females are highlighted 
by data showing that total androgen production in healthy women, as measured by 24-hour 
excretion of key conjugated metabolites of DHT, are up to 70% of those observed in men 
(Labrie et al., 1997b). As explored throughout this thesis, isolated measurement of serum 
androgens in females, circulating in relatively low concentrations, is a weak tool for 
estimation of total systemic androgen metabolism, and does not take into account the complex 
intracrine systems of androgen activation described in section 1.4.2. Urinary androgen 
metabolite excretion, perhaps in the future coupled with assessment of tissue-specific local 
androgen activation, represents a more comprehensive evaluation of androgen metabolism in 
health and disease. 
 An important physiological role for androgens in female bone metabolism is 
highlighted in both clinical and laboratory studies. Co-administration of oestrogen and 
testosterone implants to postmenopausal women results in a greater improvement in 
radiological bone mineral density at the lumbar spine than in those treated with oestrogen 
alone (Davis et al., 1995). Patients with complete androgen insensitivity syndrome (CAIS) 
have significantly reduced bone mineral density which is not ameliorated by treatment with 
oestrogen alone (Soule et al., 1995). Therefore the effect of androgens on bone density appear 
to be directly mediated via the AR and not as a consequence of aromatization to oestrogens. 
In vitro, androgens have direct effects on osteoblast differentiation and endochondral bone 
formation (Kapur and Reddi, 1989, Kasperk et al., 1989).   
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 The role of androgens in cardiovascular and metabolic health in men has been 
extensively debated. Although little consensus exists on whether cardiovascular benefits are 
derived directly from testosterone replacement in obesity-induced hypogonadism, a recent 
meta-analysis reinforced the dogma that low serum testosterone levels at the very least 
represent an indirect marker of cardiovascular risk (Srinath et al., 2015). Modest testosterone 
supplementation may also have benefits for cardiovascular health in women. Long-term 
testosterone implant therapy does not appear to adversely affect the observed improvements 
in lipid parameters associated with postmenopausal oestrogen replacement (Davis et al., 
1995). Additionally, parenteral testosterone replacement may directly induce brachial artery 
vasodilatation (Worboys et al., 2001).  
 In addition to the potential benefits described above, co-administration of androgens 
with hormone replacement therapy (HRT) may have benefits on quality of life and general 
well-being in postmenopausal women (Davis and Tran, 2001). Transdermal testosterone has 
been shown to improve libido and sexual function in women after oophorectomy (Shifren et 
al., 2000). Treatment with DHEA 50mg for four months in a study of 24 women significantly 
improved general well-being and sexuality compared to placebo in women with adrenal 
insufficiency (Arlt et al., 1999).  It is important however for clinicians to recognize the 
delicate balance between physiological androgen replacement and the potentially deleterious 
metabolic effects of androgen excess in such women. This is echoed in a recent Endocrine 
Society clinical practice guideline, which advised against routine diagnosis of androgen 
deficiency in healthy women due to insufficient supporting evidence correlating androgen 
levels with specific signs and symptoms of disease (Wierman et al., 2014).  
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1.4.4 Monogenic disorders of androgen excess 
 A number of monogenic disorders of steroidogenesis result in clinically significant 
androgen excess, the consequences of which are most severe in females. Most of these 
genotypically and phenotypically heterogeneous conditions result in adrenal androgen excess, 
and fall under the umbrella term of CAH. Specific enzymatic deficiencies may indirectly lead 
to upregulation of adrenal androgen generation. These and other monogenic causes of 
androgen excess are summarized in Table 1-3. CAH subtypes resulting in sex steroid 
deficiency are not covered here. Genetic disorders of androgen excess have severe clinical 
consequences if untreated, and require life-long multi-disciplinary follow-up unified under an 
experienced adrenal endocrinologist to maximize quality of life and satisfactory long-term 
health outcomes (Auchus and Arlt, 2013, Han et al., 2013). The most common subtypes are 
discussed in more detail below. 
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Table 1-3 Summary of clinical and genetic features of known monogenic disorders of 
androgen excess.  
Genetic defect and inheritance Impaired reaction Discriminant features 
CYP21A2  
(21-hydroxylase deficiency) 
Autosomal recessive 
Progesterone→11-deoxycorticosterone 
17OHP→11-deoxycortisol 
 
Classic: severe GC and MC 
deficiency, ACTH-mediated 
androgen excess 
Simple virisiling: 46,XX DSD  
Non-classic: Androgen excess, 
compensated GC deficiency 
 
CYP11B1 
Autosomal recessive 
11-deoxycortisol→cortisol Classic: isolated GC deficiency, 
ACTH-mediated androgen 
excess, increased MC precursors 
Non-classic: often androgen 
excess only 
HSD3B2 
Autosomal recessive 
Pregnenolone→Progesterone 
17OH-preg→17OHP 
DHEA→androstenedione 
Classic: GC and MC deficiency. 
Androgen excess with 
downstream conversion of 
accumulating DHEA to active 
androgens. 
Non-classic: Compensated 
GC/MC deficiency; androgen 
excess 
CYP19A1 (non CAH; aromatase 
deficiency 
Autosomal recessive 
Testosterone→E2 
Androstenedione→E1 
DHEA→E3 
Prenatal virilisation due to 
impaired aromatization: 46,XX 
DSD 
HSD11B1 (cortisone reductase 
deficiency) 
Autosomal recessive 
Cortisone→cortisol ACTH-mediated postnatal 
androgen excess, late 
presentation with PCOS or 
premature adrenarche 
POR  
(P450 oxidoreductase 
deficiency) 
Autosomal recessive 
All microsomal cytochrome P450 enzymes 
- impaired CYP17A1, CYP21A2, 
CYP19A1, CYP51A2 activity 
GC deficiency 
Prenatal androgen excess 
Postnatal sex steroid deficiency 
Skeletal malformations 
PAPSS2   
(apparent DHEA 
sulfotransferase deficiency) 
Autosomal recessive 
Impaired SULT2A1 activity: 
DHEA→DHEAS 
Androgen excess due to impaired 
sulfation 
Bone malformations 
H6PD 
(apparent cortisone reductase 
deficiency) 
Autosomal recessive 
Impaired HSD11B1 activity: 
Cortisone→cortisol 
Variable androgen excess, often 
presenting with premature 
adrenarche or PCOS phenotype 
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1.4.4.1 Principles of clinical management of adult patients with CAH 
 21-hydroxylase deficiency (21OHD) is the most common form of CAH, but there are 
numerous other distinct subtypes as highlighted in Table 1-3 above. Each variant has distinct 
clinical and biochemical features, and represents a distinct challenge in terms of clinical 
management. This and the subsection below will concentrate on patients with 21OHD, which 
accounts for 95% of cases. The frequency of 21OHD in newborns is 1:16,000 (Speiser and 
White, 2003). 21OHD has traditionally been referred to as ‘classic’ if the severity of enzyme 
block is sufficient to result in clinically apparent GC deficiency. ‘Non-classic’ variants have 
androgen excess but the milder degree of enzyme deficiency means that there is only 
compensated GC deficiency. Classic 21OHD is often further subdivided into ‘salt-wasting’, 
due to severe mineralocorticoid (MC) deficiency, or ‘simple virilising’ variants. Classic 
21OHD is usually diagnosed at birth, either on routine screening or upon identification of 
virilisation of external female genitalia, or occasionally on presentation with salt-wasting 
crisis in patients with severe MC deficiency. Non-classic 21OHD more frequently manifests 
in adolescence with a PCOS-like phenotype, including non-specific androgen excess and 
oligomenorrhoea. The distinction between classic and non-classic 21OHD is largely arbitrary, 
and increasingly viewed as obsolete by experts who regard both variants as a continuous 
spectrum of the same condition (Auchus and Arlt, 2013).  
 The key principles of pharmacological management in patients with 21OHD are 
treatment of adrenal hormone deficiencies and reduction of ACTH drive from the pituitary 
gland (Joint, 2002). Classic 21OHD requires treatment with oral glucocorticoids and the 
synthetic mineralocorticoid fludrocortisone. Glucocorticoids will provide physiological 
replacement in the setting of deficiency, but will simultaneously reduce pituitary ACTH 
secretion via a negative feedback mechanism. Adults with 21OHD are treated with a variety 
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of glucocorticoid regimens, and requirements exhibit a large degree of inter-individual 
variabilility. Hydrocortisone is most commonly prescribed in the paediatric population due to 
concerns about the effects of prednisolone and dexamethasone on bone density and linear 
growth (Chakhtoura et al., 2008).  
 Three daily doses of 5-10mg each are generally sufficient to maintain control. This 
may be continued in the adolescent and early adult period in the absence of specific 
indications to change, such as poor compliance or control issues with multiple daily doses. 
The next step in the event of the latter issues is initiation of prednisolone 0.5-2mg at bedtime. 
Dexamethasone is the most clinically and biochemically effective downregulator of the HPA 
axis and ACTH drive in patients with CAH, but patients are more likely to experience 
complications of glucocorticoid excess than with other steroid preparations. Dexamethasone 
is usually initiated at dose of 0.25-0.375mg/day, but it should be reserved for patients with 
complex pathology, such as oligozoospermia due to testicular adrenal rest tumours (TARTs) 
in men (Mouritsen et al., 2010). It may have a limited role in selected female cases of 
oligomenorrhoea, androgen excess and subfertility. Mineralocorticoid replacement is required 
in 21OHD patients with salt-wasting; it is not required in non-classic CAH. Clinical doses of 
fludrocortisone vary between 100 and 250mcg. Replacement is monitored clinically by 
measurement of lying and standing blood pressure, and biochemically by measurement of 
plasma renin levels, and urea and electrolytes (Oelkers et al., 1992). Adult patients are at 
increased risk of iatrogenic hypertension compared to children and require close clinical 
surveillance (Falhammar et al., 2007).   
 Biochemical monitoring in 21OHD is complex and there are misconceptions about the 
sole use of 17OHP levels as a guide to therapy. Suppression of 17OHP into the normal range 
with glucocorticoids significantly inreases the risk of over-replacement (Auchus and Arlt, 
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2013). Calculation of the free androgen index (FAI) via serum T and SHBG levels may be a 
useful test of biochemical control in 21OHD women (Vermeulen et al., 1999).  However 
measurement of the A:T ratio is a reasonable indirect marker of adrenal versus ovarian 
androgen generation, which is importance due to the co-existence of PCOS in many of these 
women. An A:T ratio >4 indicates that most of the testosterone is derived from the adrenal 
gland, and hence indicative of poor control. In women with 21OHD aiming for conception, 
follicular phase progesterone levels below 2nmol/l are an important predictor of ovulation. 
Excessive follicular phase progesterone of adrenal origin has adverse effects on menses and 
ovulation (Casteras et al., 2009). In men, A:T ratios of >0.5 indicate that a large proportion of 
T is of adrenal origin; this is due to the high rates of conversion of A to T in the testes by 
17βHSD3. An elevated ratio, coupled with reduced semen parameters and suppressed 
gonadotrophins, in a powerful indicator of poor control in the 21OHD male patient (Claahsen-
van der Grinten et al., 2007). 
 
1.4.4.2 Long-term health consequences of monogenic androgen excess in women 
 CAH and other causes of monogenic androgen excess are lifelong disorders with 
severe health consequences if untreated or poorly managed. A combination of erratic disease 
control and, in the case of CAH, over-treatment with glucocorticoids, impacts adversely on a 
variety of health parameters, including fertility, quality of life and metabolic risk. A recent 
study of 203 adult patients with CAH in the UK observed that health status is subjectively and 
objectively very poor in both sexes, but worse in females (Arlt et al., 2010). The prevalence of 
obesity, dyslipidaemia and insulin resistance was significantly higher in CAH patients than in 
healthy controls, and quality of life parameters were reduced. Over-zealous glucocorticoid 
treatment is undoubtedly a major contributor to the health deficiencies described above. 
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However, 24% of women with non-classic CAH, reflective of those patients who are unlikely 
to have had lifelong glucocorticoid exposure, had biochemical evidence of insulin resistance 
compared to 28% of those with the classic subtype. This is supported by a study showing 
unfavourable metabolic parameters, including increased risk of hypertension, higher 
stimulated insulin and increased 120-minute OGTT glucose values, in children with non-
classic CAH compared to healthy subjects (Williams et al., 2010). This points toward a 
primary role for androgens in the pathogenesis of metabolic disease in these patients. 
 
1.5 Links between insulin resistance and androgen excess 
 The relationship between insulin resistance and androgen excess in PCOS has been 
apparent for many years (Burghen et al., 1980). Burghen and colleagues found strong positive 
correlations between fasting insulin levels and serum levels of androstenedione and 
testosterone. As discussed above monogenic IR may lead to profound secondary androgen 
excess in girls of reproductive age, and these patients often present in adolescence with 
amenorrhoea and clinical hyperandrogenism. Conversely, girls with monogenic causes of 
androgen excess such as CAH have evidence of metabolic derangements that cannot be 
attributed solely to glucocorticoid treatment, while postmenopausal women with 
hyperandrogenism due to ovarian hyperthecosis have features of the metabolic syndrome and 
a clustering of cardiovascular risk factors (Barth et al., 1997). In PCOS, women with the so-
called ‘non-hyperandrogenic’ Rotterdam phenotype of Anov + PCO (as discussed in section 
1.2.1) may be at lowest risk of metabolic dysfunction (Barber et al., 2007, Moghetti et al., 
2013). However, the associations are complex, and while hyperandrogenaemic PCOS women 
appear to have the worst metabolic phenotype, even the normo-androgenaemic subgroup may 
not be entirely metabolically similar to non-PCOS control women (Di Sarra et al., 2013, 
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O'Reilly et al., 2014b). The sections below will summarise the in vivo and in vitro evidence 
linking insulin resistance and androgen excess. 
 
1.5.1 Evidence for regulation of androgen metabolism by insulin 
1.5.1.1 Insulin and the ovary 
 The observation of androgen excess in genetic syndromes of severe insulin resistance 
has been discussed above. Hyperinsulinaemia, in the setting of severe insulin resistance at the 
level of liver, muscle and adipose tissue, may lead to direct stimulation of ovarian and 
possibly peripheral androgen generation; relative preservation of insulin sensitivity at the 
level of the ovary and other organs of androgen generation may then facilitate insulin-
mediated effects on steroidogenesis. Some authors have postulated that insulin could act via 
ovarian IGF-1 receptors rather than the INSR to drive androgen production in the setting of 
pre- or post-receptor defects of insulin action (Willis et al., 1998, Willis and Franks, 1995). 
However, evidence for this is by no means conclusive, and selective inhibition of the IGF-1 
receptor has not been proven to lower insulin-stimulated androgen generation (Nestler et al., 
1998). The key role of the INSR in ovulation and ovarian androgen metabolism is further 
highlighted by a recent study showing reversal of obesity-induced subfertility and androgen 
excess after INSR deletion (Wu et al., 2014).  
 Insulin regulates ovarian androgen steroidogenesis through a number of distinct 
mechanisms (Poretsky et al., 1999). These are summarized in Table 1-4. Insulin receptors are 
widely expressed in ovarian granulosa, thecal and stromal tissues. In vitro, insulin appears to 
stimulate ovarian androgen generation in humans via upregulation of 17α-hydroxylase 
activity (Bergh et al., 1993); other possible ovarian steroidogenic targets of insulin action 
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include 3β-HSD) and P450 side chain cleavage (SCC) enzyme (McGee et al., 1995, McGee et 
al., 1996). The effects of insulin on ovarian androgen generation are likely to reflect a 
potentiation of gonadotrophin action at the level of the ovary. In granulosa cells, insulin may 
increase LH receptor number by acting synergistically with FSH (Adashi et al., 1981). This is 
supported by in vivo data showing that lowering of serum insulin levels via insulin 
sensitization results in a reduction in circulating LH levels (Nestler and Jakubowicz, 1997). 
Ovarian growth and cyst formation also appear to be crucially regulated by insulin, possibly 
via synergism with pituitary gonadotrophins. Circulating insulin levels in women with PCOS 
correlate with ovarian volume (Pache et al., 1993), and women with genetic syndromes of 
severe insulin resistance may present with abdominal pain due to enlargement, haemorrhage 
or torsion of large ovarian cysts (DeClue et al., 1991). 
 
Table 1-4 Summary of effects of insulin on ovarian androgen metabolism 
• Direct stimulation of ovarian androgen generation 
• Stimulation of steroidogenesis via synergistic action with FSH and LH 
• Upregulation of 17α-hydroxylase activity 
• Upregulation of LH receptor expression 
• Suppression of hepatic SHBG production 
• Upregulation of IGF-1 receptor expression 
• Potentiation of effect of GnRH on FSH and LH release from pituitary 
gonadotrophs  
• Potentiation of FSH effects on LH receptor recruitment 
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1.5.1.2 Insulin, circulating androgens and peripheral androgen metabolism 
 Insulin suppresses hepatic SHBG output, and low circulating levels of the latter are a 
reliable biochemical marker of underlying insulin resistance. Low SHBG levels result in 
secondary increases in circulating levels of bioavailable T, leading to a significant rise in the 
free androgen index (FAI) (Plymate et al., 1988). In vivo, the effects of insulin on circulating 
androgens have been studied extensively. Dunaif et al found an increase in A levels during 
insulin infusion in PCOS women but not in controls (Dunaif and Graf, 1989). Others have 
found increases in androgen levels (A, T and DHT) during oral glucose tolerance testing in 
hyperandrogenic and normal women (Smith et al., 1987), although these findings have not 
been consistently replicated (Tiitinen et al., 1990). No significant effects on circulating 
androgens were observed in one study during the frequently sampled intravenous glucose 
tolerance test in PCOS and control women (Falcone et al., 1990). 
 We have recently published data confirming an inverse relationship between 
circulating A levels (as measured by LC-MS/MS) and the OGTT-derived insulin sensitivity 
index (ISI) (O'Reilly et al., 2014b). Nestler et al have previously shown that lowering serum 
insulin levels with metformin therapy in obese women reduced LH concentrations, and also 
decreased GnRH-stimulated 17OHP levels (Nestler and Jakubowicz, 1996); the same group 
found similar benefits in lean PCOS women in a separate study (Nestler and Jakubowicz, 
1997).  Weight loss may also have significant benefits on circulating androgen burden in 
PCOS (Ernst et al., 2013, Jakubowicz and Nestler, 1997). This may reflect an amelioration of 
underlying insulin resistance, reduced adiposity or both. The complexity of the associations 
between hyperandrogenism and metabolic dysfunction in PCOS are highlighted by a recent 
study from Moghetti et al. Metabolic inflexibility, or impaired ability to shift substrate 
metabolism from predominantly lipid oxidation in fasting states (low serum insulin) towards 
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predominant glucose oxidation in the fed state, was worst in hyperandrogenic PCOS women 
(Di Sarra et al., 2013) (Figure 1-13); however, normo-androgenic PCOS women were still 
metabolically ‘inflexible’ compared to controls, suggesting the interplay of other poorly-
understood factors. 
 
 
Figure 1-13 Metabolic inflexibility in hyperandrogenic and normo-androgenic PCOS women 
compared to controls (Di Sarra et al., 2013). Although worst in hyperandrogenic women, 
normo-androgenic women also had lower metabolic flexibility than controls. Reproduced 
with permission from the Endocrine Society.  
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 Some studies have shown a strong correlation between urinary indices of systemic 5α-
reductase activity and insulin resistance; this association appears to be independent of BMI 
(Vassiliadi et al., 2009, Tsilchorozidou et al., 2003), and is observed in both lean and obese 
PCOS subjects (Tomlinson et al., 2008a). The effects of insulin sensitization on peripheral 
androgen and cortisol metabolism were studied by Glintborg et al (Glintborg et al., 2009). 
The effects of 16 weeks of insulin sensitization with pioglitazone were compared to those of 
placebo treatment; pioglitazone treatment significantly decreased relative 5αR activity as 
measured by 5allo-THF/THF ratio. No significant changes were observed in the An/Et ratio 
or in markers of glucocorticoid metabolism.  
 
1.5.1.3 Insulin and adrenal androgen metabolism 
 There is also some evidence of interaction between the insulin/glucose axis and 
adrenocortical dysfunction in PCOS. Circulating DHEAS levels decreased by between 18 and 
26% in 305 women treated with the insulin-sensitising agent troglitazone for 20 weeks (Azziz 
et al., 2003). Similarly, pioglitazone reduced adrenal androgen response to CRH in insulin-
resistant women with PCOS (Romualdi et al., 2007); pioglitazone administration for 6 months 
was separately shown to reduce 17OHP and A responsiveness to ACTH stimulation in obese 
PCOS patients (Guido et al., 2004). Insulin infusion enhances 17OHP secretion after ACTH 
administration in hyperandrogenic women (Moghetti et al., 1996). This effect was likely due 
to upregulation of CYP17A1 activity, with greater proportional upregulation of androgen-
generating 17, 20-lyase than 17α-hydroxylase activity. In obese adolescents with PCOS and 
IGT, insulin sensitization with metformin attenuated the exaggerated pre-treatment adrenal 
androgen response to ACTH stimulation (Arslanian et al., 2002). In vitro, insulin, IGF-1 and 
IGF-2 stimulated adrenal androgen generation by upregulating ACTH receptor expression in 
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primary human adrenal reticularis cells (l'Allemand et al., 1996). However McKenna and 
colleagues found no significant effect of insulin or IGF-1 on adrenal steroidogenesis in 
isolated guinea-pig adrenal cells (O'Connell et al., 1994).  
 
1.5.2 Evidence linking primary androgen excess with insulin  resistance   
1.5.2.1 Premature adrenarche and metabolic disease 
 There is strong evidence that early androgen exposure is causally linked to the 
development of metabolic dysfunction in women. Premature adrenarche (PA) and premature 
pubarche (PP) are risk factors for subsequent development of PCOS, insulin resistance and 
early onset of metabolic disturbance. American-Hispanic girls who presented with signs of PP 
were noted to be insulin resistant (Oppenheimer et al., 1995). Ibanez and colleagues have 
looked extensively at the association between insulin resistance and PP. Impaired insulin 
sensitivity appears to be a consistent finding in multiple studies (Ibanez et al., 1996, Ibanez et 
al., 1997); dyslipidaemia has also been documented in Catalonian PP girls, coupled with other 
adverse cardiovascular markers such as increased waist-to-hip ratio and central fat 
accumulation (Ibanez et al., 1998, Ibanez et al., 2003). Early androgen exposure also has 
potential associations with increased blood pressure (Teixeira et al., 2004). The potential role 
of androgens in fat distribution and adipose tissue function will be discussed in detail in 
section 1.7. 
 PP has a strong association with development of PCOS in subsequent years. PCOS 
was identified in 45% of Catalonian girls with a history of PP in one study (Ibanez et al., 
1993). PP has links to both ovarian and adrenal hyperandrogenism; girls with a history of PP 
had exaggerated androgen responses to both GnRH analogues and ACTH stimulation, and 
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responses to both correlated with serum insulin levels (Ibanez et al., 1996). Interestingly, PA 
and androgen excess due to sulfation defects in families harboring PAPPS2 mutations is 
strongly associated with metabolic disturbance and PCOS (Oostdijk et al., 2015, Noordam et 
al., 2009). It is also tantalizing that heterozygosity for the culprit mutation has been linked 
with PCOS and ovulatory dysfunction in apparently unaffected female family members in 
both studies. This provides strong evidence for a causal role of androgens in the development 
of metabolic disease and polycystic ovaries. There is a need for carefully controlled 
prospective longitudinal studies to unravel this association between early onset androgen 
excess and metabolic disturbance. 
 
1.5.2.2 Prenatal androgen excess and metabolic disturbance 
 Animal data highlights a key role for androgens in prenatal fetal metabolic 
programming. Studies have consistently identified the consequences of fetal androgen 
exposure in utero on early postnatal and long-term metabolic health of offspring. Prenatal 
androgenisation in multiple animal models has been shown to confer metabolic, reproductive 
and endocrine disturbances similar to PCOS (Walters et al., 2012, Padmanabhan and Veiga-
Lopez, 2013). Mice treated prenatally with DHT developed ovarian cysts, ovulatory 
dysfunction and increased adipocyte size (Caldwell et al., 2015). AR knock-out (ARKO) mice 
in the same study were protected from adipocyte hypertrophy. This highlights the key role 
played by androgens and adipose tissue in metabolic disturbances in PCOS. Prenatal 
treatment of female mice with 250µg DHT pellets between days 16 and 18 of pregnancy 
induced reproductive-metabolic abnormalities in female offspring (Roland et al., 2010). 
Metabolic disturbances included increased visceral adipocyte size, elevated fasting glucose 
and impaired glucose tolerance. In rats, prenatal exposure to a single dose of testosterone 
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(5mg at gestational day 20) resulted in increased weight and insulin resistance in female 
offspring, with differences compared to controls evident at days 30, 45, 60 and in adulthood 
(Tehrani et al., 2014). Similar findings have been reported in monkey, sheep and rat models 
of PCOS (Abbott et al., 2005, Yan et al., 2013, Padmanabhan et al., 2010). 
 It is much more difficult to study human models of prenatal androgen exposure. 
However, as in animals, the intrauterine environment is likely to play a critical role in fetal 
metabolic programming, growth and development. A prospective study of infants born to 
women with PCOS highlighted an increased prevalence of small for gestational age (SGA) 
infants compared to infants born to non-PCOS women (Sir-Petermann et al., 2005). Dunaif 
and colleagues found lower umbilical cord levels of serum androstenedione in infants of 
women with PCOS compared to controls (Anderson et al., 2010); this finding does not 
support the hypothesis that intrauterine androgen excess contributes to the development of 
PCOS. However, another study found that serum levels of anti-mullerian hormone (AMH) 
and ovarian androgens were reduced in infancy in daughters of PCOS women treated with 
metformin throughout pregnancy compared to metformin-naïve PCOS controls (Crisosto et 
al., 2012). This provides a fascinating insight into the prenatal role of insulin and androgens in 
fetal reproductive-metabolic development.  
 
1.5.2.3 In vivo evidence linking primary hyperandrogenism with metabolic disturbance 
 Insulin resistance is highly prevalent in female patients with CAH. However as 
discussed above, the confounding effects of treatment with glucocorticoids in patients with 
classic CAH means that women with non-classic CAH represent a pharmacologically 
‘cleaner’ group in whom to define the effects of androgen excess on metabolism; most 
patients are diagnosed in adulthood, and have a relatively short history of glucocorticoid 
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treatment (if any at all). Speiser found evidence of reduced insulin sensitivity in 6 females 
with non-classic CAH compared to age and BMI-matched controls (Speiser et al., 1992); 
none of the CAH patients were receiving glucocorticoid treatment at the time. Other studies 
have also found a close correlation between hyperinsulinaemia and androgen excess in newly-
diagnosed untreated adult female CAH patients compared to healthy controls (Saygili et al., 
2005, Zhang et al., 2010).  
 Children of both sexes diagnosed with non-classical CAH may also at risk of 
metabolic disturbance even by the end of the first decade of life (Williams et al., 2010). 
Insulin resistance and reduced lean body mass in these young non-classical CAH cohort are 
likely to indicate the adverse metabolic effects of early androgen exposure rather than long-
term glucocorticoid treatment. In one study, adolescents with non-classical CAH also already 
showed early signs of derangements in vascular intima media thickness, indicating a possible 
role of androgens in the pathogenesis of cardiovascular disease (Wasniewska et al., 2013). 
 There is also some evidence linking androgen treatment with metabolic disturbance in 
patients undergoing female-to-male gender reassignment, although data have shown 
conflicting results. T dosages administered to female-to-male transsexuals are similar to those 
administered to men with hypogonadism. One study showed that glucose utilization (a marker 
of peripheral insulin sensitivity) on hyperinsulinaemic euglycaemic clamp was reduced in 
female-to-male gender reassignment patients after 4 months of T treatment (Polderman et al., 
1994). Baseline indices of insulin sensitivity were unaffected by 12 months of T therapy in a 
separate study (Elbers et al., 2003). However, methyltestosterone administration to healthy 
women significantly reduced whole-body glucose uptake during high-dose insulin infusion in 
another clamp study (Diamond et al., 1998). T treatment may also result in a decline in serum 
levels of HDL cholesterol (Asscheman et al., 1994). Further longitudinal studies are required 
Chapter 1               General Introduction 
 57 
to tease out these associations. It is also notable that polycystic ovaries are a universal finding 
after long-term androgen exposure (>18 months) in such patients (Gooren and Giltay, 2008). 
Histological findings include thecal hyperplasia, luteinization and stromal hyperplasia.  
 
1.5.2.4 Direct effects of androgens on tissue-specific insulin sensitivity 
 Relatively few human or animal studies have directly examined the effects of 
androgens on insulin and glucose metabolism in target tissues of insulin action. T treatment 
for 48 hours significantly reduced insulin-stimulated glucose uptake in differentiated 
subcutaneous adipocytes of premenopausal women in one small human study (Corbould, 
2007) (Figure 1-14). The observed defects were independent of PI3K activation and were 
ameliorated by androgen receptor blockade. Studies of androgen-induced effects on skeletal 
muscle insulin sensitivity are also sparse in humans. One study found that T exposure ex vivo 
significantly increased androgen receptor and aromatase gene expression in myotubes from 
both PCOS and control women, but exerted no effects on insulin-mediated glucose disposal 
(Eriksen et al., 2014). In animals, T treatment of female rats for between 8 and 12 weeks 
caused hyperinsulinaemia in both intact and ovariectomised animals (Holmang et al., 1990); 
in the ovariectomised group, T treatment was associated with a 50% reduction in insulin-
stimulated glucose uptake into skeletal muscle.  
 
 
 
 
Chapter 1               General Introduction 
 58 
 
Figure 1-14 Effects of testosterone on insulin-stimulated glucose uptake in differentiated 
female subcutaneous adipocytes. Testosterone reduced glucose uptake in a dose-dependent 
fashion; effects were reversed after AR blockade (not shown) (Corbould, 2007). Reproduced 
with permission from BioScientifica Ltd.  
 
1.6 Adipose tissue 
1.6.1 Adipose tissue embryology and morphology  
 Human adipose tissue (fat) development begins in utero during the second trimester of 
pregnancy. In the fetus, adipose tissue develops from the embryonic mesenchyme 
(Greenwood and Johnson, 1977). Adipose tissue consists of lipid-containing adipocytes, and a 
stromal-vascular compartment containing fibroblast-like preadipocytes, supported by a matrix 
of collagen fibres (Poissonnet et al., 1984). Fetal fat includes both white (WAT) and brown 
adipose tissue (BAT); the latter is multi-locular, localized around the neck and interscapular 
region, and a crucial player in fetal thermoregulation. Most BAT is lost in early childhood, 
although small depots persist into adulthood, located in the cervical, supraclavicular, 
paravertebral, mediastinal, para-aortic and supra-renal regions (Nedergaard et al., 2007). BAT 
appears to correlate negatively with adverse metabolic risk and obesity, and is positively 
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associated with increased energy expenditure and, by inference, weight loss (Nedergaard and 
Cannon, 2013). The sections below will focus on WAT biology.  
 WAT is organised in various distinct anatomical locations, notably in the 
subcutaneous (SC) fat depot and the intra-abdominal fat depot. These depots are considered to 
be metabolically distinct, and intra-abdominal fat accumulation is a potent risk factor and 
surrogate marker for metabolic disease, including insulin resistance, dyslipidaemia and 
NAFLD (Kranendonk et al., 2015). In adulthood, SC WAT exhibits a sexually dimorphic 
pattern of distribution; in females, adipose tissue is preferentially accumulated in the 
gluteofemoral region, while men predominantly accumulate fat in the abdominal (central) 
region (Varlamov et al., 2014).  Intra-abdominal fat is distributed across the omental, 
retroperitoneal and peri-renal depots. A substantial portion of intra-abdominal WAT is also 
located around the intestines, liver and other intra-abdominal organs, and is referred to 
visceral fat (Gesta et al., 2007). The key processes of adipose tissue expansion are hyperplasia 
and hypertrophy. Hyperplasia (also called adipogenesis) refers to an increase in fat cell 
number; this process is driven by (i) preadipocyte proliferation and (ii) adipocyte 
differentiation. Fat cell hypertrophy is an increase in adipocyte size as a consequence of 
intracellular lipid accumulation. These processes are tightly regulated by a complex system of 
intracrine and paracrine factors, and are crucial mediators of metabolic health in humans. 
 
1.6.2 Adipose tissue proliferation 
 Mesenchymal stem cells (MSCs) are multipotent, with potential to differentiate into a 
variety of different tissues, including bone, adipose and muscle. After commitment to the 
adipocyte lineage, MSCs are transformed into fibroblast-like preadipocytes (Figure 1-15). The 
preadipocyte pool is located in the stromal-vascular compartment of mature adipose tissue. 
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Clonal expansion of the preadipocyte pool appears to occur in three stages; firstly with MSC 
commitment to the preadipocyte lineage, secondly as preadipocyte proliferation, and lastly via 
another later round of proliferation after the process of differentiation has begun. The 
potential to generate new fat cells from preadipocytes persists throughout life, although the 
number of cells capable of differentiating reduces significantly with age (Bjorntorp, 1979). 
Adipogenesis is tightly regulated by a complex network of endocrine, paracrine and 
nutritional factors. 
   
  
Figure 1-15 The process of adipogenesis, from MSC commitment to the preadipocyte lineage, 
followed by preadipocyte proliferation and differentiation into mature adipocytes, leading to 
adipose hyperplasia. The processes of lipid accumulation and mobilization are delicately 
balanced; increased accumulation results in adipocyte hypertrophy.  
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 Preadipocytes isolated in vitro from the stromal-vascular compartment of adipose 
tissue may be subdivided into those already committed to differentiation, and those 
comprising a persistently replicating subgroup of fibroblast-like cells (Entenmann and 
Hauner, 1996). Adipocytes themselves are capable of stimulating preadipocyte proliferation 
in a paracrine fashion, and this capacity appears to be increased in obese individuals 
(Considine et al., 1996). Furthermore, specific WAT depots may exhibit greater preadipocyte 
proliferation potential than others. Preadipocytes from visceral fat depots produce greater 
quantities of basic fibroblast growth factor (bFGF) compared to their SC WAT counterparts, 
thereby increasing proliferation potential (Teichert-Kuliszewska et al., 1992). This may 
explain the increased expansion potential observed in omental and visceral adipose tissue. 
 
1.6.3 Adipose tissue differentiation 
 Preadipocytes differentiate into mature adipocytes via a meticulously regulated 
process, which is modulated by both stimulatory and inhibitory signals (Farmer, 2006). The 
key step in the adipocyte differentiation process appears to be preadipocyte growth arrest; cell 
confluence or cell-to-cell contacts appear to be of less importance (Reichert and Eick, 1999). 
Differentiation can be divided into two stages. In the initial step (commitment), growth arrest 
takes place, and morphological changes are observed, with altered cytoskeleton and 
extracellular matrix (ECM) (Amri et al., 1986). The net effect is a change in appearance of the 
stellate-shaped preadipocytes into a more spherical cellular structure. Early markers of 
differentiation include expression of lipoprotein lipase (LPL) (Grimaldi et al., 1979). The 
second phase of adipocyte differentiation is associated with expression of late markers such as 
glycerol-3phosphate dehydrogenase (G3PDH); maturing adipocytes begin to accumulate 
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multiple small lipid droplets, which ultimately coalesce into a single large unilocular lipid 
droplet upon maturity.  
 In the initial phase of differentiation, cytoskeletal changes precede the expression of 
adipocyte transcription factors (Spiegelman and Farmer, 1982). Cytoskeletal changes 
ultimately producing the spherical-shaped mature adipocyte may therefore not depend on 
intracellular lipid accumulation. Initiation of differentiation depends on a shift in the delicate 
balance between the multiple stimulatory and inhibitory signals that regulate adipogenic 
transcription factors. Cytoskeletal and ECM changes are associated with specific changes in 
expression of key genes; for example fibroblast-expressed type I and type III collagen are 
suppressed, while α2-collagen type IV gene expression is significantly increased (Ailhaud et 
al., 1989). Similarly, pre-adipocyte factor 1 (pref-1) is a transmembrane protein which 
maintains the preadipocyte phenotype and suppresses differentiation by inhibiting peroxisome 
proliferator activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein 
(C/EBP)α expression (Berry et al., 2012, Smas and Sul, 1997); pref-1 gene expression is 
entirely abolished across differentiation.  
 PPARγ is the principal transcriptional regulator of adipogenesis, and its expression is 
reliant on the C/EBP family of transcription factors. Adipogenesis is completely inhibited in 
PPARγ-knockout mice (Kubota et al., 1999); in humans, activating missense mutations in the 
PPARγ2 splice variant result in accelerated differentiation and severe obesity (Ristow et al., 
1998). Expression of PPARγ and C/EBPα is high throughout differentiation, and remains high 
in the mature adipocyte. Another crucial player in adipocyte differentiation is the sterol-
regulatory element binding protein-1 (SREBP) subclass of transcription factors (Sewter et al., 
2002). SREBP-1c acts directly to enhance the transcriptional activity of PPARγ (Fajas et al., 
1999). It also plays a major role in fatty acid metabolism. 
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 In the late stages of preadipocyte differentiation, mRNA and protein expression of 
enzymes involved in key metabolic functions of the adipocyte are significantly upregulated. 
Induction of INSR and GLUT-4 gene expression result in increased insulin sensitivity 
(Serrano et al., 2005). Mirroring this, there is a massive increase in expression of genes 
involved in lipid metabolism; these enzymes are integral to lipid flux in the adipocyte, and 
control such processes as de novo lipogenesis, FFA uptake, β-oxidation and lipolysis. These 
enzymes include fatty acid synthase (FAS), Acetyl Coenzyme A Carboxylase (ACC), LPL 
and hormone sensitive lipase (HSL). Expression of G3PDH is also a marker of terminal 
adipocyte differentiation. Lipid metabolism is discussed in detail in section 1.6.4. 
 
1.6.3.1 Hormonal regulation of adipogenesis 
 The process of adipogenesis is also governed by a number of important hormones. 
Insulin is a key player in adipocyte differentiation, increasing the proportion of differentiating 
preadipocytes, as well as playing a major role in adipocyte lipid accumulation (see below). 
INSR expression is low in the early stages of adipogenesis; insulin action is therefore 
mediated via the IGF-1 receptor (Smith et al., 1988). In 3T3-L1 cells, INSR expression 
increases from 3,000-20,000 receptors per cell early in adipogenesis to 170,000-250,000 
receptors in the mature adipocyte (Turnbow et al., 1994). INSR activation leads to rapid 
phosphorylation of IRS-1, ultimately leading to stimulation of the PI3K and MAP kinase 
pathways. Depot-specific differences in both INSR and IRS-1 expression have been observed 
in obese females, with increased expression, binding and activation observed in femoral 
compared to omental adipocytes (Bolinder et al., 1983). Thyroid hormone also stimulates 
adipocyte differentiation (Flores-Delgado et al., 1987). Tri-iodothyronine (T3) modulates both 
proliferation and differentiation to adipocytes (Darimont et al., 1993). Mice with mutated 
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thyroid hormone-α1 receptor (TRα1) have reduced WAT mass across a variety of depots; this 
appears to be due to repression of PPARγ and C/EBPα expression, resulting in impaired 
adipogenesis (Ying et al., 2007).  
 Adipogenesis is also potently induced by glucocorticoids in the presence of insulin 
(Hauner et al., 1987). Patients with Cushing’s syndrome due to endogenous glucocorticoid 
excess, or with iatrogenic disease due to exogenous glucocorticoid treatment, have increased 
visceral adiposity. Glucocorticoids stimulate transcription of a number of important 
adipogenic genes, including G3PDH and LPL (Hauner et al., 1989). In vitro, synthetic 
glucocorticoids are an essential tool in primary adipocyte culture and in fat cell lines, 
stimulating differentiation from preadipocytes to adipocytes. Key pro-adipogenic 
transcription factors such as C/EBPs and PPARγ, are upregulated by glucocorticoids (Vidal-
Puig et al., 1997); conversely, the anti-adipogenic factor pref-1 is transcriptionally repressed 
by the potent synthetic glucocorticoid dexamethasone (Smas et al., 1999). Glucocorticoid 
effects on adipogenesis appear to be mediated via the glucocorticoid receptor (GR) (Ottosson 
et al., 1995). 
 
1.6.4 Adipocyte lipid metabolism 
 Adipocytes are, first and foremost, lipid-storing cells. Lipid flux refers to the delicate 
balance between lipid accumulation, mobilization and utilization in the adipocyte (Figure 
1-16). When this balance is tipped in favour of lipid accumulation over lipid breakdown, the 
net result is adipocyte hypertrophy. Lipid flux is tightly regulated as part of a complex 
metabolic pathway, and is dependent on factors such as nutritional status, caloric intake, 
insulin sensitivity and various lipogenic and lipolytic stimuli. The key processes in adipocyte 
lipid metabolism are summarized in the sections below. 
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Figure 1-16 Lipid flux in the adipocyte. Lipid metabolism is a balance between lipid 
accumulation on the right and lipid breakdown on the left. The main processes driving lipid 
accumulation are free fatty acid (FFA) uptake, re-esterification of FFAs with glycerol to form 
triacylglycerol (TAG), generation of glycerol from glucose (glycolysis), and de novo synthesis 
of TAG. The main pathways of lipid mobilization are lipolysis, the end products of which are 
FFAs and glycerol, and β-oxidation, by which FFAs are broken down to generate energy in 
the mitochondrion. 
 
1.6.4.1 Adipose lipogenesis 
 Adipose lipogenesis (Figure 1-17) occurs as a consequence of either re-esterification 
of dietary-derived FFAs with glycerol to form TAG, or generation of TAG within the 
adipocyte from de novo fatty acid synthesis (Gathercole et al., 2011). De novo fatty acid 
synthesis may account for up to 20% of adipocyte triglyceride turnover (Strawford et al., 
2004). Acetyl CoA is produced in the adipocyte mitochondria and is combined with 
oxaloacetate by citrate synthase to form citrate. Citrate moves from the mitochondria to the 
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cytosol, where citrate lyase releases oxaloacetate and acetyl coA. The latter is then 
carboxylated to malonyl CoA in an ATP-dependent reaction by ACC1. This is the first and 
rate-limiting step in fatty acid synthesis. Malonyl CoA is subsequently converted by a multi-
step reaction to the fatty acid palmitate by fatty acid synthase (FAS) (Ruderman et al., 2003). 
TAG is then formed by the esterification of three fatty acid chains to one glycerol-3-
phosphate molecule. In the fed state, when insulin and glucose are abundant, glycerol-3-
phosphate is derived from glucose by G3PDH via glycolysis. In the fasted state, glycerol-3-
phosphate may be generated by glyceroneogenesis.  
 
 
 
 
 
 
 
Chapter 1               General Introduction 
 67 
 
Figure 1-17 Adipocyte lipid metabolism. The balance between lipid uptake (purple arrows), 
lipogenesis (blue arrows) and lipolysis (green arrows) is tightly regulated. Extracellular 
glucose is also be taken up by the adipocyte to generate glycerol-3-phosphate via the 
glycolytic pathway (black arrows), and free fatty acids are oxidized in the mitochondrion to 
generate energy (red arrow). ACC1, acetyl coA carboxylase I; ACC2, acetyl coA carboxylase 
2; AMPK, AMP-kinase; ATGL, adipose triglyceride lipase; CPT1, carnitine palmitoyl 
transferase I; CL, citrate lyase; DAG, diacylglycerol; FFA, free fatty acid; GPAT, glycerol-3-
phosphate acyltransferase; G3PDH, glycerol-3-phosphate dehydrogenase; HSL, hormone 
sensitive lipase; LPL, lipoprotein lipase. MGL, monoglyceride lipase; VLDL, very-low 
density lipoprotein. 
 
 ACC1 is highly post-transcriptionally regulated. As well as its role as a precursor of 
acetyl CoA, cytosolic citrate is an allosteric activator of ACC. ACC1 mRNA expression is 
increased by glucose and insulin in physiological situations of fuel surplus, eg the ‘fed’ state. 
The regulatory effects of insulin on ACC1 are mediated by transcription factors such as 
SREBP1c and FOXO (Zhang et al., 2003). Protein levels of ACC1 are also susceptible to 
Chapter 1               General Introduction 
 68 
proteasomal degradation and ubuiqitination. Tribbles 3 (TRB3) is a pseudokinase which 
targets ACC for ubuiqitination (Qi et al., 2006); levels of TRB3 increase in the fasted state 
(Du et al., 2003), thereby reducing ACC protein levels and encouraging lipid mobilization 
rather than accumulation in states of reduced cellular fuel availability. AMP-Activated Protein 
Kinase (AMPK) is a crucial inhibitor of ACC1 activity (Ruderman et al., 2003), and is also 
activated by decreases in the energy state of the cell. This low-fuel state is indicated by 
increases in the AMP/ATP ratio. AMPK phosphorylates ACC1 at Ser79, 1200 and 1215, 
negatively regulating its activity. Additionally, activated AMPK inhibits allosteric activation 
of ACC by citrate.  
 Insulin and glucose can reverse the negative regulation of ACC by AMPK in the fed 
state, both by increasing cytosolic citrate concentrations and reducing AMPK activity (Itani et 
al., 2003).  Insulin and glucose increase expression of G3PDH, thereby increasing glycerol-3-
phosphate synthesis, with a secondary increase in adipocyte TAG generation (Moustaid et al., 
1996). Insulin is also a potent stimulator of FAS mRNA expression and activity in adipose 
tissue, leading to increased generation of palmitate from malonyl CoA.     
 
1.6.4.2 Lipolysis 
 In the fasted state, TAG stored in WAT is mobilized to produce FFAs, thereby acting 
as the body’s major energy reserve. TAG is hydrolysed in the fasted state, releasing FFAs and 
glycerol; this is possible in the setting of low glucose and insulin levels (Masoodi et al., 
2015). The main enzymes facilitating intra-adipocyte lipolysis are adipose triglyceride lipase 
(ATGL), HSL and monoglyceride lipase (MGL) (Figure 1-17). ATGL catalyses the initial 
step in TAG hydrolysis and is the rate-limiting step (Haemmerle et al., 2006); HSL catalyses 
the hydrolysis of TAG into diacylglycerols (DAG) and then monoacylglycerols (MAG); 
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MGL removes the final FFA group to release glycerol (Zechner et al., 2012). The lipolytic 
process is tightly regulated. The enzymes involved in lipolysis are located in droplets called 
adiposomes, located within the adipocyte, and can interact with other cellular structures such 
as mitochondria, peroxisomes and the endoplasmic reticulum via these adiposomes.  
 Lipolysis is stimulated via activation of adipose β-adrenoreceptors; this leads to 
increased intracellular cAMP levels, which in turn activates protein kinase A (PKA). PKA 
then phosphorylates HSL, facilitating translocation of the enzyme from the cytosol to the 
surface of the lipid droplet (Clifford et al., 1997). PKA also phosphorylates proteins called 
perilipins. In the non-phosphorylated state, perilipins form a protective barrier around the 
adipocyte lipid droplet, protecting it from the lipolytic action of HSL (Brasaemle et al., 2000). 
After phosphorylation by PKA, perilipins are removed from the droplet surface and HSL can 
hydrolyse its lipid substrate. Other crucial regulators of lipolysis include insulin and 
glucocorticoids. Insulin lowers intracellular levels of cAMP, thereby preventing PKA-induced 
phosphorylation of HSL, thereby suppressing lipolysis. Glucocorticoids are potent drivers of 
lipolysis through effects on HSL and ATGL (Zammit, 1999, Villena et al., 2004). 
 
1.6.4.3 Glyceroneogenesis and re-esterification 
 FFAs are released from adipocytes as part of the lipolytic process, serving as fuel for 
extra-adipose body tissues. Serum FFA levels play a crucial role in metabolic disease, and 
levels are consistently elevated in obesity, representing a ‘spill-over’ process in the setting of 
excess adiposity (Carpentier et al., 2002). Increased circulating FFAs may have consequences 
for whole-body insulin sensitivity, with effects on glucose metabolism in liver, muscle and 
peripheral tissues (Shulman, 2014, Thompson et al., 2000). FFAs exert effects on insulin 
action due to a number of inhibitory effects at crucial points in the insulin signaling pathway. 
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These include reduced phosphorylation and activation of akt, IRS-1 and PI3K (Kim et al., 
2002). This suggests that FFAs may play a prominent role in the link between obesity and 
insulin resistance. Increased insulin resistance then leads to an inability to adequately 
suppress adipose lipolysis in the fed state, leading to a vicious circle of lipolysis, FFA release 
and impaired insulin sensitivity.  
 Re-esterification of some FFAs into TAG may occur in the fasted state, even when 
lipolysis predominantes (Lisch et al., 1973). Glycerol-3-phosphate is required for this process 
of re-esterification, but it cannot be generated from glucose by the glycolytic action of 
G3PDH in the fasted state due to reduced glucose availability. Adipocytes also cannot recycle 
glycerol after lipolysis to fuel this process, although this is possible in the liver due to 
expression of the enzyme glycerol kinase. Glyceroneogenesis refers to the process whereby 
adipocytes generate glycerol-3-phosphate via dihydroxyacetone phosphate (DHAP) from 
lactate, pyruvate and amino acids (Ballard and Hanson, 1967). A crucial enzyme in this 
pathway is phosphoenolpyruvate carboxykinase (PEPCK), which converts oxaloacetate into 
phosphoenolpyruvate and carbon dioxide. Inhibition of this enzyme by insulin underpins the 
latter’s role in suppression of glyceroneogenesis (Franckhauser et al., 2002). This means that, 
in the postprandial state, insulin ensures that the glycerol-3-phosphate required for de novo 
lipogenesis is derived from the glycolytic pathway rather than from glyceroneogenesis. In 
conditions of absolute insulin deficiency, such as T1DM, failure of this controlled system 
means that glycerol (and body fuel) is generated from the breakdown of lactate, pyruvate and 
amino acids, leading to generation of ketones and potential metabolic acidosis.  
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1.6.4.4 FFA uptake 
 Adipocytes take up dietary-derived FFAs, as well as those released by the liver. 
Together with de novo lipogenesis, this represents the second major source of FFAs for TAG 
synthesis by the adipocyte. Dietary TAG is digested by pancreatic lipase in the upper segment 
of the jejunum, releasing glycerol and FFAs. FFAs are taken up from the intestinal lumen by 
the enterocytes, and packaged into chylomicrons. These are large, spherical, TAG-rich 
particles, composed of an inner lipoprotein core of TAG, cholesteryl esters and fat–soluble 
vitamins; the surface consists a hydrophilic coating of phospholipids and apoplipoproteins 
(Abumrad and Davidson, 2012). Chylomicrons are exported from the enterocyte via the ER 
into the lymphatic system, from where they enter the circulation and target tissues such as 
muscle and heart for fuel, or adipose tissue for storage.  TAG generated in the liver due to 
hepatic lipogenesis is packaged as very-low density lipoprotein (VLDL), which, like 
chylomicrons, contains TAG, cholesterol esters, phospholipids and apolipoproteins (Mayes, 
1970).  
 TAG transported in circulation in VLDL and chylomicrons cannot cross the adipocyte 
cell membrane, and must be hydrolysed to release FFA and glycerol. This reaction is 
catalyzed by lipoprotein lipase (LPL) (Li et al., 2014). LPL is expressed and secreted by 
adipocytes, and after synthesis is translocated to the vascular lumen of adipose blood vessels. 
FFA released by LPL may enter the adipocyte by simple diffusion, or via specific membrane 
transporters such as fatty acid transporter protein (FATP) (Abumrad et al., 1999), fatty acid 
translocase (FAT) (Hanssler et al., 1992) and caveolin-1 (Trigatti et al., 1999). After uptake 
into the adipocyte, FFAs may be esterified to acyl CoA by acyl CoA synthetase (ACS) 
(Hames et al., 2015), thereby preventing FFA diffusion back out of the adipocyte. FFAs are 
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bound to key fatty acid binding proteins, such as Fatty Acid Binding Protein 4 (FABP4) in the 
adipocyte cytoplasm, which facilitate their transport to important intracellular targets.  
 In its role as a promoter of lipid storage and accumulation, insulin drives FFA uptake 
into adipocytes by increasing adipocyte LPL expression and endoluminal activity (Rosato et 
al., 1997). PPARγ is a potent transcriptional activator of LPL expression, and expression of 
the former is upregulated by insulin (Vidal-Puig et al., 1996). Additionally, insulin stimulates 
adipocyte ACS transcription, favouring conversion of FFAs to acyl CoA and thereby 
preventing diffusion of FFAs out of the adipocyte (Kansara et al., 1996). 
 
1.6.4.1 β-oxidation 
 β-oxidation is the process by which fatty acyl CoAs are broken down in the 
mitochondria to generate NADH, FADH2 and acetyl CoA. This occurs in the fasted state 
when fuel availability is reduced. After feeding, insulin suppresses further β-oxidation. Acetyl 
CoA generated via this process may then enter the Krebs cycle to produce ATP. The rate-
limiting step in β-oxidation is the transport of fatty acyl CoA into the mitochondria by 
carnitine palmitoyltransferase I (CPT1) (Frayn, 2010). CPT1 is located in the outer 
mitochondria membrane, where it generates acyl carnitine by transfer of the fatty acid chain 
to a carnitine molecular. Acyl carnitine enters the inter-membrane space, and is transported 
across the inner membrane into the mitochondrion by carnitine-acylcarnitine translocase 
(CAT). Inside the mitochondria, carnitine palmitoyl transferase 2 (CPT2) regenerates fatty 
acyl CoA, which then enters a series of reactions to generate FADH2, NADH and acetyl CoA. 
FADH2 and NADH generate two and three ATP molecules respectively, while acetyl CoA 
enters the Kreb’s cycle, ultimately generating 12 ATP molecules.  
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 ACC2 is the major negative regulator of β-oxidation; it inhibits CPT1 action in the 
outer mitochondrial membrane by generating malonyl CoA. In the fed state, insulin stimulates 
ACC transcription, thereby suppressing β-oxidation and promoting lipid storage. ACC2, like 
ACC1, is itself negatively regulated by AMPK, which promotes β-oxidation and lipid 
mobilization. 
 
1.7 Adipose tissue and androgens 
 Adipose tissue is a crucial target of androgen action in humans and primates 
(Varlamov et al., 2012), and AR expression, binding and activation in adipose tissue are well-
characterised (Deslypere et al., 1985, Feher et al., 1976). Androgen action in adipose tissue 
may in part explain sexual dimorphism in patterns of body fat distribution (Nedungadi and 
Clegg, 2009, Pond, 1992). Men preferentially accumulate fat in an abdominal or android 
distribution, and have a significantly greater proportion of intra-abdominal or visceral fat 
compared to females (Lemieux et al., 1993). In contrast, women typically have a greater 
proportion of peripheral and subcutaneous fat, particularly in the gluteofemoral depot (Wells, 
2007). Abdominal, and particularly visceral, fat is a critical mediator of metabolic dysfunction 
and is associated with dyslipidaemia and metabolic syndrome, thereby conferring an 
increased risk of T2DM and cardiovascular disease (Despres and Lemieux, 2006, Despres, 
2006, Smith et al., 2001). This male predisposition to accumulate visceral fat is a major 
determinant of increased metabolic risk and IR in men compared to women (Frias et al., 2001, 
Yki-Jarvinen, 1984, Soeters et al., 2007).  In addition to its role as a target organ of androgen 
action, adipose tissue is also increasingly recognized as an important modulator of pre-
receptor metabolism, regulating its exposure to androgens in an autocrine manner (Quinkler et 
al., 2004, Blouin et al., 2003).  
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 However the precise molecular biology and metabolism of androgens in adipose tissue 
is complex, with local exposure regulated by a large network of activating and inactivating 
enzymes (Labrie, 1991). Delineation of specific pathways has proven divisive and many data 
have shown conflicting results. This field is further complicated by the sex-specific and 
depot-specific behaviour of steroids in adipose tissue (Blouin et al., 2005, Blanchette et al., 
2005, Bujalska et al., 2002). It is clear for many years, however, that adipose tissue is capable 
of both active androgen synthesis and inactivation (Bolt and Gobel, 1972), and that androgens 
themselves modulate adipose tissue function (Hansen et al., 1980). Androgen metabolism and 
action in adipose tissue may be differentially regulated in men and women, and in different 
body fat depots.  
 
1.7.1 Effects of androgens on adipose tissue function 
 As discussed above, the key processes of adipose tissue expansion are hyperplasia and 
hypertrophy. Hyperplasia (or adipogenesis) refers to an increase in fat cell number and is 
determined by (i) preadipocyte proliferation and (ii) adipocyte differentiation. Fat cell 
hypertrophy implies an increase in adipocyte size due to intracellular lipid accumulation.  
Adipogenesis and lipid flux may both be influenced by androgen action, thereby controlling 
regional fat mass and adipose tissue function. Some of these processes are discussed below 
and summarized in Table 1-5 below. 
 In men, central fat accumulation has an inverse relationship with circulating T levels 
in both cross-sectional (Pasquali et al., 1991) and longitudinal studies (Gapstur et al., 2002). 
This may be driven by reduced SHBG in the context of abdominal obesity and insulin 
resistance; the same studies show an inverse association between waist circumference and 
SHBG levels. Visceral fat accumulation on computed tomography (CT) scanning has a strong 
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negative correlation with serum SHBG in several studies (Couillard et al., 2000, Garaulet et 
al., 2000). The relationship between circulating serum sex steroids in women is more 
complex; women with PCOS and associated hyperandrogenism may have concomitant 
abdominal obesity (Mongraw-Chaffin et al., 2015). 
 
1.7.1.1 Effects of androgens on preadipocyte proliferation and adipogenesis 
 The association between androgens and body fat distribution led to the hypothesis that 
the former may exert a direct effect on adipocyte differentiation (Seidell et al., 1990, Lacasa 
et al., 1995). Androgens have been found to inhibit preadipocyte-to-adipocyte differentiation 
in rats (Dieudonne et al., 2000). Castration increases differentiation in rat perirenal 
preadipocytes but inhibits differentiation of epididymal preadipocyctes, a process mediated 
through the IGF-1 receptor and PPARϒ (Lacasa et al., 1995). T and DHT have also been 
shown to inhibit adipogenic differentiation of 3T3-L1 and C3H10T1/2 cell lines (Singh et al., 
2003, Singh et al., 2006). The adrenal androgen precursor DHEA inhibits murine 3T3-L1 
preadipocyte proliferation, differentiation and ensuing lipid accumulation (Fujioka et al., 
2012, Lea-Currie et al., 1998). We recently demonstrated that DHEA exerts a direct anti-
glucocorticoid effect in the human preadipocyte cell line, Chub-S7, increasing basal glucose 
uptake and inhibiting preadipocyte proliferation and differentiation (McNelis et al., 2013).  
 In primary human tissue, Gupta et al found that DHT inhibits the differentiation of 
male human mesenchymal stem cells (hMSCs) into adipocytes, as well as differentiation of 
preadipocytes from three different fat depots (abdominal SC, mesenteric and OM) into mature 
adipocytes (Gupta et al., 2008). This effect was ameliorated by bicalutamide, an AR 
antagonist, in hMSCs. These findings were supported in recent work showing that T and DHT 
impair commitment of SC abdominal human adipose stem cells (hASCs) isolated from SC 
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adipose tissue of non-obese women to the preadipocyte phenotype, and also reduce 
preadipocyte differentiation to adipocytes (Chazenbalk et al., 2013).  Mirroring this, Blouin et 
al found that both DHT and T markedly inhibited adipocyte differentiation in SC and OM 
primary human cultures in both sexes (Blouin et al., 2010). 
 It has been reported that distinct fat depots may differ in their differentiation response 
to androgens (Marin et al., 1996, Joyner et al., 2002, Dieudonne et al., 2000, Dieudonne et al., 
1998).  Increased androgen sensitivity is generally observed in visceral fat depots (Dieudonne 
et al., 1998, Lacasa et al., 1995). This phenomenon may be explained in part by the higher 
expression of AR in visceral fat compared to more superficial depots (Rodriguez-Cuenca et 
al., 2005, Joyner et al., 2002). Not all studies have been concordant with these observations, 
however; Blouin et al found no difference in androgen-induced inhibition of adipogenesis 
between SC and OM cultures in either sex (Blouin et al., 2010).  
 
1.7.1.2 Androgens and lipid metabolism 
 Consistent with an inhibitory effect on adipogenesis, androgens have been shown to 
increase lipolysis. In rats, isoproterenol- and noradrenaline-stimulated lipolysis were 
increased by T (but not DHT) in male preadipocytes (Xu et al., 1990). In the same study, c-
AMP-stimulated lipolysis was also stimulated by T. Catecholamine and cAMP-stimulated 
lipolysis in rats appear to be reduced by castration (Xu et al., 1991, Pecquery et al., 1988). 
The androgen precursor DHEA may also exert a key stimulatory effect on lipolysis in rats. 
Karbowska et al found that epididymal WAT from male rats treated with DHEA for 2 weeks 
had upregulation of ATGL and HSL mRNA and protein expression (Karbowska and Kochan, 
2012). DHEA-treated animals also had higher serum FFA and glycerol levels compared to 
controls.  
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  In humans, this effect may again be depot-specific. Basal lipolysis increased 
significantly in vitro in abdominal but not in gluteo-femoral adipose tissue obtained from 
female-to-male transsexuals receiving T treatment (Elbers et al., 1999). In vivo, 
catecholamine-stimulated lipolysis was increased by T in abdominal SC but not in femoral 
adipose tissue in men in another study (Rebuffe-Scrive et al., 1991). Dicker et al actually 
demonstrated inhibition of catecholamine-induced lipolysis by T in differentiated human SC 
(but not OM) preadipocytes, an effect possibly mediated by downregulation of β2-
adrenoreceptors (Dicker et al., 2004). Correlations have also been observed between plasma 
and OM fat tissue androgen levels, and OM adipocyte responsiveness to positive lipolytic 
stimuli (Belanger et al., 2006). Not all studies show concordant results in humans; in a recent 
study, androgens did not exert a stimulatory effect on either basal or stimulated lipolysis in 
paired OM and SC samples from men (Blouin et al., 2010). Gupta et al found that DHT 
exerted no effect on basal lipolysis in any depot, only significantly increasing forskolin-
induced lipolysis in SC and mesenteric-derived preadipocytes, and not in those from the OM 
depot (Gupta et al., 2008). It is possible of course that this reduced lipolytic response of DHT-
treated omental preadipocytes was the result of DHT-induced inhibition of adipogenic 
differentiation rather than a direct effect on lipolysis. 
 DHEAS, the inactive sulphated ester of DHEA, also exerted sex- and depot-specific 
effects on lipolysis in human WAT (Hernandez-Morante et al., 2008). DHEAS also increased 
glycerol release from visceral adipose tissue explants obtained from men, and in subcutaneous 
fat in women. These data, by inference, suggest the presence of the activating STS, which 
converts inactive DHEAS to active DHEA, in human adipose tissue, a supposition confirmed 
by Valle et al (Valle et al., 2006).  However, a direct DHEA effect on adipose tissue is 
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unlikely, and these data may be reflective of intra-adipose conversion of DHEA to more 
potent downstream androgens. 
 Data on the effects of androgens on other processes integral to lipid accumulation, 
such as de novo lipogenesis, re-esterification or β-oxidation, are lacking, particularly in 
humans. In rats, treatment with cyproterone acetate had no significant effect on key 
esterification enzymes in subcutaneous, epididymal or mesenteric WAT (Hansson et al., 
1991). In male chickens, castration increased expression of phosphoenolpyruvate 
carboxykinase (PEPCK), which regulates adipocyte and hepatic glyceroneogenesis (Duan et 
al., 2013). The paucity of data in this area merits future work. 
 
1.7.1.3 Androgens and adipose insulin signalling 
 High T levels have been linked to cardiovascular risk factors and insulin resistance in 
women (Oh et al., 2002). It appears likely that some of the adverse metabolic effects of 
androgens are mediated by direct effects on adipose tissue insulin sensitivity (Ezeh et al., 
2013). Chronic T treatment of female SC adipocytes impaired insulin-stimulated glucose 
uptake by impaired phosphorylation of protein kinase C (PKC) ξ. This effect was independent 
of PI3K and mediated via AR (Corbould, 2007). In non-human primates  (NHPs), DHT 
reduced insulin-stimulated fatty acid uptake in female WAT, while in vivo T replacement 
potentiated insulin-induced Akt-phosphorylation in male WAT (Varlamov et al., 2012). This 
once again underpins key differences in regulation of insulin sensitivity by androgens in 
WAT of males and females. There is a distinct lack of extensive studies on the depot- and 
sex-specific effects of androgens on adipose tissue insulin sensitivity and molecular 
mechanisms remain to be elucidated.  
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Table 1-5 Androgen effects on adipocyte function: preadipocyte proliferation, adipocyte 
differentiation, lipolysis and insulin sensitivity. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 Androgen/ 
Treatment 
Model Depot Sex Effect Reference 
Preadipocyte 
proliferation 
T, DHT 3T3-L1 N/A N/A ê (Singh et 
al., 2003, 
Singh et al., 
2006) 
 DHEA Chub-S7 N/A N/A ê (Fujioka et 
al., 2012, 
Lea-Currie 
et al., 1998) 
Adipocyte 
differentiation 
T, DHT, 
DHEA 
3T3-L1, 
C3H10T1/2, 
Chub-S7 
N/A N/A ê (Singh et 
al., 2003, 
Singh et al., 
2006, 
McNelis et 
al., 2013) 
 Castration Rat Epididymal Both ê (Dieudonne 
et al., 2000) 
 Castration Rat Perirenal Both é (Dieudonne 
et al., 2000) 
 DHT hMSCs SC, OM, 
mesenteric 
Male ê (Gupta et 
al., 2008) 
 T, DHT hASCs SC Female ê (Chazenbalk 
et al., 2013) 
 T, DHT Human 
preadipocytes 
OM+SC Both ê (Blouin et 
al., 2010) 
Lipolysis T, DHT Rat 
preadipocytes 
OM+SC Male é − (Xu et al., 
1991) 
 DHEA Rat WAT Epididymal Male é (Karbowska 
and Kochan, 
2012) 
 T Human SC  
in vitro 
SC 
abdominal 
Female-to-
male 
transgender 
é (Elbers et 
al., 1999) 
 T Human SC in 
vivo 
SC 
abdominal 
Male é (Rebuffe-
Scrive et al., 
1991) 
 T Human 
preadipocytes 
SC Both ê (Dicker et 
al., 2004) 
 T, DHT Human 
preadipocytes 
OM+SC Male −  (Xu et al., 
1990) 
 DHEAS Human WAT OM Male é (Hernandez-
Morante et 
al., 2008) 
 DHEAS Human WAT SC Female é (Hernandez-
Morante et 
al., 2008) 
Insulin 
sensitivity 
T Human 
adipocytes 
SC 
abdominal 
Female ê (Corbould, 
2007) 
Chapter 1               General Introduction 
 80 
1.7.1.4 Androgens and adipokines 
 There is abundant animal data to suggest that androgens may also modulate adipokine 
release by adipose tissue. Adiponectin is a 244-amino acid protein that is expressed 
exclusively in WAT (Halleux et al., 2001). It exists as three oligomeric complexes: high 
(HMW), middle (MMW) and low molecular weight (LMH) adiponectin (Xu et al., 2005). 
HMW adiponectin appears to be more important than the other oligomers in increasing 
insulin sensitivity and preventing atherosclerosis, and levels of this oligomer are lower in men 
than in women (Frias et al., 2001). Adiponectin is unusual among adipokines in that 
expression within adipocytes is downregulated in obesity and inversely correlated with body 
weight and adverse metabolic risk factors (Matsubara et al., 2002, Yang et al., 2001). 
Nishizawa et al demonstrated that T reduced total adiponectin secretion by 3T3-L1 adipocytes 
(Nishizawa et al., 2002). In the same study, a castration-induced increase in plasma 
adiponectin in male and female mice was associated with a significant improvement in insulin 
sensitivity. Both body fat and adiponectin are elevated in male andogen receptor knock-out 
(ARKO) mice compared to wild-type (Yanase et al., 2008), and after orchidectomy (Combs et 
al., 2003), which is an inverse pattern to the typical reduction in adiponectin that occurs with 
weight gain.  Another study found that androgens selectively modulated the various 
oligomeric forms of adiponectin in mice (Xu et al., 2005); T reduced secretion of high 
molecular weight (HMW) adiponectin but not the low or middle molecular weight forms. The 
concentration of HMW adiponectin was significantly higher in females than in males. 
However Yarrow et al found that androgens reduce total circulating adiponectin 
concentrations in a dose-dependent manner, while maintaining HMW adiponectin, in both 
male and female rats (Yarrow et al., 2012).    
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 In primary human cultures of abdominal SC and OM adipocytes, Blouin et al showed 
no significant inhibition of adiponectin secretion by androgens in male or female adipose 
tissue (Blouin et al., 2010). Interestingly, adiponectin concentrations are higher in 
hypogonadal men versus eugonadal men, despite the higher body fat associated with the 
former (Lanfranco et al., 2004).  
 
1.7.1.5 Androgens and adipose metabolomics 
 There has been evolving interest in the last decade in the proteomic and metabolomic 
assessment of adipose tissue in health and disease. A recent study examined adipokine 
expression patterns in obese women with androgen excess compared to normo-androgenic 
controls and men (Martinez-Garcia et al., 2013). Women with androgen excess had adipokine 
expression profiles similar to those of men. Men and PCOS women had higher expression of 
chemerin and lipocalin-2 in OM compared to SC adipose tissue, with the opposite observation 
noted in control women. Putative androgen response elements (AREs) were found in the 
promoter regions of the genes encoding both adipokines. It is worth noting that chemerin and 
lipocalin-2 are key regulators in adipogenesis and adipocyte differentiation (Esteve et al., 
2009). The same group further explored the potential ‘masculinization’ of female adipose 
tissue in the setting of androgen excess by comparing the adipose proteome of 
hyperandrogenic women to that of men and non-PCOS women (Montes-Nieto et al., 2013). 
Using a non-targeted proteomic approach, women with PCOS demonstrated masculinized 
patterns in the abundance of some proteins in OM and SC adipose tissue, including 
peroxiredoxin-6 (PRDX6) and creatine kinase B-type. 
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1.7.2 Pre-receptor androgen metabolism in adipose tissue 
 Adipose tissue is capable of active androgen synthesis and controls local availability 
by an intricate network of activating and inactivating enzymes (Figure 1-18) (Quinkler et al., 
2004). The AKR1C enzyme subgroup of enzymes have emerged as important pre-receptor 
regulators of androgen metabolism in adipose tissue in recent years. We have already 
discussed the importance of the enzyme 5αR in peripheral steroidogenesis (Fassnacht et al., 
2003), catalyzing the conversion of T to the highly potent androgen DHT. 5αR type 1 
(SRD5A1) is expressed in adipose tissue (Wake et al., 2007) and may contribute to androgen 
production in fat. Adipose aromatization of androgens to oestrogen may also play a role in 
limiting local availability (Bulun and Simpson, 1994). 
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Figure 1-18 Pre-receptor androgen metabolism in adipose tissue (O'Reilly et al., 2014a). 
Active T is generated from the androgen precursor A by AKR1C3; DHT is generated from T 
by SRD5A1; AKR1C2 inactivates T to 5α-androstane-3α, 17β-diol. T and A are aromatized by 
CYP19A1 to E2 and E1 respectively. Reproduced with permission from Elsevier. 
   
1.7.2.1 AKR1C isoenzymes 
 AKR1C isoenzymes are highly homologous but display different substrate 
specificities (Blouin et al., 2009b). AKR1C2 shares 86% of its amino acids with AKR1C3 
and 98% with AKR1C1. AKR1C1, AKR1C2 and AKR1C3 display ketosteroid reductase 
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activities (20α-HSD, 3α-HSD, and 17β-HSD). AKR1C1 (also called 20α-HSD) 
predominantly inactivates progesterone into 20α-progesterone via 20α-HSD activity. It is 
expressed in both SC and OM adipose tissue in women but is not an important player in 
adipose androgen metabolism (Blanchette et al., 2005). AKR1C2 (also called 3α-HSD3) is 
predominantly involved in androgen inactivation, converting the potent androgen DHT into 
the weak 3α-diol through its 3α-reductase activity. Blouin et al described mRNA expression 
of AKR1C2 in human female adipose tissue (Blouin et al., 2003); they reported increased 
inactivation of 5α-DHT by AKR1C2 in omental fat from women with visceral obesity and 
suggested that local androgen inactivation is a predominant reaction in female abdominal 
tissue. Androgen-inactivating 3α-HSD activity has also been described in primary stromal 
cells and isolated adipocytes (Blouin et al., 2005, Blouin et al., 2006). Activity appears to be 
higher in subcutaneous compared to omental fat, and androgen inactivation correlated with 
obesity. Lower DHT levels in subcutaneous than in omental fat appears to support these 
findings (Belanger et al., 2006). Despite some discordant results between studies, it appears 
that subcutaneous fat is the key depot of androgen metabolism by AKR1C isoforms in males 
and females. All isoforms appear to be upregulated in obesity or with increased visceral 
adiposity (Quinkler et al., 2004, Blouin et al., 2005, Blouin et al., 2006). Wake et al also 
hypothesized that intra-adipose androgen metabolism by AKR1C isoforms drives central fat 
accumulation and may preferentially drive android compared to gynecoid fat distribution 
(Wake et al., 2007).  
 AKR1C3 (also called 17β-HSD5) is an androgen-activating isoform with predominant 
17β-HSD activity, converting A into T (Zhang et al., 2000). AKR1C3 has emerged as a key 
mediator of androgen interconversion in the last 15 years (Penning et al., 2000, Dufort et al., 
1999). Quinkler showed that AKR1C3 is upregulated in obesity, and that expression is 
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significantly higher in SC than in OM fat (Quinkler et al., 2004). AKR1C3 expression in SC 
fat reduced significantly in six women taking part in a weight-loss study. Other 17β-HSD 
isoforms capable of androgen generation have also been detected; Corbould et al detected low 
mRNA expression of isoenzymes 2 and 3 in human adipose tissue (Corbould et al., 1998), 
and subsequently found that preadipocytes readily converted A to T (Corbould et al., 2002).  
  
1.7.2.2 Adipose tissue and 5αR activity 
 The most important isoenzyme of 5αR in terms of androgen activation and 
glucocorticoid inactivation is type 2 (SRD5A2), expressed predominantly in the epididymis, 
prostate and seminal vesicles; adipose tissue expresses only SRD5A1 (Russell and Wilson, 
1994). The precise biological role of 5αR1 is poorly understood. 5αR1 deletion in mice 
accelerates the development of hepatic steatosis but may protect against the development of 
NAFLD-related hepatocellular neoplasia (Dowman et al., 2013). This emphasizes its potential 
importance in lipid metabolism and accumulation. Whilst studies characterising the regulation 
and action of adipose 5αR1 are sparse, there is evidence that this enzyme plays an important 
role in fat. Levels of 5α-reduced metabolites are seen to increase with obesity in humans 
(Andrew et al., 1998), while weight-loss is associated with correspondingly decreased enzyme 
activity (Stimson et al., 2007, Tomlinson et al., 2008b). Increased activity of 5αR may act to 
reduce local levels of glucocorticoid by conversion to its tetrahydrometabolites and thus retain 
insulin sensitivity, but in females this beneficial effect may be offset by increased regional 
androgen activation.  
There does appear to be an element sexual dimorphism in 5αR activity, with men 
showing greater activity as measured by 5α-reduced cortisol metabolites (Finken et al., 1999, 
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Tomlinson et al., 2008a); however levels of SRD5A1 expression in SC adipose tissue were not 
found to differ between men and women (Tomlinson et al., 2008a). Differences in SRD5A1 
expression between OM and SC fat have not been demonstrated; however OM levels of DHT 
appear to be significantly higher, suggesting possible greater activity (Belanger et al., 2006).  
 
1.7.2.3 Other androgen-metabolising enzymes in adipose tissue 
 Reports of adipose mRNA expression of a large number of androgen-metabolising 
enzymes have been published in recent years. 3β-HSD type 1, 17β-HSD types 2, 3 7 and 12, 
and 17α-hydroxylase are amongst potentially interesting isoforms expressed in fat (Kershaw 
and Flier, 2004, Corbould et al., 1998, Corbould et al., 2002, Puche et al., 2002, Bellemare et 
al., 2009), but detailed functional assessments and evaluation of clinical significance are for 
the most part lacking. The advent of LC-MS/MS offers the prospect of accurate adipose 
androgen quantification in health and disease, and early data are already exciting (Kinoshita et 
al., 2014). 
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1.8 Summary, hypotheses and aims 
 The role of adipose tissue as a potential source of androgen excess in PCOS has only 
been partially defined. The most recent body of work from key figures in the field suggests 
that SC and OM fat are host to an intricate network of androgen-activating and inactivating 
enzymes. The nature of the interaction between these enzymes in health and disease remains 
poorly understood. The ability of LC-MS/MS to sensitively and specifically elucidate 
androgen generation within fat is potentially exciting, but further work is needed to expand on 
embryonic developments. Current data on the impact of androgens on adipose lipid 
metabolism are conflicting and confusing, and focus largely on lipolysis. There are few 
published studies on the effects of androgens on other processes integral to lipid metabolism, 
such as beta-oxidation or free fatty acid uptake. The work undertaken in this doctoral thesis 
will attempt to clarify discrepancies in the literature and knowledge gaps in the area of 
adipose androgen metabolism using an integrated in vivo, ex vivo and in vitro approach. 
Specific hypotheses and study aims are listed below. 
  
1.8.1 Adipose tissue is a key organ of androgen generation in PCOS  
 To test this hypothesis, I aim to: 
• Examine mRNA expression of the androgen-activating enzyme AKR1C3 in primary 
human adipose tissue (Chapter 4). To control for the confounding effects of gender 
and depot-specificity, results will be compared between male and female patients, as 
well as between SC and OM fat depots.  
• Explore the potential of the human preadipocyte cell line SGBS to activate the weak 
androgen precursor A to T. Results will be validated by replicating experiments in 
primary cultures of human adipocytes derived from SC and OM fat depots.  
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• Examine in vivo SC adipose androgen activation after oral administration of the 
androgen precursor DHEA in PCOS patients and healthy controls (Chapter 6).  
 
1.8.2 Insulin is a key regulator of adipose and systemic androgen metabolism 
 The role of insulin in ovarian hyperandrogenism has been comprehensively studied in 
in vivo and in vitro models. However, evidence for regulation by insulin of systemic androgen 
metabolism is lacking. To test the above hypothesis, I aim to: 
• Explore the association of the OGTT-derived insulin sensitivity index (ISI) with 
circulating androgen burden and urinary markers of systemic androgen metabolism 
(Chapter 3).  
• Delineate the primary in vivo role of insulin in androgen generation by administration 
of oral DHEA to three patients with loss-of-function mutations of the INSR compared 
to PCOS women and controls (Chapter 6). 
• Examine in vitro the role of insulin in adipose androgen generation by exposing 
primary adipocytes and SGBS cells to hyperinsulinaemic conditions, with 
measurement of AKR1C3 expression (Chapter 4). Functional effects of insulin on 
adipocyte androgen generation will be determined by LC-MS/MS. 
 
1.8.3 Androgens play a crucial role in adipose tissue function, including adipogenesis 
and lipid metabolism 
 A role for androgens in adipose tissue function is suggested by sex-specific 
differences in body fat distribution. Studies on the role of androgens in adipocyte function 
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have yielded conflicting results, and are limited by sexual dimorphism and depot-specificity. 
In order to test the above hypothesis, I aim to: 
• Perform a comprehensive in vivo study of the effects of androgens on female 
SC adipose tissue biology (Chapter 6).  
• Examine effects of DHEA exposure on insulin-dependent processes in adipose 
tissue, such as lipolysis and glucose uptake (Chapter 6).  
• Examine the role of androgens in adipose lipid metabolism and pancreatic 
insulin secretion in vitro (Chapter 5) 
 
 
  
2  General Methods 
 
 
 
 
 
 
 
 
 The procedures described in this chapter are commonly used throughout this doctoral 
thesis. Any methods specific to individual chapters are described separately in the appropriate 
section. General chemicals were obtained from Sigma-Aldrich Company Ltd, Gillingham, 
Dorset, UK or Fisher Scientific, Loughborough, UK, unless otherwise stated. Reagents for 
reverse transcription and real-time polymerase chain reactions were obtained from Life 
Technologies Ltd, Paisley, UK, unless otherwise stated.
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2.1 Primary human preadipocyte and adipocyte isolation 
2.1.1 Principle 
 This method of adipocyte isolation from the stromo-vascular cell fraction using 
collagenase was first described by Rodbell in 1964 (Rodbell, 1964). The protocol described in 
this chapter is similar with only minor modifications. Incubation of adipose tissue with class 1 
or 2 collagenase at 37°C breaks down connective tissue within fat, thereby releasing 
adipocytes and the stromo-vascular cell population. Subsequent centrifugation leads to 
separation of these two fractions into distinct layers, where fat-containing intact adipoyctes 
form a top layer and the stromo-vascular cells form a pellet at the bottom. Preadipocytes were 
cultured until confluent, at which point the process of differentiation was initiated by addition 
of chemically defined media (Figure 2-1). 
 
2.1.2 Solutions 
• Gibco® Dulbecco’s Modified Eagle Medium:Nutrient Mixture (1:1) F-12 (DMEM/F-
12, Life Technologies) 
• Collagenase Type II from Clostridium Histolyticum (Sigma), 2mg/ml in DMEM/F-12 
• Serum-free, chemically-defined medium: insulin (10nM), biotin 33µM, pantothenate 
17µM and tri-iodothyronine (T3) 1nM. Medium was created according to well-
established protocols in our laboratory (Bujalska et al., 1999). 
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2.1.3 Method 
 Paired primary human subcutaneous (SC) and omental (OM) fat samples were 
obtained from consented patients before elective abdominal surgery for non-malignant, non-
inflammatory conditions. Sample collection was facilitated via the University of Birmingham 
Tissue Biorepository. Adipose tissue samples were dissected into 2-3mm3 pieces and digested 
with type II collagenase at 37°C for 60 minutes. Samples were then centrifuged at 12,000 rpm 
for 5 minutes. Intact adipocytes were extracted using plastic Pasteur pipettes, and 
preadipocytes were extracted from a pellet containing the stromovascular components. Intact 
lipid-containing adipocytes were placed in serum-free DMEM/F12 and seeded into 1ml wells.  
 Preadipocytes were resuspended in DMEM/nutrient mixure F12 containing fetal 
bovine serum (FBS) 10% (Sigma Aldrich) and penicillin-streptomycin 1% (Life Technologies 
Ltd). Cells were seeded into 12- or 24-well plates depending on sample size (cells from 1g of 
adipose tissue per one 6-well plate, approximately 10,000 cells/cm2) and incubated overnight. 
Cells were washed the next morning with serum-free DMEM/F12, after which they were 
again placed in serum-enriched growth media. Preadipocytes were allowed to proliferate to 
90% confluence. Differentiation was initated by washing the cells in serum-free media, 
followed by culture with differentiation media containing biotin 33µM, pantothenate 17µM 
and T3 1nM. Cortisol (0.1µl/ml of 10-2M stock), rosiglitazone (1µl/ml of 1mM stock) and 
insulin (1µl/ml of 1mg/ml stock) were added fresh (Bujalska et al., 2002). Methyl-3-
isobutylxanthine (cyclic AMP-elevating agent, IBMX) was added fresh to the mixture for the 
first 4 days of differentiation only (5µl of 10mg/ml stock per ml of differentiation media). 
Chemically-defined media was changed at Days 4, 8 and 12.  
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Figure 2-1 Preadipocyte differentiation primary fat. 
 
2.2 Preadipocyte cell line 
 The human Simpson-Golabi-Behmel syndrome (SGBS) preadipocyte cell line was 
obtained from Professor Martin Wabitsch at the University of Ulm. Cells were differentiated 
into adipocytes according to previously published protocols (Fischer-Posovszky et al., 2008). 
The SGBS cell line was derived from the stromal cell fraction of SC adipose tissue from a 
male infant with Simpson-Golabi-Behmel syndrome (SGBS), a rare X-linked congenital 
overgrowth syndrome. We acknowledge the limitations associated with the use of a 
preadipocyte cell line in this doctoral thesis, including altered proliferation and differentiation 
capacity compared to primary human tissue. However, previous work has validated SGBS 
cells as a reasonable model for the study of human adipocyte biology. 
 
2.2.1 Solutions 
• 0F medium – DMEM/F12 mixture with 33µM biotin, 17µM pantothenate and 
penicillin-streptomycin 1%. 
• Growth medium – 0F medium supplemented with FBS 10% 
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• Quick Diff medium – 0F medium with transferrin (0.01mg/ml), insulin (20nM), 
cortisol (100nM), T3 (0.2nM), dexamethasone (25nM), IBMX (250µM) and 
rosiglitazone (2µM) (all reagents Sigma Aldrich Company Ltd) 
• 3FC medium – 0F medium with transferrin (0.01mg/ml), insulin (20nM), cortisol 
(100nM) and T3 (0.2nM) 
 
 SGBS cells were grown to 90% confluence in 5ml flasks. Trypsin-EDTA (0.25%, Life 
Technologies) 1ml was added for dissociation. Cells were suspended in growth medium, 
centrifuged for 10 minutes at 12,000 rpm and then resuspended. SGBS preadipocytes were 
seeded into 12- or 24-well plates at a density of 100,000/cm2. At 90% confluence per well, 
growth media was removed and cells washed three times with 0F media. Quick Diff media 
was added for 4 days; at Day 4, media was changed to 3FC until Day 14 (changed at day 4, 
day 8 and day 12).  
 
2.3 MIN6 mouse insulinoma cell line 
 An established mouse pancreatic β-cell line was obtained as a gift from Professor 
Kevin Docherty at the University of Aberdeen, UK (Miyazaki et al., 1990). Cells were 
cultured in Dulbecco’s modified Eagles’ Medium (DMEM) with glucose 4.5g/l, 10% FBS 
(Sigma Aldrich), 1% penicillin/streptomycin (Sigma Aldrich) and 100µM beta-
mercaptoethanol. Cells were incubated at 37°C.  
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2.4 Realtime quantitative PCR 
2.4.1 RNA extraction and quantification 
 Total RNA was extracted from cells after treatments as appropriate using the Tri-
Reagent system (Sigma). All steps were performed on ice to preserve RNA integrity. 
Typically, 1ml of Tri-Reagent was added to wells per 107 cells as recommended by 
manufacturer. Cells were then incubated at room temperature for 10 minutes to allow cells to 
homogenise completely. RNAse-free chloroform was added to samples, which were then 
mixed vigorously and incubated at room temperature for 10 minutes before centrifugation at 
13,000 rpm for 20 minutes at 4°C. The upper aqueous phase containing RNA was transferred 
to a fresh 1.5ml tube. RNA was precipitated by incubating samples in 500µl isopropranolol 
for 16 hours at -20°C. The resultant RNA pellet was washed in 70% ethanol twice, followed 
by centrifugation, and resuspended in 20-30µl of RNase-free water. RNA concentration and 
purity was calculated using NanoDrop technology (ND1000, ThermoScientific, Wilmington, 
DE, USA). Total RNA was extracted from whole adipose tissue explants by homogenizing 
100-200mg of adipose tissue in Tri-Reagent using an Ultra Turrax homogenizer (Cole-
Palmer, UK). Further steps were carried out as outlined above.  
 
2.4.2 Complementary DNA synthesis and amplification – reverse transcription  
 Reverse transcription is the process of converting single stranded RNA into 
complementary DNA (cDNA). RNA was diluted to a final concentration of 50-100ng/µl. 
Reverse transcription was carried out using Taqman Reverse Transcription Reagents (Applied 
Biosystems/Life Technologies Ltd). In this protocol, gRNA was reverse transcribed into 
cDNA using the following reagents: 
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 - 10XRT buffer 
 - 25mM MgCl2 
 - dNTP mix (10mM each) 
 - RNase inhibitors 
 - Multiscribe Reverse Transcriptase (50U/µl) 
 
Total RNA is heated to denature secondary structures, followed by cooling which facilitates 
annealing of random hexamers. After annealing, and in the presence of an RNase inhibitor, 
these are extended with reverse transcriptase. Single stranded cDNA can then be used in a 
PCR reaction. All reactions were run according to the following cycle programme: 
 
 - 25°C for 10 minutes 
 - 37°C for 60 minutes 
 - 48°C for 30 minutes 
 - 95°C for 5 minutes 
 
2.4.3 Realtime PCR  
2.4.3.1 Principle 
 Taqman Realtime PCR technology employs a fluorogenic probe which allows 
detection of a specific PCR product as it accumulates in ‘real time’ during the PCR reaction. 
An oligonucleotide probe is synthesized containing fluorescent reporter dye on its 5’ end and 
a quencher dye on its 3’ end. The quencher dye reduces fluorescence emitted by the report 
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dye. The probe anneals downstream from one of the primer sites and during primer extension 
is cleaved by the 5’ nuclease activity of Taq DNA polymerase. Removal of the probe 
facilitates primer extension, separating the reporter and quencher dye, thereby allowing the 
reporter dye signal to increase. Additional reporter dye molecules are cleaved during 
successive cycles, which allows the fluorescence intensity to increase proportional to the 
amount of PCR product generated. The method detects when the target is first detected rather 
than the amount of target produced after a fixed number of cycles. The value at which the 
product is first detected is referred to as the Ct value. The higher the target copy number in 
the sample, the lower the cycle number when fluorescence is first observed, therefore the 
lower the Ct value. This allows relative quantification compared to a housekeeping gene (see 
below). 
2.4.3.2 Method 
 mRNA expression levels were determined using an ABI sequence detection system 
(Perkin-Elmer Applied Biosystems, Warrington, UK). All reactions were carried out in 10µl 
final volume in reaction buffer, containing 2 X Taqman Universal PCR Master mix (5.0µl, 
Applied Biosystems), probe-primer mix for gene of interest (0.5 µl) and 4.5µl cDNA (100ng) 
(Gathercole et al., 2007). All reactions were normalized against the housekeeping genes 18S 
rRNA or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data were expressed as the 
cycle number at which logarithmic PCR plots crossed a calculated threshold line (Ct values) 
and used to determine Δct values [Δct=(ct of target gene)-(ct of housekeeping gene)]. 
Arbitrary units were calculated using the formula (1000*2-Δct). All statistics were performed 
on Δct values. 
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2.5 Steroid extraction and measurement by liquid chromatography/tandem 
mass spectrometry (LC-MS/MS) 
2.5.1 Serum steroid extraction and measurement 
 Serum steroids were measured by liquid chromatography/tandem mass spectrometry 
(LC-MS/MS) using a Waters Xevo mass spectrometer with Acquity uPLC system. LC-
MS/MS conditions were an electrospray ionization source with capillary voltage 4.0kV, a 
source temperature of 150°C, and a desolvation temperature of 500°C. A linear calibration 
series of increasing concentrations was used, and internal standard solution added to both 
samples and calibrants. Serum steroid oxime analysis was employed using the technique 
described by Kushnir (Kushnir et al., 2010). This technique facilitates enhanced detection of 
androgens at low serum concentrations by formation of oxime derivatives of the steroid oxo-
groups. Measurement of T, A and DHEA was carried out in positive mode, whereas 
measurement of DHEAS was performed in negative mode. Steroids were extracted from 
200µl serum via liquid-liquid extraction using 1ml tert-butyl-methyl-ether (MTBE), with 
subsequent derivitisation into steroid oximes using 100µl derivitisation cocktail (0.16g 
hydroxylamine in 8ml pyridine). DHEAS was extracted by adding 20µl ZnS04 0.1mM and 
100µl acetonitrile to 20µl serum for protein precipitation, and subsequent evaporation under 
constant nitrogen flow (Chadwick et al., 2005). All steroids were separated using an 
optimized gradient system consisting of methanol with 0.1% formic acid. Quantification was 
carried out by reference to a linear calibration series with appropriate internal standards. 
Individual steroids were identified by matching retention times and two mass transitions in 
comparison to a deuterated reference compound.  
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2.5.2 Cell media steroid extraction and measurement 
 After treatment with androgens or androgen precursor, cell media (1-2ml) was 
extracted from tissue culture wells and placed in sylinised glass TLC tubes. For quantitative 
analysis, 20µl internal standard was added. A calibration series was prepared for each 
experiment as follows: 
 
Table 2-1 Sample calibration series for cell media steroid measurement 
Calibration number Added volume of 
serum steroid stock 2 
(µl) 
Added volume of cell 
media (µl) 
Concentration (ng/ml) 
C0 0 1000 0 
C1 0.5 999.5 0.5 
C2 1 999 1 
C3 5 995 5 
C4 10 990 10 
C5 25 975 25 
C6 50 950 50 
C7 100 900 100 
C8 250 750 250 
C9 500 500 500 
 
 
 Steroids were extracted via liquid-liquid extraction as described above by adding 3ml 
MTBE to each sample. After vortexing and centrifugation at 12,000rpm for 5 minutes, 
samples were frozen at -20°C for least 60 minutes. Subsequently, the upper clear layer was 
transferred to a 96-well plate using glass Pasteur pipettes, with alternating cycles of 
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evaporation at 55°C under nitrogen followed by further liquid transfer until the samples were 
evaporated in entirety. After evaporation, samples were reconstituted with 125µl of 
methanol:H20 (50:50) and frozen at -20°C until ready for LC-MS/MS analsysis.   
 
 
2.5.3 Urinary steroid metabolite excretion analysis 
 Urinary steroid metabolite excretion from 24-hour urine samples was analysed by 
experienced laboratory staff with gas chromatography/mass spectrometry (GC/MS) using the 
techniques described by Shackleton and colleagues (Arlt et al., 2004, Shackleton, 1993). 
Steroids were released from conjugation enzymatically before extraction; individual steroid 
metabolites were identified by Selected-Ion-Monitoring analysis.  
 First, steroids were extracted from urine with a SepPak column (Waters, Milford, Ma, 
USA): 5 ml of urine sample were loaded after washing the columns with 4 ml methanol and 4 
ml of ddH2O. Then, the loaded column was washed with 4 ml ddH2O and the steroids were 
eluded in 4 ml methanol into a clean borosilicate tube. After evaporation (heat block at 55oC 
under N2), sulfate and glucoronide groups were enzymatically removed from conjugated 
steroids by incubating for 3 hours at 55oC in the hydrolysis buffer (3 ml 0.1M acetate buffer 
[pH 4.8-5.0] + 10 mg ascorbate + 10 mg sulfatase/glucoronidase; all ingredients purchased 
from Sigma, Pool, UK). The cooled sample was then loaded again on a SepPak column and 
eluded into a clean glass tubes with 4 ml methanol. Derivatization: After evaporation, three 
drops of 2% methoxyamine-pyridine was added; the tube was vortexed vigorously and 
incubated at 55oC for one hour. After evaporation under N2, 75µl of N-
trimethylsilylimidazole (Sigma, Pool, UK) were added, vortexed and incubated at 120oC 
overnight. Then, the samples were extracted by adding (1) 2 ml cyclohexane and (2) 2 ml 
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dH2O (vortexing after each step). After centrifugation (1,000g for 5 minutes), the bottom later 
layer was removed into waste. Then, another 2 ml dH2O were added, vortexed, centrifuged 
and removed. Finally, the top layer containing the extracted in cyclohexane was transferred 
into injection vials. The samples were then injected into an Agilent 5973 GC mass-
spectrometer. 
 The sum of androsterone (An) and etiocholanolone (Et) was considered representative 
of active androgen metabolite excretion (Silfen et al., 2002). Total body 5α-reductase activity 
was estimated using the ratios of An/Et and 5α-THF/THF. Activity of systemic 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) was calculated using the ratios of 
tetrahydrometabolites of cortisol (5α-THF+THF) to tetrahydrocortisone (THE) (Stewart et al., 
1999), while 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity was estimated 
by the ratio of urinary free cortisol to cortisone (UFF/UFE). Total glucocorticoid metabolite 
excretion was assessed as the sum of 5α-THF + THF + THE + cortolones + cortols + cortisol 
+ cortisone.  
 
2.6 Serum insulin, glucose and free fatty acid measurements 
2.6.1 Human and Mouse insulin ELISA kit (Mercodia, Sweden) 
 This is a solid phase two-site enzyme immunoassay using two monoclonal antibodies 
(abs) against separate antigenic determinants on the insulin molecule. Each kit contains the 
following:  
• Mouse monoclonal anti-insulin-coated plate 
• Calibrators 0-5 containing set concentrations of recombinant human insulin 
• Enzyme Conjugate 11X (1.2ml) –mouse monoclonal anti-insulin 
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• Enzyme Conjugate Buffer (12ml) – added to Enzyme Conjugate 11X to make Enzyme 
Conjugate 1X solution 
• Wash buffer 21X (50ml) – added to 1L distilled H20 to make wash buffer 1X solution 
• Substrate TMB (light sensitive) 
• Stop solution 
Human serum or cell media from mouse MIN6 cells was defrosted on ice at room 
temperature. Calibrators and samples (10µl each) in duplicate were transferred to 96-well 
plate. Enzyme conjugate 1X solution 100µl was added to each well, and samples incubated on 
a plate shaker (700-900 rpm) for 2 hours at room temperature (18-25°C). Reaction volume 
was discarded by inverting the microplate over a sink and plates then washed manually by 
adding 350µl wash buffer 1X solution to each well. Wash solution was discarded and the 
plate tapped firmly against absorbent paper to remove excess liquid. This step was repeated 5 
times, followed by addition of Substrate TMB 200µl to each well. After incubation for 15 
minutes at room temperature, 50µl Stop Solution was added and the plate placed on the 
shaker for 5 seconds to ensure mixing. Optical density of plates was measured at 450nm on 
spectrophotometer.  
 
2.6.2 Serum free fatty acids 
 Serum free fatty acids were measured in human serum samples using a commercially 
available kit (ZenBio, NC, US).  Assessment of serum fatty acids is via a coupled reaction to 
measure non-esterified fatty acids (NEFA). The initial step is catalyzed by acyl-CoA 
synthetase (ACS), which produces fatty acyl-CoA thiol esters from the NEFA, ATP, 
magnesium and CoA in the reaction. Subsequently acyl-CoA esters react with oxygen in the 
presence of acyl-CoA oxidase to produce hydrogen peroxide. In the presence of peroxidase, 
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hydrogen peroxide allows the oxidative consensation of 3-methyl-N-ethyl-N-(β-
hydroxylethyl)-aniline with 4-aminoantipyrine, forming a purple product which absorbs light 
at 550nm. 
 
2.6.2.1 Solutions 
• Dilution buffer 100ml 
• Free fatty acid (FFA) standard 
• FFA Diluent A 
• FFA Diluent B 
• FFA Reagent A 
• FFA Reagent B 
  
2.6.2.2 Procedure 
1. A standard curve was prepared using the Standard Solution by means of serial dilutions 
with dilution buffer, with final concentrations of 0, 1.4, 4.1, 12.3, 37, 111 and 333µM. 
2. FFA Reagent A and B was prepared by adding 50ml FFA Diluent A and B respectively. 
5µl  of serum samples were added in duplicate to a 96-well plate. 45µl of dilution buffer was 
added to each well to give a total volume of 50µl (1:10 dilution). 
3. 100 µl of Reagent A was added to each well. The plate was placed on an orbital shaker for 
10 seconds to ensure mixing, then placed in an incubator at 37°C for 10 minutes. 
4. 50 µl of Reagent B was next added to each well and the plate placed on an orbital shaker 
for 10 seconds to ensure mixing. The plate was then placed in an incubator at 37°C for 10 
minutes 
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5. The plate was allowed to equilibrate at room temperature for 5 minutes. 
6. The optical density of each well was then measured at 540nm. 
 
2.6.3 Measuring glucose using near-patient YSI machine 
 Serum glucose was measured using the 2300 STAT PLUS Analyser (YSI 
Incorporated, Life Sciences, Ohio, USA).  
Required equipment: 
• 2 ml plastic tubes to present to the sipper 
• Rinsing buffer 
• Calibrators 
After calibration, the YSI machine was placed in ‘RUN’ mode. Serum samples were 
automatically aspirated and glucose result displayed on screen in 15-30 seconds. The YSI 
automatically self-calibrates every 15 minutes when in RUN mode. 
 
2.7 Body composition assessment using DXA 
 Dual-energy x-ray absorptiometry (DXA) was employed for body composition 
assessment using Hologic Discovery/W DXA (software version Apex 3.0, Hologic Inc.). 
Specific fat phenotype was measured using android, gynecoid, peripheral (arms and legs), and 
trunk regions of interest, with subsequent calculation of android:gynecoid and 
trunk:peripheral fat ratios (Gregson et al., 2013). 
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2.8 Statistical analysis 
 Experimental data were graphically presented and statistically analysed with Prism 6.0 
(CA, USA), SPSS Statistics (Version 22.0, IBM Corp., Armonk, NY, USA) and Microsoft 
Excel for Mac 2011 (Version 14.4.5). Independent samples t tests were used to compare 
means of two different groups when samples were drawn from normally distributed 
populations with the equal variance. Mann-Whitney Rank Sum test was used when two 
groups were not drawn from a normally distributed population. P-values, meaning the 
probability of having the observed data if the null hypothesis is true (ie difference occurring 
by chance), were calculated using the above tests; P<0.05 was deemed to be statistically 
significant. 
 When comparing means from multiple groups, one-way ANOVA with post-hoc 
Tukey testing was employed for multiple comparisons between different groups. Correlation 
testing was employed to examine positive and negative linear relationships between 
continuous variables, using Pearson’s test (parametric) or Spearman’s rank test (non-
parametric data) as appropriate. Multiple linear regression was used to examine relationships 
between continuous variables while adjusting to the effects of confounding factors.  
 
 3 Circulating androgens and metabolic 
phenotype in PCOS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter have been published as: 
Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the 
utility of serum androstenedione 
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3.1 Introduction 
 A lack of clarity persists on which androgens should be measured in PCOS, 
what constitutes normal reference ranges and which analytical technique should be employed 
(Barth et al., 2007).  Equally we have little insight into whether different patterns of 
biochemical hyperandrogenemia define distinct PCOS sub-groups in terms of metabolic risk. 
The most accurate strategy for quantification of biochemical androgen excess in PCOS is 
measurement of total 24-h urinary androgen metabolite excretion (Silfen et al., 2002); 
however, urinary steroid profiling by gas chromatography/mass spectrometry (GC/MS) is 
time-consuming and expensive. In routine clinical practice, and as defined by PCOS 
diagnostic criteria, serum total T remains the most commonly measured and widely available 
marker for estimation of biochemical androgen excess (Azziz et al., 2004). However, 
measurement of T is severely limited by a number of factors: (i) T circulates bound to SHBG 
and other proteins such as albumin, and only the unbound or free fraction enters into target 
tissues (Pardridge, 1986), such that circulating levels may not represent tissue exposure, (ii) 
measurement of free T by direct RIA is highly inaccurate (Vermeulen et al., 1999), resulting 
in the recommendation to calculate the free androgen index from T and SHBG instead, (iii) 
direct immunoassays for total T are highly variable (Boots et al., 1998), and (iv) T circulates 
in low nanomolar range concentrations and the lower end of the normal female reference 
range is below the limit of quantitation in all assays available, including tandem mass 
spectrometry (LC-MS/MS). 
Androgen excess in PCOS originates from ovaries and adrenals (Loughlin et al., 
1986); moreover, increased peripheral conversion of T to the most potent androgen 5α-DHT 
by systemically upregulated 5αR activity has been well-documented (Stewart et al., 1990, 
Fassnacht et al., 2003). A is the immediate precursor of T. In addition to direct secretion by 
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ovaries and adrenals, A can be generated in peripheral tissues from its precursor DHEA by the 
enzyme 3β-HSD2 (Ehrmann et al., 1995). The vast majority (95-97%) of DHEA and its 
sulfated ester DHEAS are secreted by the adrenocortical zona reticularis and elevated serum 
levels are observed in 20-30% of women with PCOS (Kumar et al., 2005). In addition to 
mainly ovarian production, about 25% of plasma testosterone derives from the conversion 
from A by 17β-HSD5 (also called AKR1C3) in adipose and other peripheral tissues (Quinkler 
et al., 2004). Serum A is inconsistently measured in routine clinical investigation of suspected 
PCOS as clinicians remain uncertain about its additional diagnostic value or clinical utility. 
Limited previous work suggests that 10% of PCOS patients may be misclassified as 
normoandrogenemic if A is not measured (Knochenhauer et al., 1998). 
The independent health risks of androgen excess in women are increasingly apparent 
(Jones et al., 2012). We hypothesized that patients with co-elevation of A and T and therefore 
increased circulating androgen burden represent a distinct subgroup with adverse metabolic 
parameters compared to those with normal androgens or solitary elevation of either A or T. In 
women, A circulates at ten-fold higher concentrations than serum T (Horton et al., 1966) and 
is therefore more easily and accurately detected than T, not only by mass spectrometry but 
also by widely-available immunoassays. We thus also hypothesized that A represents a more 
sensitive marker for the biochemical detection of androgen excess. We therefore carried out a 
detailed analysis of androgen synthesis and metabolism to test these hypotheses in a large 
cohort of women with PCOS according to Rotterdam criteria in comparison to a group of 
BMI-matched healthy controls. 
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3.2 Materials and methods 
3.2.1 Research strategy 
 In this chapter, we will examine the metabolic phenotype of a large cohort of PCOS 
and control patients according to their circulating androgen burden as measured by LC-
MS/MS. Insulin sensitivity indices, as determined by OGTT, and other metabolic markers 
such as lipids and blood pressure, will be correlated with serum androgens and 24-hour 
urinary steroid excretion. The relationships between central and peripheral fat mass 
distribution with markers of androgen metabolism and insulin sensitivity will also be 
explored.  
 We will test the hypotheses that (1) women with co-elevation of T and the androgen 
precursor A have a higher metabolic risk than those with solitary androgen derangements, and 
(2) that A is a more sensitive biochemical marker of androgen excess in PCOS than 
conventional T. Lastly, we will examine the utility of application of the current Rotterdam 
classification criteria as a tool to predict the prevalence of insulin resistance and dysglycaemia 
in PCOS. 
 
3.2.2 Subjects 
 Women with PCOS were recruited from outpatient clinics at the Queen Elizabeth 
Hospital Birmingham (QEHB) and Birmingham Women’s Hospital (BWH). This 
observational, cross-sectional study was approved by South Birmingham Research Ethics 
Committee (REC) and all participants gave written informed consent.  PCOS was diagnosed 
according to the Rotterdam ESHRE 2004 criteria, with the presence of two or more of the 
following: oligo-/anovulation, clinical signs of hyperandrogenism, and polycystic ovaries on 
Chapter 3   Circulating androgens and metabolic phenotype 
 
 110 
ultrasound (Rotterdam, 2004b). Other causes of oligomenorrhea and/or androgen excess were 
excluded by history, physical examination, biochemical assessment and, where appropriate, 
imaging. Healthy controls were recruited via local advertisement, with a diagnosis of PCOS 
excluded by clinical and biochemical parameters. Exclusion criteria for both groups were 
current or recent treatment with glucocorticoids, CAH, hyperprolactinemia, thyroid 
dysfunction, pregnancy, age <18 or >45 years, oral contraceptive use within 3 months prior to 
recruitment, and diabetes mellitus.  
 
3.2.3 Clinical protocol 
 Participants attended the National Institute of Health Research/Wellcome Trust 
Clinical Research Facility at the Queen Elizabeth Hospital Birmingham after an overnight fast 
for a single day of integrated assessment. Each patient provided a 24-h urine sample for 
urinary steroid metabolite analysis by gas chromatography/mass spectrometry (GC/MS) as 
previously reported (Arlt et al., 2004). Baseline anthropometric assessment included height, 
weight, body mass index (BMI, kg/m2), waist:hip ratio and blood pressure (BP) measurement. 
A modified Ferriman-Gallwey scoring system for hirsutism was used, where each of nine 
body areas were rated from 0 (absence of terminal hairs) to 4 (extensive terminal hairs) 
(Yildiz et al., 2010). Dual-energy x-ray absorptiometry (DXA) was employed for body 
composition assessment using Hologic Discovery/W DXA (software version Apex 3.0; 
Hologic Inc., Bedford, MA). Specific fat phenotype was measured using android, gynaecoid, 
peripheral (arms and legs) and trunk regions of interest, with subsequent calculation of 
android:gynaecoid and trunk:peripheral fat ratios (Gregson et al., 2013).  
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 Bloods were drawn for fasting plasma glucose and insulin and serum T, A, DHEA, 
DHEAS, SHBG, FSH and LH, total cholesterol (TChol), high-density lipoprotein (HDL) and 
triglycerides (TG). Each participant underwent a 75-g OGTT with blood sampling at 30-
minute intervals for 2 hours. Glucose and insulin were measured using methods described 
previously (Vassiliadi et al., 2009) and in secton 2.6. Subjects were categorized as having 
normal glucose tolerance (NGT) or dysglycemia on the basis of 2-h glucose values (NGT 
<7.8mmol/L, dysglycemia ≥7.8mmol/L). Homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated using the formula [fasting glucose (mmol/L)*fasting insulin 
(mIU/L)/22.5]. HOMA-IS (insulin sensitivity) was calculated using the formula 100/HOMA-
IR. Insulin sensitivity index (ISI) was calculated using the formula [75,000 + (Gluc0-
Gluc120)*1.15*180*0.19*body weight (kg)]/120*log(Insmean)*Glucmean] 
(mg*L2*/mmol*mU*min)  (Cederholm and Wibell, 1990, Stumvoll et al., 2000). 
 
3.2.4 Serum and urine steroid measurements 
 Serum steroids were measured by liquid chromatography/tandem mass spectrometry 
(LC-MS/MS) employing a Waters Xevo mass spectrometer with Acquity uPLC system, as 
described in section 2.5.1. Briefly, LC-MS/MS conditions were an electrospray ionization 
source with capillary voltage 4.0kV, a source temperature of 150°C, and a desolvation 
temperature of 500°C. Serum steroid oxime analysis, which facilitates enhanced detection by 
formation of oxime derivatives of the steroid oxo-groups (Kushnir et al., 2010), was 
employed for the measurement of T, A and DHEA and carried out in positive mode, whereas 
measurement of serum DHEAS was performed in negative mode. T, A and DHEA were 
extracted from 200µl serum via liquid-liquid extraction using 1ml tert-butyl-methyl-ether 
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(MTBE) followed by derivatization into steroid oximes employing 100µl derivatization 
mixture (0.16g hydroxylamine in 8ml pyridine). For protein precipitation and extraction of 
DHEAS, 20µl ZnSO4 0.1mM and 100µl acetonitrile were added to 20µl serum before 
evaporation under constant nitrogen flow (Chadwick et al., 2005). All steroids were separated 
using an optimized gradient system consisting of methanol with 0.1% formic acid and 
quantified referring to a linear calibration series with appropriate internal standards. Each 
steroid was identified by matching retention times and two mass transitions in comparison to 
a deuterated reference compound. 
 Serum A and T were categorized as normal based on locally-derived LC-MS/MS 
reference values for premenopausal women (T, 0.3-1.9nmol/L; A, 1.4-7.4nmol/L; 2.5th-97.5th 
percentiles of an unselected healthy female control cohort). Serum androgens were used to 
categorize PCOS patients into four subgroups: normal A/normal T (NA/NT), high A/normal 
T (HA/NT), normal A/high T (NA/HT) and high A/high T (HA/HT). The free androgen index 
(FAI) was calculated in each patient using the formula (T*100)/SHBG. In an additional 
analysis, we also subdivided the PCOS patients into the four phenotypic subgroups arising 
from the Rotterdam criteria recommended at a recent NIH meeting (Fauser et al., 2012). 
These subgroups are defined by the presence of (i) androgen excess, anovulation and 
polcystic ovaries on ultrasound (AE+Anov+PCO), (ii) Anov+PCO, (iii) AE+PCO and (iv) 
AE+Anov.  
 Urinary steroid metabolite excretion analysis was carried out by GC/MS as described 
previously (Arlt et al., 2004) and as summarized in section 2.5.3. The sum of androsterone 
(An) and etiocholanolone (Et) was considered representative of active androgen metabolite 
excretion (Silfen et al., 2002). Net systemic 5α-reductase activity was assessed by the ratios of 
An/Et and 5α-tetrahydrocortisol/tetrahydrocortisol (5α-THF/THF). 11β-hydroxysteroid 
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dehydrogenase type 1 (11β-HSD1) activity was estimated using the ratio of the 
tetrahydrometabolites of cortisol (5α-THF + THF) to tetrahydrocortisone (THE) (Stewart et 
al., 1999) and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity by the ratio of 
free urinary cortisol to cortisone (UFF/UFE). Total glucocorticoid metabolite excretion was 
assessed as the sum of 5α-THF + THF + THE + cortolones + cortols + cortisol + cortisone. 
 
3.2.5 Statistical analysis 
 Statistical Package for the Social Sciences (SPSS, Chicago, Il.) Version 21 was used 
for data analysis. All data is expressed as mean ± standard deviation (SD) unless otherwise 
stated. Data was log-transformed if necessary to normalize before using parametric tests. 
Independent samples t tests or Mann-Whitney were used as appropriate for comparison 
between two groups. One-way ANOVA with post hoc Tukey testing was used for multiple 
comparisons between different groups. Categorical variables were compared using Pearson’s 
Chi-Square test. Correlation testing was performed using Pearson’s correlation co-efficient 
for normally distributed data or Spearman’s test for non-normally distributed data. Multiple 
linear regression was used to adjust for the confounding effects of different variables. 
Differences were considered statistically significant at p<0.05.  
 
 
 
 
 
Chapter 3   Circulating androgens and metabolic phenotype 
 
 114 
3.3 Results 
 Baseline clinical and metabolic characteristics of PCOS and age- and BMI-matched 
healthy controls are shown in Table 3-1. Complete clinical, biochemical and radiological data 
were available in 86 women with PCOS, all fulfilling the clinical phenotype criteria for PCOS 
as defined by the Rotterdam consensus (Rotterdam, 2004b). Results were compared to those 
obtained from 43 age- and BMI-matched controls. Hirsutism and oligomenorrhea were 
present in 87% and 92% of PCOS patients, respectively. Polycystic ovaries were present on 
ultrasound in 73%. PCO subgroups arising from the Rotterdam criteria were also matched for 
age and BMI and were categorized as per the following clinical phenotype groups: (i) AE, 
Anov, PCO (n=51, 59%), (ii) AE+PCO (n=6, 7%), (iii) Anov+PCO (n=9, 11%) and (iv) 
AE+Anov (n=20, 23%). 
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Table 3-1 Clinical, biochemical and metabolic characteristics in the overall PCOS cohort 
(n=86), PCOS androgen phenotype subgroups and age- and BMI-matched controls (n=15). 
PCOS subgroup classification according to high (H) or normal (N) serum androstenedione 
(A) and serum testosterone (T) concentrations as measured by liquid chromatography/tandem 
mass spectrometry (normal T (NT) ≤1.9nmol/l; normal A (NA) ≤7.4nmol/l). Normal glucose 
tolerance, 2-h glucose oGTT ≤7.7mmol/l. Dysglycemia, 2-h glucose oGTT ≥7.8mmol/l.  
a, p<0.05, b, p<0.01, c, p<0.001 as compared to BMI-matched healthy controlsd. d, p<0.05; 
e, p<0.01; f, <0.001 as compared to NA/NT group  
Variable 
 
 
Controls 
(n=43) 
 
All PCOS 
(n=86) 
NA/NT (n=10) HA/NT 
(n=20) 
HA/HT 
(n=56) 
 
Age (years) 32.4±9.8 30.0±7.2 
 
32.9±2.9 30.8±7.9 28.8±7.0 
BMI (kg/m2) 30.3±6.4 
 
31.9±7.1 30.2±6.5 30.0±5.9 32.1±6.5 
Ferriman-
Gallwey Score 
2.1±1.6 12.4±6.7c 9.9±5.3c 10.1±6.4c 13.9±7.2c,d 
Testosterone 
(nmol/L) 
1.3±0.4 2.2±0.8c 1.2±0.3 1.6±0.4 2.6±0.7c,f 
FAI 
(Tx100/SHBG) 
3.2±1.8 
 
9.1±6.1c 5.5±3.9a 7.3±4.6a 10.5±6.5c,d 
SHBG (nmol/L) 49.8±26.6 32.3±18.4c 28.8±11.8c 30.8±21.2c 31.8±16.5c 
Androstene- 
dione (nmol/L) 
3.5±1.4 13.4±5.6c 5.1±1.7 11.4±4.2c,f 14.2±5.1c,f 
DHEA 
(nmol/L) 
20.5±7.9 57.5±30.0c 24.4±8.6 59.8±34.8c,e 58.0±26.8c,e 
DHEAS 
(µmol/L) 
3.9±2.0 6.2±3.0c 2.4±1.2 6.3±2.6f 6.2±2.7c,f 
DHEA/ 
DHEAS ratio 
7.8±3.7 12.9±6.8a 12.6±8.5a 14.0±10.0a 15.4±5.4a 
LH (IU/L) 5.2±2.4 
 
9.9±5.8a 4.7±3.2 9.0±6.3a 11.4±9.2a,d 
LH/FSH ratio 0.8±0.5 
 
2.0±1.5a 0.9±0.7 2.1±1.9a 2.3±1.4a,d 
Fasting glucose 
(mmol/L) 
4.6±0.5 4.8±0.7 5.0±0.5 4.7±0.5 4.8±0.8 
2-h OGTT 
glucose 
(mmol/L) 
6.7±1.5 6.5±2.2 5.5±1.2 6.7±1.9 6.7±2.3 
Fasting insulin 
(mIU/L) 
2.0±1.5 10.4±8.6b 8.2±5.5a 
 
11.7±8.3a 12.3±6.6c 
HOMA-IR 0.9±0.8 
 
2.3±0.2b 1.9±1.1a 2.4±1.5a 2.8±1.0b,d 
ISI (Cederholm) 
(mg*L2/mmol*m
U*min) (25) 
78.7±38.0 54.6±24.1c 73.4±54.6 51.0±17.1 c,f 54.4±25.2c,f 
Dysglycemia  
(n; %) 
3 (6.9%) 17 (19.7%)a 0 3 (15%) 14 (25%)a,d 
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3.3.1 Circulating androgens and androgen excretion 
 Both serum A and T were significantly higher in PCOS than in healthy controls 
(p<0.0001 for both, Table 3-1). PCOS patients also had significantly higher FAI, DHEA and 
DHEAS (all p<0.0001) than controls. Total urinary androgen excretion as a reference marker 
of 24-h net production was also significantly higher in PCOS (p<0.0001, Table 3-2), with 
higher excretion of An (p<0.001), Et (p<0.05) and DHEA (p<0.05). T and A correlated 
strongly with FAI and total androgen metabolite excretion (Figure 3-1). 
  Serum A was elevated in 76 out of 86 (88.3%) PCOS patients, while T was elevated in 
56 (65.1%). A was also elevated in 1/43 (2.3%) healthy controls; T was elevated in 5/43 
(11.6%). Serum levels of A and T were in the normal range in 10 and 30 PCOS patients, 
respectively. Patients with PCOS were subsequently divided into four androgen phenotype 
groups dependent upon circulating androgens; normal A and concurrently normal T (NA/NT), 
normal A and high T (NA/HT), high A and normal T (HA/NT), and the most severe degree of 
androgen excess, high A and high T (HA/HT). Our analysis showed that the majority of 
patients fell into the HA/HT group (n=56), with 20 and 10 patients classified as HA/NT and 
NA/NT respectively; no patient had high T but normal A (Figure 3-2).  
 PCOS women in the group with the mildest degree of biochemical androgen excess 
(NA/NT) were similar to BMI-matched controls with regard to circulating DHEA, DHEAS, 
T, A, LH and the LH/FSH ratio. However they differed significantly from controls with 
regard to SHBG and FAI (Table 3-1). NA/NT PCOS women had androgen metabolite 
excretion rates similar to controls, while androgen excretion in the two other PCOS groups 
was significantly higher (Table 3-2, Figure 3-3). Similarly, serum DHEA and DHEAS were 
significantly higher in HA/HT and HA/NT patients as compared to the NA/NT group and the 
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controls (Figure 3-3). Clinically, the Ferriman-Gallwey score was significantly higher in 
HA/HT women compared to NA/NT (p=0.04) (Table 3-1).  
Table 3-2 24-h urinary steroid excretion in PCOS patients, controls and PCOS androgen 
phenotype subgroups. Androgen and glucocorticoid metabolites were measured by gas 
chromatography/mass spectrometry. PCOS subgroup classification according to high (H) or 
normal (N) androstenedione (A) and testosterone (T) concentrations as measured by liquid 
chromatography/tandem mass spectrometry (normal T (NT) ≤1.9nmol/l; normal A (NA) 
≤7.4nmol/l). Data expressed as mean±SD unless otherwise stated. 
a, p<0.05, b, p<0.01, c, p<0.001 as compared to BMI-matched healthy controls 
d, p<0.05; e, p<0.01; f, <0.001 as compared to NA/NT group  
Variable 
 
 
Controls 
(n=43) 
 
All PCOS 
(n=86) 
NA/NT 
(n=10) 
HA/NT 
(n=20) 
HA/HT 
(n=56) 
Total androgen 
metabolites 
(µg/24h) 
2882±2018 5493±2781c 2751±1760 4886±1968a,d 5727±2530c,d 
An (µg/24h) 1413±906 2824±1651c 1452±1178 
 
2594±1207a 3016±1553c,d 
Et (µg/24h) 1468±1208 
 
2457±725c 1299±733 2292±1211 2683±1469a,e 
An/Et ratio (5α-
reductase activity) 
 
1.1±0.4 1.3±0.6a 1.2±0.6 1.3±0.6 1.3±0.6 
Urinary 
DHEA(µg/24h) 
457±721 1740±954a 477±400 1586±960 1960±854a, d 
Total 
glucocorticoid 
metabolites 
(µg/24h) 
6821±3572 9624±4214b 8449±4181 8935±3404 9803±4390a 
5α-THF (µg/24h) 940±608 
 
1313±814a 1250±1135 1259±759 1359±842b 
THF (µg/24h) 1206±607 
 
1520±549a 1489±924 1477±475 1634±822a 
5α-THF/THF (5α-
reductase activity) 
0.8±0.3 
 
0.9±0.5 0.8±0.4 0.8±0.5 0.9±0.5 
(5α-
THF+THF)/THE 
(11β-HSD1 
activity) 
0.9±0.3 
 
0.9±0.3 0.9±0.3 0.9±0.2 0.9±0.4 
Urinary 
cortisol/urinary 
cortisone (11β-
HSD2 activity) 
0.6±0.5 0.6±0.2 0.5±0.1 0.6±0.2 0.7±0.2 
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Figure 3-1 Relationship of serum testosterone (T) and androstenedione (A) with free 
androgen index (FAI), total urinary androgen metabolites and insulin sensitivity index (ISI).  
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Figure 3-2 Relationship of serum testosterone (T) and androstenedione (A) with stratification 
of androgenemic subgroups: normal A and normal T (NA/NT, n=10); high A and normal T 
(HA/NT, n=20); high A and high T (HA/HT, n=56). 
 
3.3.2 Metabolic characteristics 
 Overall, PCOS patients had higher fasting insulin and HOMA-IR values than BMI-
matched controls but fasting glucose and 2-hour values did not differ significantly (Table 
3-1). The incidence of dysglycemia was 19.7% in the PCOS group compared to 6.9% in 
controls (p=0.03). SHBG was significantly lower in the PCOS group compared to controls 
(p<0.001). No significant correlation was observed between BMI and T (R=0.14, p=0.13), A 
(R=0.01, p=0.91), or the T:A ratio (R=0.01, p=0.98). However, BMI was positively correlated 
with FAI (R=0.4, p<0.0001) and systemic 5α-reductase activity (An/Et, R=0.21, p=0.01; 5α-
Chapter 3   Circulating androgens and metabolic phenotype 
 
 120 
THF/THF, R=0.20, p=0.02). T, A, and FAI all correlated positively with HOMA-IR (T: 
R=0.23, p=0.02; A: R=0.21, p=0.02; FAI: R=0.56, p<0.0001). ISI and HOMA-IS values were 
lower in PCOS patients compared to controls (p<0.001 for both). After correcting for age and 
BMI, ISI had a strong negative correlation with serum T and A (R=-0.41, p<0.001, and R=-
0.55, p<0.00001, respectively, Figure 3-1). When PCOS and control patients were considered 
separately, a negative association between A and ISI was observed in both groups (R=-0.53, 
p<0.00001, and R=-0.41, p<0.001, respectively). In obese control patients, this negative 
association between A and ISI persists (R=-0.25, p=0.04). On multiple linear regression 
analysis, a significant negative association was confirmed only between A and ISI (coefficient 
-2.69, 95% CI -1.57, -3.81, p<0.0001, Table 3-3); no such association was observed between 
ISI and either serum T, DHEAS or DHEA.  
HOMA-IR in all three PCOS subgroups was significantly higher than in controls and 
HA/HT women had significantly higher values than NA/NT women (p<0.05 for both) (Figure 
3-3). However, only HA/NT and HA/HT had lower ISI values (Table 3-1). PCOS women in 
the NA/NT group had significantly higher fasting insulin and HOMA-IR than BMI-matched 
controls but did not have any cases of dysglycemia, as documented by OGTT (Table 3-1). In 
contrast, 15% and 25% of women in the HA/NT and HA/HT groups, respectively, had an 
abnormal OGTT result. No significant differences were observed in systolic BP, TChol, HDL 
or TG between each group. In contrast to the significant differences found between the groups 
defined by A and T levels, no difference in insulin sensitivity was observed between the four 
PCOS phenotype groups defined by the presence of Rotterdam criteria (Figure 3-4). 
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Figure 3-3 Total androgen metabolites (A), HOMA-IR (B), ISI (C), fasting insulin (D), serum 
DHEA (E) and DHEAS (F) in the three androgen phenotype PCOS sub-groups and healthy 
controls. *p<0.05; **p<0.01; ***p<0.001. 
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Table 3-3 Multiple linear regression model for insulin sensitivity index (ISI). a, p<0.05; b, 
p<0.001, c, p<0.0011. 1Represents unit change in ISI (mg*L2/mmol*mU*min) for each unit 
increase in variable. 
Variable Coefficient1 95% CI  
(Upper, Lower) 
Age -1.39b -0.53, -2.24 
BMI -1.93c -1.07, -2.80 
Testosterone 6.58 18.79, -5.60 
Androstenedione -2.69 c -1.57, -3.81 
DHEA -0.10 0.14, -0.34 
LH -0.61 0.06, -1.28 
Total androgen metabolites 0.003 0.006, -0.001 
Total GC metabolites -0.003a -0.001, -0.005 
 
 
 
Figure 3-4 Insulin sensitivity index (ISI) in each of the four PCOS phenotype groups derived 
from the Rotterdam criteria.  
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3.3.3 Body composition 
No significant differences in fat distribution or total lean mass were observed between 
PCOS and control women on DXA imaging. Similarly, there were no significant differences 
in body composition between the three PCOS androgen phenotype subgroups or the four 
PCOS phenotype groups. After controlling for age and BMI (partial correlation testing), the 
android:gynaecoid ratio was strongly correlated with HOMA-IR (R=0.53, p<0.0001), FAI 
(R=0.37, p<0.0001), An/Et (R=0.38, p<0.0001) , 5α-THF/THF (R=0.31, p<0.0001) and total 
glucocorticoid metabolites (R=0.26, p=0.01). There was also a strong negative correlation 
between the android:gynaecoid ratio and ISI (R=-0.41, p<0.01). Gynaecoid fat had a negative 
association with HOMA-IR (R=-0.36, p=0.003) and FAI (R=-0.29, p=0.03).   
 
3.3.4 Cortisol metabolism 
 PCOS patients and controls did not differ significantly in indices of 11β-HSD1 or 11β-
HSD2 activity (Table 3-2). However, total glucocorticoid excretion was higher in the PCOS 
group (9624±4214 vs. 6821±3572µg/24h, p=0.01). Total glucocorticoid metabolites 
correlated positively with HOMA-IR and negatively with ISI (R=0.45, p<0.0001, and R=-
0.43, p<0.0001). On multiple linear regression (Table 3-3), total glucocorticoid metabolites 
were negatively associated with the ISI (coefficient -0.003, 95% CI -0.001, -0.005, p=0.048). 
When carrying out a separate analysis for the PCOS androgen phenotype subgroups, 
urinary glucocorticoid excretion appeared to gradually increase with the degree of androgen 
excess, with significantly higher levels in the HA/HT group than in controls. Urinary levels of 
5α-THF and THF were significantly higher (p=0.005 and p=0.03, respectively) in HA/HT 
women compared to controls.  
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3.4 Discussion 
 We have performed a detailed assessment of the clinical, metabolic and androgen 
phenotype of a cohort of PCOS, revealing that PCOS patients with co-elevation of A and T 
have impaired indices of insulin sensitivity compared to those with normal androgens or a 
solitary androgen elevation. In addition, using multiple linear regression, we found a strong 
negative relationship between A and insulin sensitivity as measured by the ISI, independent of 
age and BMI; such a relationship was not observed between T and ISI. All our patients were 
diagnosed according to consensus criteria and fulfilled at least two out of the three criteria 
oligo-/anovulation, polycystic ovaries on ultrasound and clinical signs of androgen excess, 
with other relevant etiologies excluded. Until relatively recently it has been unclear whether 
women with hyperandrogenic PCOS are at increased cardio-metabolic risk compared to those 
without clinical or biochemical signs of androgen excess. However, recent data suggest that 
biochemical androgen excess poses a higher risk of liver disease, insulin resistance and 
subclinical atherosclerosis compared to those with ovulatory dysfunction and polycystic 
ovaries alone (Jones et al., 2012, Barber et al., 2007). These findings suggest that 
hyperandrogenic PCOS represents a distinct metabolic phenotype, and that patients without 
androgen excess may have a phenotype similar to healthy controls (Dewailly et al., 2006).  
However, in our cohort we also found higher insulin and HOMA-IR values in normo-
androgenemic PCOS compared to healthy controls, suggesting that women without androgen 
excess are not entirely protected from metabolic dysfunction.  
 Women with hyperandrogenic PCOS in our cohort had a significantly reduced ISI; 
those with normal serum androgens had ISI values comparable to healthy controls. However 
it is interesting that HOMA-IR and HOMA-IS values were still unfavorable in the NA/NT 
group, suggestive perhaps of impaired fasting indices but preserved ability to handle an oral 
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glucose load. Such an observation needs to be explored further and corroborated in future 
studies. Serum androgens, and in particular A, had a strong negative association with the ISI 
after correction for age and BMI, and this association was also observed in control patients 
with circulating A levels within the normal range. Overall these data lend support to the 
hypothesis that metabolic disease in PCOS should be considered as a continuous variable, 
with metabolic dysfunction observed across a worsening spectrum of severity of androgen 
excess.  It is important to remember that serum cut-off values and normal ranges are relatively 
arbitrarily defined, and that androgen exposure across all patients with PCOS may contribute 
to their metabolic phenotype. Women with normal circulating androgens may still exhibit 
subtle hyperandrogenemia after LH stimulation (Gilling-Smith et al., 1997), which could 
explain the higher indices of insulin resistance observed. The long-term implications of this 
are unclear without longitudinal, prospective studies but these findings have also been 
observed by Barber and colleagues (Barber et al., 2007). When we subdivided our PCOS 
cohort into the four phenotypic groups arising from the Rotterdam consensus (Figure 3-4), no 
significant differences were observed in insulin sensitivity or body composition between each 
group. Therefore it is reasonable to argue that this strategy of sub-phenotyping of PCOS 
patients may not accurately predict those at highest metabolic risk. Interestingly Barber and 
colleagues found that patients in their AE+Anov+PCO subgroup were more insulin resistant; 
however, it is important to note that mean BMI of that group in the Barber study was 
significantly higher than in the other three phenotypic groups, whereas in our study the four 
groups were BMI-matched. For this reason we believe that co-measurement of A and T might 
offer a better alternative in terms of metabolic risk prediction than the previously suggested 
categorization by phenotype. 
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It is crucial that PCOS patients are correctly and accurately categorized as 
normoandrogenemic or hyperandrogenemic if they are to be stratified into low and high-risk 
metabolic groups on this basis. Our data show that measurement of serum T alone fails to 
adequately make this differentiation. Elaborate investigative tools such as LH stimulation 
testing or 24-h urinary androgen metabolite excretion as the reference standard for total 
androgen production are not universally available in routine clinical practice. By contrast, 
concurrent measurement of serum T and A provides a strategy that is easily applicable in 
clinical practice.  In our view, only those with normal serum levels of both androgens should 
be categorized as normoandrogenemic; as discussed above, even this cohort may still exhibit 
occult hyperandrogenism, and without prospective studies it is impossible to be certain if they 
are protected from more severe metabolic disease over time. To date, there are only very 
limited data on the effects of androgen-lowering therapies on metabolic parameters in PCOS 
(Fruzzetti et al., 2010, Studen et al., 2011) and clearly larger prospective trials are needed.  
 Previous work has advocated measurement of a single morning serum testosterone 
sample during the early follicular phase as the diagnostic criterion for hyperandrogenemia 
(Barth et al., 2007). The limitations of total T as a solitary diagnostic tool for 
hyperandrogenemia have been described in the introduction of this paper and direct 
measurement of free T has been largely abandoned due to its notorious inaccuracy 
(Vermeulen et al., 1999), unless equilibrium dialysis is used, which is cumbersome, expensive 
and has very limited accessibility for routine clinical samples. The clearance and 
bioavailability of T are affected by serum SHBG levels, which are lowered by 
hyperinsulinemia, but A levels are not affected by this phenomenon (Anderson, 1974), and 
this may explain some of the observed discrepancies between T and A measurements. 
Appropriateness and reliability of analytical methods has equally been a major issue in this 
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debate, and the Endocrine Society has appealed to international laboratories to refine 
techniques for androgen measurement in women (Rosner et al., 2007). However the advent of 
LC-MS/MS has dramatically improved the rapid detection and reliable quantification of a 
range of serum steroids in both clinical and research practice (Cawood et al., 2005). Accurate 
A measurement could now emerge from these developments as a sensitive diagnostic test for 
hyperandrogenemia in PCOS. 
Patterns of body fat distribution on DXA did not differ between PCOS and control 
patients, supporting previously published work (Barber et al., 2008). These and other studies 
point towards a qualitative rather than quantitative defect in adipose biology in PCOS (Barber 
and Franks, 2013). 17β-HSD5 is expressed in adipose tissue, and significant extra-ovarian 
conversion to testosterone may occur in obesity (Quinkler et al., 2004). Interestingly, there 
was also no difference in fat distribution phenotype between androgenemic subgroups in our 
cohort, and no correlation between BMI and serum androgens. 17β-HSD5 is also highly 
expressed in the ovary, and activating variants result in a PCOS phenotype with severe insulin 
resistance (Qin et al., 2006). This suggests a possible primary role for androgen excess in 
insulin resistance. However, the prevalence of increased insulin resistance in patients with 
elevated T and A in our study could also point towards an insulin-mediated effect on ovarian 
thecal steroidogenesis.  The observation that insulin plays a key role in thecal androgen 
generation in vivo and in vitro supports this hypothesis (Cara and Rosenfield, 1988, Tosi et 
al., 2012). Insulin-stimulated A generation from the ovarian theca may create an enlarged 
circulating pool for conversion to T, and elevated levels of the former may therefore be a 
surrogate marker for metabolic dysfunction.  
One limitation of our study is its cross-sectional nature. Longitudinal studies will 
reveal whether initial increases in androgen precursors later followed by additional increases 
Chapter 3   Circulating androgens and metabolic phenotype 
 
 128 
in T may represent a sequence observed over time in individual patients. We also accept that 
HOMA-IR measurement is not the gold-standard test assessment of tissue-specific insulin 
sensitivity. However the ISI devised by Cederholm and calculated in our cohort has been 
shown to perform with comparable accuracy to a hyperinsulinemic euglycemic clamp 
(approx. R=0.8) (Cederholm and Wibell, 1990, Stumvoll et al., 2000). Similarly, it was not 
possible to measure serum androgens in the early follicular phase of all patients, largely due 
to the fact that most PCOS patients were oligo- or amenorrhoeic. Finally the debate over what 
constitutes normal androgen values continues, and quoted reference ranges refer to normative 
values in 95% of an unselected presumptively healthy female population, implying that 
‘abnormal’ levels will be observed in 5% of women with no evidence of endocrinopathy.  
In conclusion, these data endorse the hypothesis that serum A is a more sensitive 
indicator of PCOS-related androgen excess that serum total T concentrations. We found that 
increasing androgen burden is associated with an adverse metabolic phenotype, and 
concurrent measurement of both A and T has highlighted a cohort of PCOS women that 
appears to be at increased metabolic risk. The utility of this novel tool for predicting 
metabolic risk in PCOS women warrants investigation in prospective and longitudinal studies 
and these may ultimately afford a personalized approach to the management of PCOS. The 
next challenge is to tease out the specific contribution of adipose tissue to androgen 
generation in PCOS, and how local androgen exposure adversely impacts on the metabolic 
phenotype. These will be explored in chapters 4 and 5, respectively. 
 
  
4 AKR1C3 expression and activity in 
human adipose tissue 
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4.1 Introduction 
 Hyperandrogenism in PCOS has classically been attributed to increased ovarian and 
adrenal secretion of androgen precursors and active androgen metabolites (Franks, 1995). 
However, recent focus has increasingly shifted to peripheral tissues, which are not only 
targets of androgen action, but also play an important role in pre-receptor metabolism and 
androgen activation (Labrie et al., 2003). This process of intracrine activation is discussed in-
depth in section 1.4.2. Adipose tissue is a key peripheral organ of androgen activation and 
secretion (Blouin et al., 2009a). Evidence for the role of adipose tissue in systemic androgen 
metabolism is highlighted in studies showing positive correlations between circulating sex 
steroid levels, BMI and fat mass in females (Mongraw-Chaffin et al., 2015, Borruel et al., 
2013). These associations are complex and may exhibit sexual dimorphism; obesity in men is 
associated with low circulating sex steroid levels and hypogonadism (Mongraw-Chaffin et al., 
2015). However, it is increasingly clear that androgen excess in females is intimately 
connected to both total adiposity and fat distribution, and may represent a component of the 
metabolic syndrome in premenopausal women (Corbould, 2008). 
 As discussed in section 1.7.2, adipose tissue has a complex network of androgen 
activating and inactivating enzymes (O'Reilly et al., 2014a). Important androgen-activating 
enzymes include 5αR1 and AKR1C3. 5αR1 converts T to the more potent DHT. AKR1C3 has 
predominant 17β-HSD activity, converting A into T, and is also referred to as 17β-HSD type 
5. Expression and activity were correlated with body mass index in one small human study, 
and weight loss resulted in significant downregulation of mRNA expression (Quinkler et al., 
2004). AKR1C3 is also highly expressed in the ovaries and adrenals, and activating 
polymorphisms are associated with an increased risk of PCOS (Ju et al., 2015). Adipose tissue 
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is also capable of androgen inactivation; AKR1C2 (also called 3α-HSD3) converts DHT into 
the weak 3α-diol through its 3α-reductase activity (Blouin et al., 2003). It is believed that 
androgen activation and inactivation are delicately balanced in adipose tissue, but factors 
influencing this equilibrium are poorly understood.  
 Severity of hyperandrogenism in PCOS is closely correlated with obesity, insulin 
resistance and circulating insulin levels (Nestler and Jakubowicz, 1997). The effects of insulin 
on ovarian hyperandrogenism are well documented in vivo and in vitro (Dunaif and Graf, 
1989, Poretsky et al., 1999), and are summarized in Table 1-4. Insulin acts in synergy with 
pituitary gonadotrophins to increase ovarian thecal androgen generation. It drives local LH 
receptor recruitment, and directly stimulates thecal 17α-hydroxylase activity (Nestler et al., 
1998). Systemically, insulin is correlated with total body 5α-reductase activity (Vassiliadi et 
al., 2009, Tsilchorozidou et al., 2003), implying a significant role in global rather than organ-
specific androgen metabolism. This relationship is observed independent of BMI. The role of 
insulin in adipose androgen metabolism has not been delineated to date. Insulin-responsive 
transcriptional regulators of AKR1C3 have recently been characterized (Du et al., 2009), 
raising the exciting possibility of a direct role for insulin in adipose androgen activation. As 
discussed above, obesity per se may also play an important role in androgen metabolism; 
most studies have found a positive association between T and adiposity in women, but the 
converse appears to be the case in men (Mongraw-Chaffin et al., 2015, Oh et al., 2002). 
Whilst fat mass itself may drive adipose androgen generation, some of the observed effects in 
PCOS might also be mediated by obesity-induced hyperinsulinaemia. 
 We hypothesise that hyperinsulinaemia in PCOS drives adipose androgen activation in 
a similar manner to that observed in the ovary. We also hypothesise that mRNA expression of 
androgen-activating enzymes in adipose tissue is closely associated with body mass index in 
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female patients. In order to test these hypotheses, I will measure mRNA expression of 
enzymes of interest in adipose tissue explants obtained from male and female subjects, across 
both subcutaneous and omental fat depots, and correlate expression levels with age and BMI. 
Furthermore, I will examine the role of insulin in adipose androgen metabolism in a human 
adipocyte cell line, SGBS, and validate findings where possible in primary differentiated 
female OM and SC adipocytes. Cells will be exposed to hyperinsulinaemic conditions in 
vitro, with measurement of AKR1C3 mRNA expression by realtime-PCR, and determination 
of functional activity by measurement of conversion of A to T by LC-MS/MS. 
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4.2 Methods 
4.2.1 Research strategy 
 In this chapter, I will study mRNA expression of the androgen-activating enzymes 
AKR1C3 and 5αR1, and the inactivating enzyme AKR1C2, in adipose tissue explants from 
both male and female patients undergoing abdominal surgery at the Queen Elizabeth Hospital 
Birmingham. Expression levels will be examined across SC and OM fat depots, and 
correlated with age and BMI in both sexes. Furthermore, I will examine the SGBS 
preadipocyte cell line as a valid representative model for adipose androgen metabolism in 
humans. mRNA expression of key markers of adipogenesis and lipid metabolism will be 
examined across differentiation (days 0, 7 and 14). Androgen receptor (AR), AKR1C3 and 
SRD5A1 expression will also be determined to validate the utility of the SGBS model as a 
tool to study adipose androgen metabolism.  
 In order to study the effects of hyperinsulinaemia on androgen generation from 
adipocytes in vitro, differentiated SGBS cells will be exposed to incremental doses of insulin. 
Realtime PCR will be used to examine the effect of insulin exposure on AKR1C3 mRNA 
expression. Additionally, I will employ LC-MS/MS as a functional tool to study adipocyte 
AKR1C3 activity under normal and hyperinsulinaemic conditions, by measuring T generation 
after incubation with A. Findings will be replicated and validated where possible in primary 
human OM and SC cultures differentiated ex vivo. Finally, pharmacological inhibition of 
AKR1C3 and of the insulin-stimulated PI3K pathway will be employed to determine if local 
androgen metabolism can be ameliorated by selective modulation of the androgen and insulin 
metabolic pathways.  
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4.2.2 Subjects 
 Local research ethics committee (REC) approval was obtained. Patients undergoing 
abdominal surgery at the Queen Elizabeth Hospital gave written informed consent in order to 
provide paired OM and SC fat biopsies to the Human Biorepository at the University of 
Birmingham. Exclusion criteria included pregnancy, diabetes, glucocorticoid treatment, and 
inflammatory or neoplastic disease. Samples obtained were used for primary cell culture 
experiments (section below), or were dissected into whole tissue explants. These explants 
were stored in RNALater at -20°C until RNA extraction.  
 
4.2.3 SGBS cell culture 
 Proliferating SGBS cells were seeded in 12- or 24-well plates and grown to 
confluence in DMEM-F12 with 10% FCS, additionally supplemented with 33µM biotin, 
17µM pantothenate and penicillin-streptomycin 1% (growth media). In preadipocyte studies, 
cells were exposed to treatments, and biomaterial extracted, before differentiation. In 
adipocyte studies, SGBS cells were differentiated over 14 days in OF media, which was 
further supplemented according to the differentiation protocol described in section 2.2. All 
cells were cultured in serum-media (OF only without additives) for 24 hours before 
experiments.  
 
4.2.4 Human preadipocyte cell culture 
 Primary human fat samples were obtained as described in section 4.2.2, and extracted 
from whole OM and SC tissue according to the protocol described by Bujalska et al (Bujalska 
et al., 1999) and summarized above in section 2.1. Briefly, adipose tissue samples were 
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digested with type 2 collagenase at 37°C for one hour, followed by sterile filtration through 
layered gauze to remove solid components. After centrifugation, the stromovascular pellet 
containing preadipocytes was resuspended in media and plated in 12- or 24-well plates. 
Preadipocytes were grown to 80% confluence before differentiation into mature adipocytes 
over 14 days in chemically-defined media. All treatment protocols involved use of serum-free 
media without additives for 24 hours.  
 
4.2.5 Cell treatments 
   All treatments were diluted as appropriate in serum-free media. AKR1C3 activity 
assays were performed by the addition to A to wells containing serum-free media for 4, 8 or 
24 hours (as appropriate to the experiment). The AKR1C3 inhibitor, 3-4-trifluoromethyl-
phenylamino-benzoic acid (Merck Millipore, UK), was added to wells for 15 minutes at a 
concentration of 500nM before addition of A. The PI3K inhibitor wormannin (500nM) was 
added 15 minutes before addition of insulin in selected experiments. 
 
4.2.6 RNA extraction, reverse transcription and real-time PCR 
 Total RNA was extracted using the Tri-Reagent protocol (section 2.4.1). RNA 
concentration and purity were assessed using NanoDrop technology as described above. One 
microgram of total RNA was used for reverse transcription (see section 2.4.2); cDNA was 
diluted 1:10 with RNase-free water. Real-time PCR was used to determine adipose mRNA 
expression of the key adipogenic markers LPL and PPAR-γ, components of the insulin-
signalling pathway (PI3K and IRS-2), and crucial regulators of androgen metabolism (AR, 
AKR1C3, SRD5A1 and SRD5A2). Real-time PCR reactions were performed as described in 
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section 2.4.3. mRNA levels were detected using an ABI 7500 sequence detection system 
(Applied Biosystems/Life Technologies, Paisley, UK). All probes and primers were supplied 
by Applied Biosystems/Life Technologies as expression assays (Taqman probe/primer mix). 
All reactions were normalized against two housekeeping genes, 18S and GAPDH.  
 
4.2.7 Cell media steroid extraction and LC-MS/MS analysis 
 Steroids were extracted for LC-MS/MS analysis of AKR1C3 activity as described in 
section 2.5.2. Briefly, A substrate (200nM) was added to wells of SGBS cells or primary 
differentiated adipocytes containing serum-free media without additives. After 4, 8 or 24 
hours (as appropriate to each experiment), media was removed and placed in sylinised glass 
TLC tubes, to which 20µl internal standard was added. A calibration series was prepared for 
each experiment as described in Table 2-1. MTBE (3ml) was added to each sample, followed 
by freezing (1-24 hours). After evaporation, samples were reconstituted in 125µl of 
methanol:H20 (50:50) and frozen at -20°C until ready for LC/MS-MS analsysis. AKR1C3 
activity was determined by the generation of T from A substrate over a defined time period. 
Comparison for T generation between treatments and controls was performed by normalizing 
control data to 100%.  
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4.2.8 Statistical analysis 
 Normally distributed data were analysed using unpaired student t tests to compare 
single treatments to controls; non-parametric tests were used when normality tests failed. 
When comparing means from multiple groups, one-way ANOVA with post-hoc Tukey testing 
was employed. All statistical analysis on realtime PCR data was performed for minimum of 
n=3 on Δct values between different treatment groups. Arbitrary mRNAunits were log-
transformed. Correlation testing was employed to examine linear relationships between 
continuous variables, using Pearson’s test (parametric) or Spearman’s rank test (non-
parametric data) as appropriate. 
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4.3 Results 
4.3.1 Androgen-metabolising enzyme mRNA expression in male and female adipose 
tissue explants 
4.3.1.1 Subjects 
 Paired SC and OM fat samples were obtained from 66 participants (26 male). Baseline 
demographic data is shown in Table 4-1. No significant differences were observed in age and 
BMI between male and female patients (p=0.36 and p=0.45, respectively).  
 
Table 4-1 Baseline characteristics of study group 
 
Variable  
(mean±SEM, range) 
Male (n=26) Female (n=40) 
Age (years) 61.6±2.8 (28-82) 58.3±2.2 (27-84) 
BMI (kg/m2) 27.6±0.8 (20.7-37.4) 28.6±1.0 (21.3-53.3) 
 
No significant differences were observed in SC and OM mRNA expression of AKR1C3, 
AKR1C2 or SRD5A1 between male and female patients, Table 4-2. 
 
Table 4-2 Comparison of mRNA expression of androgen-metabolising enzymes between 
males and females in SC and OM adipose tissue (data expressed as mean Δct±SEM) 
Gene Male (n=26) Female (n=40) P-value 
AKR1C3 SC 7.5±1.0 7.3±0.7 0.83 
AKR1C3 OM 9.5±0.6 9.2±0.6 0.67 
AKR1C2 SC 19.5±0.9 20.3±0.9 0.57 
AKR1C2 OM 19.3±1.5 21.2±0.5 0.14 
SRD5A1 SC 11.9±0.7 11.8±0.7 0.95 
SRD5A1 OM 12.7±0.5 12.4±0.4 0.71 
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4.3.1.2 Depot-specific differences 
 When male and female patients were analysed together, AKR1C3 expression was 
significantly higher in SC compared to OM fat (mean Δct 7.1±0.6 v 9.2±0.4, p=0.004, Figure 
4-1). Expression of AKR1C2 and SRD5A1 did not differ significantly between SC and OM 
tissue (20.6±0.6 v 19.3±0.8 and 12.8±0.4 v 11.8±0.5, p=0.22 and p=0.09, respectively).  In 
male patients, no differences in SC compared to OM mRNA expression of AKR1C3, 
AKR1C2 or SRD5A1 were observed (7.5±1.0 v 9.5±0.6, p=0.10, 19.5±1.0 v 19.3±1.5, 
p=0.89, and 11.9±0.7 v 12.7±0.5, p=0.35, respectively). However, in female patients, 
AKR1C3 expression was significantly higher in SC compared to OM fat (7.3±0.7 v 9.2±0.6, 
p=0.04).   
 
 
Figure 4-1 Relative AKR1C3 mRNA expression in SC and OM adipose tissue (all patients, 
n=66). **p<001 for Δct. 
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4.3.1.3 Associations between androgen gene expression, age and BMI 
 Subject samples were next categorized into those from patients aged <55 years and 
those ≥55 years. Expression of AKR1C3, AKR1C2 and SRD5A1 in OM fat did not differ 
significantly between the two age categories (Table 4-3). However, AKR1C3 expression was 
significantly higher in SC fat in patients aged <55 years compared to those aged 55 years or 
above (5.6±1.4 v 8.2±0.5, p=0.04, Table 4-3). 
 
Table 4-3 mRNA expression of androgen-metabolising enzymes according to age category in 
SC and OM adipose tissue (data expressed as mean Δct±SEM) 
Gene Age <55 years 
(n=19) 
Age≥55 years 
(n=47) 
P-value 
AKR1C3 SC 5.6±1.4 8.2±0.5 0.04* 
AKR1C3 OM 8.6±0.8 9.6±0.4 0.24 
AKR1C2 SC 19.2±1.5 20.3±0.6 0.45 
AKR1C2 OM 21.5±0.6 20.3±0.8 0.41 
SRD5A1 SC 10.6±0.9 12.4±0.6 0.09 
SRD5A1 OM 12.8±0.7 13.0±0.5 0.88 
 
 Samples were further categorized into those obtained from non-obese 
(BMI<29.9kg/m2) and obese patients (BMI≥30.0kg/m2).  Differences in mRNA expression of 
key genes between obese and non-obese patients are shown in Table 4-4 for SC and OM fat. 
 
Table 4-4 mRNA expression of androgen-metabolising enzymes according to BMI category in 
SC and OM adipose tissue (data expressed as mean Δct±SEM) 
Gene Non-obese (n=49) Obese (n=17) P-value 
AKR1C3 SC 8.1±0.7 5.3±1.2 0.04* 
AKR1C3 OM 9.8±0.4 8.0±0.9 0.06 
AKR1C2 SC 20.6±0.5 18.2±1.7 0.10 
AKR1C2 OM 20.6±0.6 20.6±1.5 0.97 
SRD5A1 SC 12.1±0.5 11.1±1.1 0.38 
SRD5A1 OM 13.0±0.5 12.8±0.9 0.84 
 
Chapter 4      AKR1C3 expression and activity in human adipose tissue 
 
 141 
No significant differences in mRNA expression of AKR1C3, AKR1C2 or SRD5A1 were 
observed in SC or OM adipose tissue samples between non-obese and obese male patients. In 
female OM adipose tissue, expression of our genes of interest did not differ significantly 
between obese and non-obese patients. However, in female SC adipose tissue, AKR1C3 
expression was significantly higher in obese compared to non-obese patients (4.2±1.9 v 
8.2±0.6, p=0.02). Expression of AKR1C2 (17.8±3.0 v 21.0±0.7, p=0.13) and SRD5A1 
(10.9±1.7 v 12.1±0.7, p=0.51) in female SC tissue was similar in obese and non-obese 
patients. 
 Using correlation testing, we next examined the relationship of AKR1C3, AKR1C2 
and SRD5A1 expression with age and BMI. In male OM tissue, no associations were 
observed between gene expression and age or BMI. In male SC, expression of AKR1C3 was 
negatively associated with age (R=0.65 for Δct, p=0.003). In female OM fat, no associations 
were observed between gene expression and age. OM AKR1C3 expression was positively 
associated with BMI (R= -0.41, p=0.025). The relationships between age, BMI and gene 
expression in female SC fat are summarized in Table 4-5. AKR1C3 expression had correlated 
positively with BMI (Figure 4-2), as well as with expression of AKR1C3 and SRD5A1. 
AKR1C2 expression was also positively associated with BMI. 
 
 
Table 4-5 Relationship of age and BMI with mRNA expression (Δct) of androgen-
metabolising genes (R-value) in female SC adipose tissue. *p<0.05; **p<0.01; ***p<0.001. 
 Age BMI AKR1C3 AKR1C2 SRD5A1 
Age - -0.25 -0.22 0.23 0.12 
BMI -0.25 - -0.51* -0.71** -0.10 
AKR1C3 -0.22 -0.51* - 0.71** 0.72** 
AKR1C2 0.23 -0.71** 0.71** - 0.83** 
SRD5A1 0.12 -0.10 0.72** 0.83** - 
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Figure 4-2 Postive relationship between BMI and relative AKR1C3 mRNA expression (log-
transformed) in female SC adipose tissue (n=38; Pearson’s correlation testing for BMI and 
AKR1C3 Δct)   
 
4.3.2 Validation of SGBS cells as model of human adipocyte and adipose androgen 
metabolism 
4.3.2.1 Lipid accumulation 
 Morphological changes were observed across differentiation in SGBS cells over 14 
days. Cytoskeletal changes resulted in loss of fibroblast appearances. Cells also became more 
round in shape, and intracellular lipid accumulated consistent with differentiation into 
adipocytes (Figure 4-3).  
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Figure 4-3 SGBS cells as confluent preadipocytes (day 0) and after differentiation process for 
14 days in chemically-defined medium (magnification x10).   
 
4.3.2.2 Markers of differentiation, androgen metabolism and insulin signaling cascade in 
SGBS cells 
 Using real-time PCR, we compared mRNA expression of key markers of adipocyte 
differentiation, androgen metabolism and the insulin signalling cascade across differentiation 
in SGBS cells, from Day 0 (preadipocyte) to Day 14 (adipocyte). Significant upregulation in 
mRNA expression of almost all key component genes was observed between Day 0 and Day 
14 (Table 4-6, Figure 4-4). 
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Table 4-6 Changes in mRNA expression of markers of adipocyte differentiation, androgen 
metabolism and the insulin signalling cascade across SGBS differentiation (data expressed as 
mean Δct±SEM for n=3-5 experiments) 
Gene SGBS Day 0 
(preadipocyte) 
SGBS Day 7 SGBS Day 14 
(adipocyte) 
P-value  
(Day 0 v 14) 
PPAR-γ 7.2±0.8 3.8±0.3 4.0±0.2 0.03 
LPL Undetectable 8.3±0.5 6.3±0.1 <0.0001 
AR 18.8±0.7 16.8±0.9 15.4±0.4 0.02 
AKR1C3 13.3±0.1 8.8±0.7 7.9±0.9 0.02 
AKR1C2 23.5±0.9 - 19.1±0.4 0.01 
SRD5A1 10.6±0.5 7.8±0.3 8.3±0.3 0.02 
IRS-2 12.3±1.2 12.5±0.2 10.4±0.6 0.03 
PI3Kca 16.9±0.5 17.1±0.2 14.7±0.8 0.04 
ACC1 6.5±0.6 - 5.6±0.3 0.19 
ACC2 9.5±0.4  5.9±0.5 0.001 
FAS 5.0±0.2 - 4.1±0.3 0.04 
FABP4 17.1±0.3 - 3.8±0.4 <0.0001 
 
 
 
Figure 4-4 Relative mRNA expression across SGBS differentiation of (a) lipoprotein lipase 
(LPL) and (b) androgen receptor (AR). *p<0.05; ****p<0.0001 for Δct compared to Day 0. 
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4.3.3 AKR1C3 expression and activity in SGBS cells 
4.3.3.1 AKR1C3 expression and activity across differentiation 
 AKR1C3 mRNA expression increased significantly across SGBS differentiation 
between Day 0 and Day 14 (mean Δct at Day 0 and Day 14 13.3±0.1 v 7.9±0.9, respectively, 
p=0.02, Figure 4-5).  
 
 
 
Figure 4-5 Relative AKR1C3 mRNA expression in SGBS cells across differentiation. *p<0.05 
compared to Day 0.  
 
AKR1C3 activity, determined by the generation of T from 200nM A over 24 hours, was 
significantly higher in differentiated adipocytes compared to preadipocytes (7.9±2.7 v 0.9±0.1 
nM/24 hours, p=0.01, Figure 4-6). 
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Figure 4-6 AKR1C3 activity as determined by testosterone generation from androstenedione 
(200nM) over 24 hours in undifferentiated and differentiated SGBS cells. *p<0.05. 
 
T generation was significantly higher in SGBS cells incubated with A for 24 hours compared 
to those incubated for 4 and 8 hours (16.2±3.1 v 2.4±0.2 and 3.5±0.3nM respectively, p=0.01 
for both, Figure 4-7). 
 
Figure 4-7 Time course of AKR1C3 activity in differentiated SGBS cells at 4, 8 and 24 
hours.*p<0.05. 
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4.3.3.2 Effect of insulin on AKR1C3 expression and activity in SGBS cells 
 Incubation of SGBS cells with 10nM insulin had a trend towards increasing AKR1C3 
expression but this effect did not reach statistical significance (mean Δct control 9.9±0.6 v 
10nM insulin 7.3±0.1, p=0.057). However, incubation with 20nM insulin significantly 
increased AKR1C3 expression compared to both control and 10nM treatment (mean Δct 
6.5±0.1 v 9.9±0.6 and 7.3±0.1, p=0.03 and 0.02, respectively, Figure 4-8).  
 
 
Figure 4-8 Effect of insulin on AKR1C3 mRNA expression in SGBS cells. *p<0.05. 
 
 AKR1C3 activity, as determined by generation of T after 24-hour incubation with A 
200nM, increased significantly after exposure of SGBS cells to insulin (100% [control] v 
131±9.8% [10nM], p=0.01; 100% [control] v 161.3±11.3% [20nM], p=0.0006, Figure 4-9). 
AKR1C3 inhibition significantly reduced T generation in both control adipocytes and those 
treated with 10nM insulin (100% [control] v 58.6±2.5% [inhibitor], p<0.0001; 131±9.8% 
[10nM] v 76.9±15.5% [inhibitor], p=0.02). Inhibitor treatment of cells exposed to 20nM 
insulin had a trend towards reducing T generation compared to insulin alone but this did not 
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reach statistical significance (161.3±11.4% [20nM] v 112.5±10.2% [inhibitor], p=0.08, Figure 
4-9). 
 
 
Figure 4-9 Effect of insulin and AKR1C3 inhibition with 3-4-trifluoromethyl-phenylamino-
benzoic acid (Merck Millipore, UK) on T generation in SGBS cells. Differentiated adipocytes 
were treated with and without insulin (10 or 20nM) and AKR1C3 inhibitor (500nM) for 24 
hours. Insulin-stimulated increases in adipocyte testosterone generation are reduced by 
AKR1C3 inhibition in cells treated with 10nM insulin, although there is only a trend towards 
significant reduction in cells treated with 20nM insulin + inhibitor. Data represented as 
mean±SEM % change from control (100%); *p<0.05 vs control; ***p<0.001 compared to 
control; § p<0.05 for inhibitor vs corresponding treatment.  
 
Treatment of control and insulin-treated adipocytes with the PI3K inhibitor wortmannin had 
no significant impact on T generation in SGBS cells, Figure 4-10).  
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Figure 4-10 Effect of insulin and wortmannin (500nM) on T generation in SGBS cells. 
*p<0.05 compared to control; ***p<0.001 compared to control. 
 
4.3.4 AKR1C3 expression and activity in primary human adipocytes 
4.3.4.1 AKR1C3 expression and activity across differentiation in primary human 
adipocytes 
 AKR1C3 mRNA expression increased significantly across differentiation between 
preadipocytes and adipocytes in both SC and OM primary adipocytes (mean Δct for SC tissue 
16.4±0.5 [preadipocytes] v 11.7±1.3 [adipocytes], p=0.03; mean Δct for OM tissue 19.5±0.1 
[preadipocytes] v 11.4±1.1 [adipocytes], p=0.001, Figure 4-11). AKR1C3 activity, as 
determined by T generation after incubation of cells with A 200nM for 24 hours, was 
significantly upregulated across adipocyte differentiation in both fat depots (mean T for SC 
tissue 0 [preadipocytes] v 14.6±4.7nM/24h [adipocytes], p=0.02; mean T for OM tissue 
0.2±0.1 [preadipocytes] v 10.9±4.9 nM/24h [adipocytes], p=0.04, Figure 4-12). 
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Figure 4-11 Relative AKR1C3 mRNA expression across differentiation in primary human (A) 
SC and (B) OM adipocytes. Data presented as mean±SEM Δct of n=3 experiments. *p<0.05; 
**p<0.01 compared to preadipocytes.  
 
 
 
 
Figure 4-12 AKR1C3 activity as determined by testosterone generation from androstenedione 
(200nM) over 24 hours in primary SC (A) and OM (B) adipocytes across adipocyte 
differentiation. Data presented as mean±SEM Δct of n=3 experiments. *p<0.05 compared to 
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4.3.4.2 Effect of insulin on AKR1C3 expression and activity in primary human adipocytes 
 AKR1C3 mRNA expression increased significantly in primary differentiated SC 
adipocytes from female patients (n=3) after incubation with insulin at a dose of 20nM 
compared to control (mean Δct 10.1±0.9 [control] v 7.6±0.2 [insulin 20nM], p=0.049, Figure 
4-13). No effects on AKR1C3 expression were observed in SC adipocytes at a dose of 10nM 
insulin. Similarly, incubation with insulin did not significantly increase AKR1C3 mRNA 
expression in differentiated OM adipocytes from females (n=3, mean Δct 9.8±0.2 [control] v 
10.9±0.7 [20nM insulin], p=0.18, Figure 4-13). 
 
 
 
Figure 4-13 Effect of insulin on AKR1C3 mRNA expression in (A) primary female SC 
adipocytes and (B) primary female OM adipocytes. *p<0.05 compared to control. 
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 In primary differentiated SC adipocytes, incubation with insulin 10nM significantly 
increased AKR1C3 activity compared to control (100% [control] v 118.3±3.1% [10nM], 
p=0.004, Figure 4-14). Activity in cells treated with 20nM insulin was not significantly 
increased (p=0.44). Insulin did not significantly increase AKR1C3 activity in primary 
differentiated OM adipocytes compared to control, although a trend was observed at a dose of 
20nM (100% [control] v 93.1±6.8% [10nM], p=0.27; 100% [control] v 148.4±27.1% [20nM], 
p=0.14).  
 
 
 
Figure 4-14 Effect of insulin compared to control on AKR1C3 activity in primary SC (A) and 
OM (B) adipocytes. **p<0.01 compared to control.  
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4.4 Discussion 
 The observations in this chapter highlight a key role for adipose tissue as an organ of 
androgen generation in human health and disease. Tantalisingly, these data suggest that 
hyperinsulinaemia and obesity, both highly prevalent in PCOS, may be potent regulators of 
adipose androgen metabolism, and appear to preferentially drive androgen activation in SC 
compared to OM adipose tissue. Our findings of a greater relative contribution by SC 
compared to OM fat to adipose androgen metabolism are supported by previous studies 
(Blouin et al., 2003, Quinkler et al., 2004, MacKenzie et al., 2008). Similarly, we found that 
AKR1C3 mRNA expression was highly correlated with BMI in SC tissue in females; these 
associations were not observed in OM fat or in males. These data broadly mirror those of 
Wake et al, who found a significant positive association between AKR1C3 expression and 
waist:hip ratio in SC adipose biopsies from 45 healthy men and women (Wake et al., 2007). 
Similar to the study by Wake, we also found obesity was associated with increased expression 
of the androgen-inactivating enzyme AKR1C2, but not with expression of SRD5A1. This 
suggests that intra-adipose conversion of A to T by AKR1C3 may be more sensitive to weight 
fluctuations than 5α-reduction of T to DHT by SRD5A1.  Net local androgen exposure in fat 
is determined by the delicate equilibirium between activating and inactivating enzyme 
activity; increased AKR1C2 expression in obesity may therefore represent a physiological 
counter-balance to excessive local androgen activation by AKR1C3 (O'Reilly et al., 2014a). It 
is not clear which pathophysiological factors might disturb this balance in favour of increased 
androgen production. 
 Hyperinsulinaemia in PCOS is a possible complicit factor in the upregulation of 
adipose androgen generation. We know that insulin has a potent effect on ovarian androgen 
metabolism, directly driving activity of 17α-hydroxylase and other enzymes in thecal cells 
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(Nestler et al., 1998). AKR1C3 is a key enzyme in androgen biosynthesis in the adrenals, 
ovaries, prostate and adipose tissue (Nakamura et al., 2009), and polymorphisms are 
associated with an increased prevalence of PCOS and severity of hyperandrogenism in 
women (Ju et al., 2015). In the experiments described above, insulin significantly increased 
both expression and activity of AKR1C3 in SGBS cells. The finding of increased AKR1C3 
expression with insulin was validated in primary differentiated adipocytes from the SC depot 
of female patients. Insulin significantly increased AKR1C3 activity in differentiated SC 
adipocytes, although this effect was only observed at the lower insulin dose. This observation 
may be due to insufficient replicate experiments, the notorious variability of primary culture 
and a lack of sufficient samples from male and female patients to power analysis of sex-
specific effects. No significant increases in AKR1C3 activity after insulin exposure in 
primary OM adipocytes were observed, mirroring our mRNA expression data.  
 There is an emerging body of observational evidence to support a role for insulin in 
adipose androgen generation. Kruppel-like factor 15 (KLF15), which acts as transcriptional 
regulator of human AKR1C3 (HSD17B5) by binding to its promoter region, is potently 
stimulated by insulin in human adipose tissue (Mori et al., 2005), and appears to mediate both 
T generation and adipogenesis in response to insulin (Du et al., 2009). KLF15 plays a role in 
glucose homeostasis, and is highly expressed in liver, fat, muscle, heart and other metabolic 
tissues (Gray et al., 2002); targeted hepatic deletion in mice leads to reduced hepatic 
gluconeogenesis and hypoglycaemia (Gray et al., 2007). A further possible mechanistic link 
between insulin and adipose AKR1C3 regulation could be the transcription factor 
CAAT/Enhancer-binding protein-β (C/EBP-β), which has recently been identified as essential 
for transcription of HSD17B8 in the liver (Villar et al., 2007); C/EBP-β activity is also 
stimulated by insulin (Guo et al., 2001). In steroidogenic tissues such as fat, 
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hyperinsulinaemia, leading to increased expression of KLF15, C/EBPβ and other important 
transcription factors, could directly drive adipose AKR1C3 activity, providing a link between 
metabolic dysfunction, adipose tissue and androgen activation.    
 It is interesting that incubation of insulin-stimulated adipocytes with wortmannin did 
not significantly reduce AKR1C3 activity as determined by T generation. These data would 
suggest that insulin-induced effects on adipose androgen metabolism are not mediated via the 
PI3K pathway downstream from the INSR. Furthermore, previous studies have shown that 
insulin resistance in PCOS does not appear to encompass ovarian steroidogenic responses to 
insulin, with granulosa and thecal cells from PCOS ovaries demonstrating normal 
physiological responses to insulin stimulation in culture (Willis et al., 1996, Poretsky, 1991). 
This raises a number of distinct possibilities. Firstly, insulin could exert its effects on 
steroidogenesis independent of the INSR, perhaps via the type I or type II IGF receptors. 
Insulin is known to upregulate the IGF-I receptor, and amplifies the actions of IGF-I and IGF-
II at the level of the ovary (Poretsky et al., 1999). IGFs are important regulators of human 
follicle growth, and accelerated preantral follicle growth in PCOS may be due to increased 
endogenous IGF action, or due to the action of insulin on the type I or type II IGF receptors 
(Stubbs et al., 2013). However, other studies have suggested that this is unlikely to be the 
case, and that the ovary maintains selective sensitivity to insulin action via the INSR in PCOS 
(Willis and Franks, 1995). Whether these data can be extrapolated to adipose tissue is less 
clear; adipose insulin resistance has been well-characterised in PCOS (Ciaraldi et al., 1998, 
Dunaif, 1997). A more plausible possibility is that insulin action on steroidogenesis in adipose 
tissue, the ovary and other organs is mediated via the mitogenic MAPK pathway after INSR 
binding and not via the metabolic PI3K pathway. We know that MAPK activation mediates 
most of the growth-promoting effects of insulin. This possibility is supported by the inability 
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of wormannin to reduce T generation in SGBS cells in the experiments described above, and 
by a limited number of in vitro studies (Mendez et al., 2005, Kempna et al., 2007). Further 
work is needed to corroborate these findings. 
 Evidence for adipose-specific androgen generation in PCOS supports the theory that 
weight loss may be a potent strategy to ameliorate the clinical and biochemical phenotype in 
obese women with the disorder. We found a strong positive correlation between SC adipose 
AKR1C3 expression and BMI in female patients in the study described above. AKR1C3 
expression was significantly downregulated in 6 women after a weight loss intervention in the 
study by Quinkler et al (Quinkler et al., 2004). In a recent cohort study, serum testosterone 
levels in postmenopausal women fell by approximately 10% for each kg/m2 reduction in BMI 
(Jones et al., 2013). Another study showed that weight loss is an effective strategy to lower 
both serum androgens and oestrogens in postmenopausal women, and may thereby afford 
protection against development of breast cancer (Campbell et al., 2012). A recent weight loss 
intervention using metformin with or without a novel phosphodiesterase inhibitor in 31 
women with PCOS found significant reductions in weight in both groups, mirrored by 
reductions in serum androgens (Jensterle et al., 2014). Bariatric surgery is also likely to be an 
effective intervention in the hyperandrogenic morbidly obese. Two studies showed 
normalization of serum androgens, including DHEAS, after bariatric intervention in obese 
women with PCOS (Escobar-Morreale et al., 2005, Kopp et al., 2006). Another study showed 
that bariatric surgery significantly reduced serum androgen levels in obese women without 
PCOS and that this effect was observed even when preoperative levels were within the normal 
reference range (Ernst et al., 2013). Although some of the observed effects of weight loss on 
androgen metabolism may be attributable to increases in SHBG in the context of increased 
insulin sensitivity, changes in A and free T cannot be explained by increases in binding 
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proteins alone. Weight loss may also improve insulin sensitivity, thereby reducing the effects 
of hyperinsulinaemia on adipose androgen activation. Clinicians should have a low threshold 
to offer bariatric intervention to severely obese patients with androgen excess and subfertility.  
 Selective inhibition of AKR1C3 in adipose tissue may offer a novel therapeutic 
strategy to reduce local androgen exposure in PCOS. We significantly reduced adipose 
testosterone generation in the above experiments with a highly selective AKR1C3 inhibitor, 
even under insulin-stimulated conditions. AKR1C3 inhibition is currently under investigation 
as a possible future therapeutic direction in castration-resistant prostate cancer (Liedtke et al., 
2013). It is worth remarking that AKR1C3 is also over-expressed in invasive hormone-
positive ductal carcinoma of the breast (Shibuya et al., 2008), which might be importance in 
the context of developing future anti-proliferative treatments.  Non-steroidal anti-
inflammatory drugs (NSAIDs) such as salicylic acid have inhibitory effects on various 
AKR1C isoforms; some, such as indomethacin, have selective activity against AKR1C3 
(Bauman et al., 2005), and might have a useful role in future clinical studies in PCOS. 
Modulation of androgen activation selectively in adipocytes could offer a novel therapeutic 
option in PCOS by ameliorating the adverse consequences of intra-adipose androgen 
generation. The systemic consequences of androgen excess in women have been investigated 
and discussed extensively. However, it is not clear how adipose androgen generation might 
impact locally on adipocyte biology, including adipogenesis and lipid metabolism, and this 
will be explored in chapter 5.  
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5.1 Introduction 
 In chapter 4, we demonstrated that human adipocytes are capable of androgen 
activation and secretion. In obesity and under hyperinsulinaemic conditions, both highly 
prevalent in PCOS, this process of adipose androgen generation appears to be upregulated. It 
is now increasingly clear that androgens exert important effects on adipose tissue and are 
capable of regulating adipocyte function (O'Reilly et al., 2014a). It therefore seems reasonable 
to hypothesise that androgens generated in fat via this intracrine pathway are capable of 
modulating local adipocyte biology, including regulation of adipose tissue mass. The key 
processes involved in regulation of adipose tissue mass are hyperplasia (increase in fat cell 
number) and hypertrophy (increase in fat cell size) (Hausman et al., 2001). Hyperplasia is 
driven by preadipocyte proliferation and differentiation into adipocytes (adipogenesis). 
Hyperplasia depends upon a number of crucial transcriptional regulators and hormonal signals 
and has been discussed in section 1.6.3.1. Differentiation into mature adipocytes is 
synonymous with induction of genes involved in lipid metabolism. Upon maturation, 
adipocyte size is then determined by lipid flux, which refers to the tightly regulated balance 
between lipid accumulation and lipid breakdown (Gathercole et al., 2011); de novo 
lipogenesis, glucose uptake and FFA uptake drive lipid accumulation (and hence adipocyte 
hypertrophy), while lipolysis and β-oxidation favour lipid breakdown. Data on the role of 
androgens in regulation of lipid flux and adipocyte size are thus far conflicting. 
 Lipogenesis refers to the de novo synthesis of fatty acids within the adipocyte, uptake 
of dietary FFAs into the adipocyte, and re-esterification of these FFAs with glycerol to form 
TAG which can be stored as fuel; de novo lipogenesis may account for up to 20% of lipid 
turnover within adipose tissue (Strawford et al., 2004). As discussed in section 1.6.4, the rate-
limiting step in this process is the carboxylation of mitochondrial-derived acetyl CoA to 
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malonyl CoA in an ATP-dependent reaction by ACC1; malonyl CoA is subsequently 
converted by a multi-step reaction to palmitate by FAS (Ruderman et al., 2003). ACC2 is 
localized to the mitochondrial membrane, where it serves as a major negative regulator of β-
oxidation by generating malonyl CoA and thereby inhibiting CTP1. ACC1 and ACC2 are 
themselves negatively regulated by AMPK-induced serine phosphorylation, which promotes 
β-oxidation and lipid mobilization in low energy states. In the fed state, insulin then 
inactivates AMPK, allowing ACC1 and ACC2 to predominate and drive lipid accumulation.  
 It has been shown that glucocorticoids drive lipogenesis by upregulation of ACC 
expression and activity in the fed state (Gathercole et al., 2011). However, studies on the role 
of androgens in this and other key processes in lipid metabolism are lacking. There is ample 
observational data to suggest that androgens play an important role in fat mass expansion and 
distribution in females. Hyperandrogenic women with PCOS have higher global adiposity and 
visceral adipose tissue compared to control women. Intra-abdominal adiposity correlates with 
serum androgens (Borruel et al., 2013), and circulating androgens in women are positively 
associated with BMI (Mongraw-Chaffin et al., 2015). Ex vivo, prenatally androgenized female 
mice have increased adipocyte size compared to control animals (Roland et al., 2010). 
However, to our knowledge, there are no comprehensive studies on the effect of androgens on 
de novo lipogenesis, FFA uptake, β-oxidation and glucose uptake under fasted or fed 
conditions. Furthermore, insulin is a critical hormonal regulator of adipocyte lipid metabolism 
but there are few data on the effect of androgens on pancreatic β-cell function and insulin 
secretion. Limited data suggest that androgens may drive insulin secretion through the 
androgen receptor in the female sheep pancreas (Rae et al., 2013), and in vivo markers of 
insulin secretion may be increased in PCOS women compared to controls (Panidis et al., 
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2006). Androgen action on β-cell insulin secretion could have significant consequences for 
lipid metabolism, with secondary effects on regulation of adipose tissue mass. 
 We hypothesise that androgens exert direct effects on adipose tissue lipid metabolism. 
To test this hypothesis, we will examine the effect of T and DHT in vitro on de novo 
lipogenesis, β-oxidation, FFA uptake and insulin-stimulated glucose uptake in SGBS cells, 
under both fasted and fed conditions. We also hypothesise that androgens exert effects on 
pancreatic β-cell function, and will characterize these effects in a cellular model.  
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5.2 Methods 
5.2.1 Research strategy 
 In this chapter, we will validate the utility of SGBS cells as an appropriate cellular 
model for the study of lipid metabolism in humans. We will then explore the role of the 
potent androgens T and DHT on mRNA expression of key lipogenic genes in both SGBS 
cells and primary human SC adipocytes where available. We will study the functional impact 
of androgens on de novo lipogenesis in SGBS cells using isotope studies as described below. 
Functional studies of androgen action on β-oxidation, FFA uptake and insulin-stimulated 
glucose uptake in SGBS cells will also be employed to tease out the effects of androgens on 
these key processes of lipid metabolism. 
 To study the role of androgens in pancreatic β-cell physiology, we will examine 
mRNA expression of the AR in a mouse insulinoma cell line, and then characterize the effects 
of T and DHT on insulin secretion in a time- and dose-dependent fashion.  
 
5.2.2 SGBS cell culture 
 Proliferating SGBS cells were seeded in 12- or 24-well plates and grown to 
confluence in DMEM-F12 with 10% FCS, additionally supplemented with 33µM biotin, 
17µM pantothenate and penicillin-streptomycin 1% (growth media). In preadipocyte studies, 
cells were exposed to treatments, and biomaterial extracted, before differentiation. In 
adipocyte studies, SGBS cells were differentiated over 14 days in OF media, which was 
further supplemented according to the differentiation protocol described in section 2.2. In 
experiments studying the effect of androgens on mRNA expression of key lipogenic genes, 
androgens were added at the appropriate concentration to 0F media for the entire 
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differentiation period (14 days). All cells were cultured in serum-media (OF only without 
additives) for 24 hours before experiments.  
 
5.2.3 Human preadipocyte cell culture 
 Primary human SC fat samples were obtained as described in section 4.2.2, and 
extracted from whole SC tissue according to the protocol described by Bujalska et al 
(Bujalska et al., 1999) and summarized in section 2.1. Briefly, adipose tissue samples were 
digested with type 2 collagenase at 37°C for one hour, followed by sterile filtration through 
layered gauze to remove solid components. After centrifugation, the stromovascular pellet 
containing preadipocytes was resuspended in media and plated in 12- or 24-well plates. 
Preadipocytes were grown to 80% confluence before differentiation into mature adipocytes 
over 14 days in chemically-defined media. In experiments studying the effect of androgens on 
mRNA expression of key lipogenic genes, androgens were added at the appropriate 
concentration to the chemically-defined for the entire differentiation period (14 days).  All 
treatment protocols involved use of serum-free media without additives for 24 hours.  
 
5.2.4 Min6 mouse insulinoma cell line  
 Min 6 cells were cultured to confluence as described in section 2.3. Briefly, cells were 
cultured in DMEM with high glucose (4.5g/l; 25nM), 10% FBS (Sigma Aldrich), 1% 
penicillin/streptomycin (Sigma Aldrich) and 100µM beta-mercaptoethanol.  At confluence, 
cells were seeded into tissue culture plates and incubated at 37°C for functional studies of 
insulin secretion.  
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5.2.5 Cell treatments 
 All treatments were diluted as appropriate in serum-free media. In SGBS experiments, 
T was added at doses of 20nM and 40nM, and DHT at doses of 5nM and 20nM, to mimic 
physiological concentrations. In primary SC cell culture, treatments with T 20nM and DHT 
5nM were used due to limited treatment well availability. In all functional studies, treatments 
with T and DHT were added acutely; in studies of mRNA expression of lipogenic genes, 
treatments were added across differentiation to mimic physiological conditions. Where 
relevant, the aromatase inhibitor letrozole was added at a dose of 100nM for 15 minutes 
before the addition of T to the cell culture media.  
 
5.2.6 RNA extraction, reverse transcription and real-time PCR 
 Total RNA was extracted using the Tri-Reagent protocol (section 2.4.1). RNA 
concentration and purity were assessed using NanoDrop technology as described above. One 
microgram of total RNA was used for reverse transcription (see section 2.4.2); cDNA was 
diluted 1:10 with RNase-free water. Real-time PCR was used to determine mRNA expression 
of the key lipogenic genes ACC1, ACC2, FAS and FABP4 in SGBS cells, ACC1 and ACC2 
in primary SC adipocytes, and AR and insulin in MIN6 cells. Real-time PCR reactions were 
performed as described in section 2.4.3. mRNA levels were detected using an ABI 7500 
sequence detection system (Applied Biosystems/Life Technologies, Paisley, UK). All probes 
and primers were supplied by Applied Biosystems/Life Technologies as expression assays 
(Taqman probe/primer mix). All reactions were normalized against two housekeeping genes, 
18S and GAPDH.  
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5.2.7 De novo lipogenesis 
 Lipogenesis was measured by the uptake of 1-[14C] acetate into the lipid component of 
adipocytes (Jamdar, 1978, Gathercole et al., 2011). After differentiation for 14 days, SGBS 
cells were washed and cultured in serum-free media for 4 hours. Cells were then treated with 
androgens (T 20-40nM and DHT 5-20nM) with and without insulin in serum-free media for 
18 hours. The aromatase inhibitor letrozole (100nM, Sigma Aldrich) was added where 
appropriate 15 minutes before addition of T. Hot (1-[14C]) and cold sodium acetate were then 
added to treatment wells for a further 6 hours. Cells were then washed three times and scraped 
with 250µl cold phosphate-buffered saline (PBS); cell lysate was transferred to glass TLC 
tubes. Folch solvent (chloroform:methanol 2:1) 5ml was added to each tube to recover the 
lipid fraction; samples were mixed vigorously, followed by the addition of 1ml distilled water 
to each tube. Samples were separated into two phases after centrifugation at 12,000 for 5 
minutes – aqueous (upper) and solvent (lower), with protein interface. The solvent fraction 
was recovered and transferred to scintillation tubes, followed by evaporation to dryness 
overnight. Liquid scintillation cocktail (4ml, Fisher Scientific, Loughborough, UK) was 
added to each vial. Radioactivity retained in the cellular lipid was determined by scintillation 
counting and expressed as disintegrations per minute (DPM)/per well. Due to inter-assay 
variability, results were expressed as % change from controls per well.  
 
5.2.8 β-oxidation 
 β-oxidation rates were measured by the conversion of [3H]-palmitate to [3H]-H20 
(Gathercole et al., 2011). At day 14 of differentiation, SGBS cells were cultured in low-
glucose/0.5% BSA serum-free media for 6 h. Cells were then incubated with 300µl of low-
glucose/0.5% BSA serum-free media with hot (1mCi/ml [3H]-palmitate) and cold palmitate to 
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a final concentration of 100µM palmitate, and treated with (5nM) or without insulin and 
androgens, as described above, at 37°C. After 24 hours, incubation medium was recovered 
and precipitated with 600µl 10% acetic acid. The aqueous component of the mixture was 
recovered, and extracted with 2.5ml of 2:1 methanol:chloroform solution and 1ml of 2mM 
KCl:HCl per well. After addition of liquid scintillation cocktail, radioactivity was determined 
by scintillation counting and expressed as disintegrations per minute (DPM)/well. Due to 
inter-assay variability, results were expressed as % change from controls per well. 
 
5.2.9 FFA uptake 
 FFA uptake was estimated by measurement of intracellular [3H]-palmitate 
accumulation. Differentiated SGBS cells were washed and cultured in low-glucose/0.5% BSA 
serum free media for 6 h. Cells were then incubated with 300µl of low-glucose/0.5% BSA 
serum-free media with hot (1mCi/ml [3H]-palmitate) and cold palmitate to a final 
concentration of 100µM palmitate, and treated with (5nM) or without insulin and androgens 
as described above. After 24 h, cells were lysed using cold PBS; lysate was recovered and 
radioactivity measured by scintillation counting, with results expressed as disintegrations per 
minute (DPM)/well. Due to inter-assay variability, results were expressed as % change from 
controls per well. 
 
5.2.10 Insulin-stimulated glucose uptake 
 Glucose uptake was measured by analyzing the uptake of 2-deoxy-D-[3H] glucose 
(Gathercole et al., 2007, Liu et al., 2001). SGBS cells were grown to confluence and 
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differentiated in 24-well plates as described above. Krebs-Ringer Bicarbonate (KRB) Buffer 
was prepared as follows: 
• D-glucose 1.8g/L 
• Magnesium Chloride (anhydrous) 0.0468g/L 
• Potassium Chloride 0.34g/L 
• Sodium Chloride 7.0g/L 
• Sodium Phosphate Dibasic (anhydrous) 0.1g/L 
• Sodium Phosphate Monobasic (anhydrous) 0.18g/L 
Krebs-Ringer bicarbonate buffer was then further supplemented with 30mM HEPES (pH 7.4) 
and 0.5% BSA (KRBH/BSA).  
 SGBS cells were washed three times and incubated with 0.9ml KRBH/BSA and 
2.5mM glucose at 37°C for 30 minutes. Insulin (0.5ng/ml) and treatments were then added, 
and the cells were incubated at 37°C for a further 15 minutes. Glucose uptake was initiated by 
the addition of 0.1ml KRBH/BSA buffer with 37mBq/l 2-deoxy-D-[3H] glucose (GE 
Healthcare) and 0.1mmol/l glucose as final concentrations. Glucose uptake was terminated 
after 15 minutes by washing three times with cold PBS. Cell lysate was transferred to 
scintillation vials and 4ml liquid scintillation cocktail added. Radioactivity retained by the cell 
lysates was determined by scintillation counting.  
  
5.2.11 Measuring effect of androgens on insulin secretion from MIN6 cells 
 MIN6 cells were seeded in 12-well plates in growth media as described in section 
5.2.4. At confluence, medium was changed to serum-free, low glucose (1g/L, 5.5nM) 
DMEM; T (10nM and 100nM) and DHT (5nM and 50nM) were added for 24 hours (pre-
treatment). After 24 hours, cells were washed and 1ml/well of fresh serum-free, low glucose 
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DMEM added; treatments with T and DHT at the above concentrations were again added to 
selected wells. A treatment time course was created by removing 50µl of media for insulin 
measurement at time points 0, 15, 30, 60, 120, 180, 240 and 300 minutes. Secreted insulin 
was measured using Mouse Insulin ELISA (Mercodia, UK) as described in section 2.6.1. 
Area-under-the-curve (AUC) measurements were used to compare differences between 
treatments across the time course.  
 
5.2.12 Statistical analysis 
 Normally distributed data were analysed using unpaired student t tests to compare 
single treatments to controls; non-parametric tests were used when normality tests failed 
(Microsoft Excel or SPSS Version 22). When comparing means from multiple groups, one-
way ANOVA with post-hoc Tukey testing was employed. All statistical analysis on realtime 
PCR data was performed for a minimum of n=3 on mean Δct values between different 
treatment groups. Due to inter-assay variability in functional studies of lipid metabolism, 
statistics were performed on the % change from controls per well.  
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5.3 Results 
5.3.1 Validation of SGBS cells as a model of human adipocyte lipid metabolism 
 Morphological changes in SGBS cells across differentiation have already been 
described in 4.3.2.1 and are shown in Figure 4-3. Briefly, typical cytoskeletal changes were 
observed between Day 0 and Day 14, with loss of the fibroblast-like appearance of 
preadipocytes, and intracellular lipid accumulation consistent with differentiation into lipid-
storing adipocytes. Using real-time PCR, we compared mRNA expression of key markers of 
lipid metabolism across differentiation, from Day 0 (preadipocyte) to Day 14 (adipocyte). 
Significant upregulation in mRNA expression of most key component genes in lipid 
metabolism was observed across differentiation as shown in Table 5-1. 
 
Table 5-1 Changes in mRNA expression of key markers of lipid metabolism across SGBS 
differentiation (data expressed as mean Δct±SEM for n=3-5 experiments). Statistical analysis 
performed on Δct.  
Gene SGBS Day 0 
(preadipocyte) 
SGBS Day 14 
(adipocyte) 
P-value  
(Day 0 v 14) 
LPL Undetectable 6.3±0.1 <0.0001 
ACC1 6.5±0.6 5.6±0.3 0.19 
ACC2 9.5±0.4 5.9±0.5 0.001 
FAS 5.0±0.2 4.1±0.3 0.04 
FABP4 17.1±0.3 3.8±0.4 <0.0001 
 
5.3.2 Lipogenesis 
5.3.2.1 mRNA expression of lipogenic genes 
 Androgen exposure across differentiation significantly increased ACC1 mRNA 
expression compared to control cells (% change in Δct v control [100%]: T 20nM, 
92.7±2.7%, p=0.02; T 40nM, 89.8±1.2%, p<0.001; DHT 5nM, 83.3±5.6%, p=0.006; DHT 
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20nM, 83.5±8.7, p=0.02, Figure 5-1). No other significant changes were observed in mRNA 
expression of key lipogenic genes after treatment with androgens. 
 
 
 
Figure 5-1 Relative change in ACC1 mRNA expression in SGBS cells (expressed as fold 
change compared to control) with increasing doses of T and DHT. Statistical analysis was 
performed on Δct compared to control. Androgens were added to chemically-defined media 
throughout differentiation in order to determine chronic effects of androgen exposure. 
*p<0.05; **p<0.01; ***p<0.001 compared to controls. 
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Table 5-2 Changes in mRNA expression in key markers of lipid metabolism after androgen 
exposure across differentiation in SGBS cells. Data expressed as mean Δct±SEM for n=3-5 
experiments. Statistical analysis performed on Δct; p-values compared to control cells. 
 Control T 20nM T 40nM DHT 5nM DHT 20nM 
ACC2 5.9±0.5 6.2±0.4 
(p=0.72) 
6.3±0.2 
(p=0.47) 
6.6±0.9 
(p=0.51) 
6.9±1.1 
(p=0.43) 
FAS 4.1±0.3 4.4±0.2 
(p=0.53) 
4.4±0.3 
(p=0.54) 
4.5±1.2 
(p=0.72) 
4.3±1.1 
(p=0.89) 
FABP4 3.8±0.4 3.9±0.3 
(p=0.87) 
3.4±0.1 
(p=0.33) 
4.0±0.4 
(p=0.79) 
4.3±0.6 
(p=0.48) 
 
 
 Significant changes in ACC1 mRNA expression were not observed with chronic 
androgen treatment across differentiation in primary SC adipocytes (mean Δct 3.1±0.9 
[control] v 4.4±1.9 [T 20nM], p=0.38; v 3.5±0.5 [DHT 5nM], p=0.9). Similarly, no 
significant changes were observed in ACC2 mRNA expression in primary SC adipocytes after 
androgen exposure (mean Δct 2.1±1.5 [control] v 1.7±0.9 [T 20nM], p=0.82; v 1.1±0.5 [DHT 
5nM], p=0.54).  
 
5.3.2.2 De novo lipogenesis as measured by acetate incorporation into TAG 
 The effect of androgens on de novo lipogenesis was determined by measuring the 
incorporation of 1-[14C]-acetate into cellular lipid. Insulin, at a dose of 5nM, significantly 
upregulated de novo lipogenesis compared to control (100% [control] v 250.0±19.1% [insulin 
5nM], p=0.009, Figure 5-2).  
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Figure 5-2 Basal and insulin-stimulated 1-[14C]-acetate incorporation into cellular lipid in 
differentiated SGBS adipocytes. Lipogenesis increased significantly with insulin treatment. 
Data are expressed as % change in disintegrations per minute (DPM) compared to control 
(basal, 100%). **p<0.01. 
 
In the absence of insulin, T 40nM increased ACC activity compared to basal controls (100% 
[control] v 150.4±7.3% [T 40nM], p=0.02, Figure 5-3a). This effect was also observed with 
DHT 50nM (100% [control] v 121.9±8.4% [DHT 50nM], p=0.03). No effects were observed 
at the lower androgen doses of T 20nM and DHT 10nM. Co-incubation of T-treated cells with 
the aromatase inhibitor (AI) letrozole (100nM) did not result in a significant change in ACC 
activity compared to those treated with T alone (149.5±13.2% [T 40nM+AI] v 150.4±7.3% [T 
40nM], p=0.90).  
 In the presence of insulin, T 40nM and DHT 50nM both increased ACC activity 
significantly compared to basal controls (100% [control] v 260.8±82.9% [T 40nM], p=0.02; v 
261.8±82.5% [DHT 50nM], p=0.04). However, neither T nor DHT in combination with 
insulin increased ACC activity compared to the effect of insulin alone (p=0.90 for both).  
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Figure 5-3 In the absence of insulin, T 40nM and DHT 50nM significantly increased de novo 
lipogenesis (DNL) in differentiated SGBS cells compared to controls, as measured by 
incorporation of 1-[14C]-acetate into cellular lipid (A). To determine if some of the observed 
effects of T on DNL were mediated via aromatisation of T to oestrogen, the aromatase 
inhibitor (AI) letrozole (100nM) was added. However, no change in the effects of T were 
observed. In the presence of insulin alone, DNL was significantly upregulated compared to 
basal controls (B). Similarly, in the presence of insulin, T 40nM and DHT 50nM significantly 
increased DNL compared to basal controls. However, no significant differences were 
observed between treatments with insulin and androgens compared to insulin alone. *p<0.05; 
**p<0.01 compared to basal control. Results expressed as % ±SEM change from basal 
control. 
 
5.3.3 β-oxidation 
 β-oxidation was measured by the conversion of [3H]-palmitate to [3H]-H20 in 
differentiated SGBS cells. In the absence of insulin, DHT 20nM significantly reduced β-
oxidation compared to basal controls (100% [control] v 83.2±5.9% [DHT 20nM], p=0.03, 
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Figure 5-4a). This effect was not observed with T 20nM (125.9±28.4%, p=0.4) or T 40nM 
(89.7±10.6%, p=0.30). Insulin failed to suppress β-oxidation in SGBS cells compared to 
control (100% [control] v 107.2±6.1% [insulin 5nM], p=0.28, Figure 5-4b). The addition of T 
20nM, T 40nM and DHT 20nM to insulin-treated cells also failed suppress β-oxidation 
compared to control (100% [control] v 95.9±7.6% [T 20nM], p=0.3; v 107.5±12.4% [T 
40nM], p=0.99; v 95.2±12.9% [DHT 20nM], p=0.42). Similarly, no changes in β-oxidation 
were observed compared to insulin alone when T 20nM, T 40nM and DHT 20nM were added 
to insulin treated cells (p=0.54, p=0.57 and p=0.72, respectively). 
 
 
 
Figure 5-4 β-oxidation in SGBS cells in the absence (A) and (B) presence of insulin. Rates of 
β-oxidation were calculated by the conversion of [3H]-palmitate to [3H]-H20. Results are 
expressed as % ±SEM change from basal (without insulin) controls (100%).  DHT 20nM 
significantly suppressed β-oxidation compared to controls (A). Insulin did not suppress β-
oxidation in SGBS cells. Similarly, no significant effects were observed by co-treatment with 
insulin and androgens (B).  
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5.3.4 FFA uptake 
 We examined the effect of androgens on FFA uptake in differentiated SGBS cells by 
measuring intracellcular accumulation of [3H]-palmitate. Under basal conditions (absence of 
insulin), T 40nM did not significantly impact upon FFA uptake in SGBS cells compared to 
control (100% [control] v 87.1±7.9%, [T] p=0.15, Figure 5-5a). However, DHT 20nM 
suppressed FFA uptake (100% [control] v 86.3±6.6% [DHT 20nM], p=0.04). Insulin 
stimulation (5nM) significantly increased FFA uptake compared to basal controls (100% 
[control] v 149.7±5.4% [insulin], p=0.0001, Figure 5-5b). Co-treatment with insulin and T 
40nM significantly increased FFA uptake compared to basal control (100% [control] v 
165.4±28.1% [T40 nM], p=0.03), but uptake did not differ significantly compared to cells 
treated with insulin alone (p=0.65). Uptake did not differ significantly between basal control 
and those co-treated with insulin and DHT 20nM (100% [control] v 114.1±24.5% [DHT 
20nM], p=0.58).  
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Figure 5-5 Free fatty acid (FFA) uptake in SGBS cells as measured by intracellcular 
accumulation of [3H]-palmitate. Results are expressed as %±SEM change from basal 
(without insulin) controls (100%). Under basal conditions (A), DHT 20nM suppressed FFA 
uptake compared to controls. Both insulin and T+insulin had similar effects on FFA uptake, 
but co-treatment with DHT and insulin removed the stimulatory effect of insulin. 
 
5.3.5 Insulin-stimulated glucose uptake 
 To assess the functional impact of androgens on insulin-stimulated glucose uptake in 
adipocytes, 2-deoxy-D-[3H]-glucose uptake was measured in differentiated SGBS cells. 
Under basal conditions, T 20nM significantly increased glucose uptake compared to control 
(100% [control] v 113.5±4.7% [T 20nM], p=0.02, Figure 5-6). A trend towards increased 
uptake with T 40nM failed to reach significance (115.2±14.4%, p=0.30). Incubation with 
insulin alone (50nM) significantly upregulated glucose uptake compared to controls (100% 
[control] v 118.0±5.5% [insulin], p=0.005). Co-treatment with insulin and T 20nM did not 
stimulate additional glucose uptake compared to insulin alone (p=0.85); however, incubation 
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with insulin and T 40nM significantly increased glucose uptake compared to insulin alone 
(118.0±5.5% [insulin] v 164.3±19.4% [insulin + T40nM], p=0.04).  
 
 
 
 
Figure 5-6 2-deoxy-D-[3H]-glucose uptake in differentiated SGBS cells (n=6). Results are 
expressed as % ±SEM change from basal (without insulin) controls (100%). In the absence of 
insulin, T 20nM significantly increased glucose uptake compared to control. Incubation with 
insulin significantly increased glucose uptake. Co-incubation with insulin and T also 
increased glucose compared to control; however co-treatment with insulin and T 40nM 
enhanced the stimulatory effect of insulin alone. *p<0.05; **p<0.001 compared to control;   
§ p<0.05 compared to insulin alone. 
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5.3.6 Effects of androgens on insulin secretion from MIN6 β-cell line 
5.3.6.1 mRNA expression 
 Realtime PCR was used to measure expression of androgen receptor (AR) mRNA in 
MIN6 cells; mean baseline Δct values for AR were 4.5±0.1. Incubation of MIN6 with 
increasing doses of DHT did not significantly change either insulin (mean Δct [18S] 7.6±0.5 
[control] v 7.7±0.7 [DHT 5nM], p=0.91; v 7.4±0.5 [DHT 50nM], p=0.86) or AR (mean AR 
Δct [GAPDH] 4.5±0.1 [control] v 5.1±0.9 [DHT 5nM], p=0.53; v 4.7±0.1 [DHT 50nM], 
p=0.26) mRNA expression compared to control, Figure 5-7).  
  
  
 
Figure 5-7 Relative mRNA expression of (A) insulin and (B) androgen receptor (AR) in the 
mouse insulinoma cell line MIN6. Acute treatment with DHT 5 and 50nM did not significantly 
change insulin or AR mRNA expression. Statistical analysis was performed on Δct values 
compared to control. 
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5.3.6.2 Insulin secretion time course 
 Insulin release from MIN6 cells in response to androgens was measured every 60 
minutes for 4 hours (Figure 5-8a). Changes in area under the curve (AUC) for insulin 
secretion are shown in Figure 5-8b. T 10nM and 100nM increased AUC for insulin compared 
to control (100% [control] v 144.6±5.3% [T 10nM], p=0.02; v 340.2±144.9% [T 100nM], 
p=0.04). Mirroring this, significant increases in insulin secretion across the time course were 
observed at both concentrations of DHT (100% [control] v 573.2±31.2% [DHT 5nM], 
p=0.004; v 564.6±9.9% [DHT 50nM], p=0.0004).  
 
 
 
Figure 5-8 (A) Insulin secretion time course in MIN6 pancreatic β-cell line after androgen 
exposure. Both T and DHT significantly increased insulin secretion compared to controls in a 
dose-dependent manner. (B) Area under the curve calculation for insulin shows a significant 
increase in secretion for both androgens at both concentrations. Results expressed as % 
±SEM change in AUC compared to control (100%). *p<0.05; **p<0.01; ***p<0.001 
compared to control.  
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5.4 Discussion 
 In the above chapter, we have demonstrated important androgen-mediated effects on 
lipid metabolism in the SGBS cell line, which we have validated as a useful tool for the study 
of lipid flux in humans. The results described above suggest that androgens promote lipid 
accumulation in human adipocytes by driving de novo lipogenesis, through upregulation of 
ACC1, and suppressing β-oxidation, although DHT may also modestly suppress free fatty 
acid uptake. We could not replicate our finding of increased ACC1 mRNA expression after 
androgen exposure in primary SC adipocytes, but it is important to note that these 
experiments were restricted by a small number of replicates and limited treatment wells, and 
the notorious variability of primary culture should also be acknowledged. We further 
demonstrated that T has a stimulatory effect on glucose uptake in SGBS cells, both in the 
fasted and fed state, providing substrate for further lipid synthesis in the form of glycerol-3-
phosphate. The net effect of these observed androgen actions on lipid flux is therefore 
promotion of adipocyte hypertrophy, thereby potentially fuelling the adverse metabolic 
phenotype observed in PCOS. We have also demonstrated that both T and DHT have potent 
dose-dependent insulinotropic effects in a mouse insulinoma β-cell line. Women with PCOS 
have relative hyperinsulinaemia compared to healthy controls (Dunaif, 1997) and although 
this is likely to be predominantly secondary to insulin resistance, it is reasonable to 
hypothesise that these differences are driven in part by androgen-mediated pancreatic insulin 
secretion. Androgen action as insulin secretagogues could further exacerbate metabolic 
dysfunction, with enhanced lipogenesis, fat accumulation and weight gain.  
 The observed in vitro associations between hyperandrogenism and lipid homeostasis 
support a growing body of animal data on the effects of androgens on the phenotype of WAT. 
In non-human primates (NHPs), androgen deprivation reduces adipocyte size in males, which 
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is restored by treatment with DHT (Varlamov et al., 2012). The same study found broadly 
similar effects of androgens on FFA uptake as we observed above, with reduced insulin-
stimulated FFA uptake compared to controls in female NHP adipocytes. Androgen treatment 
in female rhesus macaques induces insulin resistance, not only in adult animals but also in 
offspring (Varlamov et al., 2013), while lipogenic gene expression is upregulated by 
androgens in WAT in both sexes (Varlamov et al., 2012). In rats, postnatal androgen exposure 
results in enlarged mesenteric adipocytes in adult animals, with insulin resistance and an 
atherogenic lipid profile (Alexanderson et al., 2007). These findings have been replicated in 
prepubertally-androgenised mice; abnormalities in DHT-treated animals include enlarged 
adipocyte size in the retroperitoneal, inguinal and gonadal fat depots, impaired glucose 
tolerance and increased atretic ovarian antral follicles (van Houten et al., 2012).  
 Hyperandrogenism in women is associated with central adiposity and increased waist 
circumference (Evans et al., 1988). Evidence suggests that androgens play a role in 
preferentially driving visceral fat accumulation in both animal (Nohara et al., 2014) and 
human (Bjorntorp, 1992) studies; recent work has also suggested that androgen exposure 
leads to ‘masculinisation’ of the proteomic signature of female adipose tissue (Montes-Nieto 
et al., 2013). However, as demonstrated in chapter 4, adipose tissue itself is an important 
organ of androgen generation and is therefore likely to contribute to circulating androgen 
burden in PCOS. This raises the prospect of a ‘vicious circle’ of adipose androgen generation 
and lipid accumulation, with hyperandrogenism exacerbating central fat deposition and vice 
versa.  Our data suggest that androgens have important action on lipid homeostasis, with 
locally-generated androgens driving de novo lipogenesis and glucose uptake, and, in lower 
energy states, suppressing β-oxidation. The stimulatory effects of androgens on lipogenesis, 
and suppressive effects on β-oxidation, were observed under basal rather than 
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hyperinsulinaemic conditions, suggesting that androgens may drive lipid accumulation in the 
fasted state. This raises the possibility that hyperandrogenic women may be at a significant 
disadvantage in terms of weight loss potential from dietary interventions. These adverse 
effects on lipid flux and adipocyte hypertrophy may be compounded in the fed state, with 
increased androgen-mediated postprandial adipose glucose uptake providing further substrate 
for conversion to TAG, and contributing to a ‘double-hit’ phenomenon. 
 The observation of increased adipose glucose uptake after T exposure is interesting, 
and contrasts with that of Corbould et al, who demonstrated impaired insulin-stimulated 
glucose uptake in human female differentiated adipocytes exposed to T for 48 hours 
(Corbould, 2007). In our protocol, adipocytes were treated with T for 4 hours before glucose 
uptake was initiated, suggesting a possible divergence between acute and chronic effects of T 
on glucose uptake. Insulin resistance in PCOS may be tissue-specific, and one ex vivo study 
found that insulin-stimulated glucose uptake in PCOS adipocytes was comparable to that of 
healthy women, but was significantly reduced in skeletal myotubes (Ciaraldi et al., 2009). In 
the same study, whole-body insulin responsiveness of glucose uptake was significantly 
reduced in PCOS women. This is perhaps unsurprising, as muscle is the most critical site of 
postprandial insulin-mediated glucose uptake, and therefore the major determinant of whole-
body insulin sensitivity. Reduced whole-body glucose uptake in the setting of androgen 
exposure has also been reported in other studies (Diamond et al., 1998, Polderman et al., 
1994), with hepatic insulin sensitivity unchanged, supporting a role for skeletal muscle in the 
insulin resistance of PCOS. The elevated glucose uptake in T-treated adipocytes observed in 
our study could also represent a compensatory mechanism in the setting of reduced glucose 
uptake in skeletal muscle, but at the expense of enhanced adipose lipogenesis.   
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 Studies of androgen action in adipose tissue are complicated by gender-specific 
differences in biology and should be interpreted with caution. Abdominal obesity in 
premenopausal women is associated with androgen excess, while in men it is linked with low 
circulating sex steroid levels (Mongraw-Chaffin et al., 2015). It is also interesting to note that 
the adverse metabolic phenotype commonly associated with male hypogonadism mirrors that 
of androgen excess in women (Escobar-Morreale et al., 2014), with central fat accumulation, 
dyslipidaemia and insulin resistance. In healthy females, high oestrogen and low androgen 
levels facilitate preferential accumulation of SC fat in the gluteofemoral region rather than 
visceral fat in the abdominal region, contributing to the so-called female ‘pear-shape’ (Wells, 
2007). Hyperandrogenic women with PCOS are generally believed to have a more central fat 
distribution pattern (Escobar-Morreale et al., 2005), although some data suggest that 
differences reside in total fat mass rather than in a specific regional distribution (Barber et al., 
2008). In healthy men, physiologically high androgen levels are associated with a degree of 
abdominal fat distribution, but this is also counter-balanced by the increased lean mass 
(largely muscle) conferred by very high T levels. In the setting of untreated male 
hypogonadism, with circulating androgens often broadly comparable to levels observed in 
PCOS, this balance is disturbed, with increased central adiposity, reduced lean mass, and an 
unfavourable metabolic profile (Rao et al., 2013). Further studies are required to understand 
these complex associations, but it is apparent that androgens play a major role in adipose lipid 
metabolism and regulation of fat mass in both sexes. 
 The effects of androgens on pancreatic β-cell insulin secretion demonstrated above 
were potent and are likely to be of physiological significance; AR mRNA was highly 
expressed in MIN6 cells. Women with androgen excess have significantly higher basal insulin 
secretory rates, as well as abnormal postprandial insulin release (O'Meara et al., 1993, Holte 
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et al., 1994). Chronic androgen exposure in female mice induces β-cell hyperfunction, and 
ultimately islet failure (Roland et al., 2010). β-cell function appears to be intimately linked 
with free T levels in PCOS. There is convincing evidence of β-cell overactivity in those with 
androgen excess, strongly supporting the hypothesis that hyperandrogenism drives insulin 
hypersecretion (Goodarzi et al., 2005). Metabolic consequences of androgen-induced 
stimulation of pancreatic insulin secretion include acceleration of overt β-cell failure and 
onset of hyperglycaemia, as well as exacerbation of adipose lipogenesis and fat mass 
expansion.  
 The data presented in this chapter support our hypothesis that androgens act at 
multiple levels to adversely impact on adipose lipid homeostasis, insulin action and global 
metabolic function. In the final results chapter, we will attempt to tease out the role of 
androgens in adipose tissue function and global metabolism in a dedicated in vivo study in 
both PCOS women and healthy female volunteers.    
  
 
 
 
 
 
 
 
 
 
  
 
6 The role of androgens in adipose tissue 
biology in vivo 
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6.1 Introduction  
 In chapter 5, we examined the role of androgens in adipose lipid metabolism and 
pancreatic insulin secretion in vitro, demonstrating upregulation of lipogenesis in adipocytes 
and insulinotropic effects on β-cell function. The effects of acute androgen exposure on in 
vivo adipose physiology, lipid metabolism and insulin secretion in human subjects have not 
been extensively investigated. In chapter 4, we highlighted the role of adipose tissue as an 
intracrine androgen-generating organ, expressing androgen-activating enzymes and actively 
converting precursor hormones into more potent metabolites. However, the potential of 
adipose tissue for androgen activation after oral exposure to precursor hormones has not been 
explored in the human setting. Furthermore, there are few studies on the differences in intra-
adipose androgen concentrations between PCOS women and the background female 
population. The evolution of LC-MS/MS in recent years has allowed for accurate 
identification and quantification of steroids in a variety of human tissues, even when present 
at low concentrations (Fahlbusch et al., 2015, Vitku et al., 2015). These techniques have been 
extended in recent years to intra-adipose steroid quantification (Methlie et al., 2013, Wang et 
al., 2013), but estimation of adipose-specific androgen generation has been limited to only a 
small number of studies to date (Wang et al., 2011). 
 Observational studies have shown abnormal expression of genes involved in lipid 
metabolism in SC abdominal adipose tissue of women with PCOS (Chazenbalk et al., 2012). 
Adipocyte hypertrophy appears to be more prevalent in PCOS than comparably obese control 
women (Manneras-Holm et al., 2011). Adipocyte diameter is closely linked to insulin 
resistance and metabolic dysfunction (Villa and Pratley, 2011). Our in vitro findings of 
enhanced de novo lipogenesis in androgen-treated adipocytes in Chapter 5 provide a plausible 
mechanistic link between androgen excess and adipocyte hypertrophy; further support for this 
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association includes the observation of T-induced suppression of lipolysis in SC adipocytes 
(Dicker et al., 2004). However, to our knowledge, these findings have not been tested in the in 
vivo setting after acute androgen exposure, using real-time markers of lipid flux in a human 
model. Equally, we are not aware of any human clinical studies examining the impact of 
androgen exposure on serum insulin levels. Testosterone has been shown to acutely increase 
insulin secretion in primary cultures pancreatic islets from rats (Morimoto et al., 2001), while 
androgens increased insulin secretion and β-cell number in female sheep exposed to 
androgens in utero (Rae et al., 2013). However, it is imperative to replicate our in vitro 
findings of chapter 5 in human in vivo studies to provide convincing evidence of their 
physiological significance.  
 We hypothesise that acute androgen exposure in vivo induces alterations in adipose 
tissue lipid homeostasis and androgen generation in women with PCOS, as well as changes in 
pancreatic insulin release. To test these hypotheses, we will study androgen metabolism and 
lipid biology after an oral DHEA challenge in PCOS women and healthy controls. This is a 
validated tool for the study of in vivo androgen physiology in human health and disease 
(Fassnacht et al., 2003). Androgen exposure after oral intake also provides an opportunity to 
study the acute consequences of hyperandrogenism on metabolic parameters and adipose 
tissue biology. To understand the in vivo associations between insulin sensitivity and 
androgen metabolism, we will study the hyperandrogenic phenotype of a small cohort of 
severely insulin-resistant women with loss-of-function mutations in the INSR (Semple et al., 
2011), and measure serum insulin levels before and after DHEA in all three study groups. We 
will also study the consequences of androgen exposure on realtime markers of adipose lipid 
metabolism and insulin sensitivity, using adipose tissue microdialysis (Hazlehurst et al., 
2013), as well as on adipose-specific androgen generation using LC-MS/MS.  
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6.2 Methods 
6.2.1 Research strategy 
 In this chapter, we will compare patterns of serum androgen generation and urinary 
androgen excretion after DHEA in women with PCOS and compared to healthy volunteers. 
To examine the role of hyperinsulinaemia in androgen metabolism, we will measure serum 
androgens and urinary androgen excretion in a small cohort of women (n=3) with inactivating 
mutations of the INSR. Furthermore, we will test for evidence of adipose-specific androgen 
generation in all three groups using the technique of adipose microdialysis (Hazlehurst et al., 
2013), and determine if oral DHEA intake increases local androgen activation in fat. In the 
baseline protocol, participants will remain fasted for the duration of the DHEA challenge test. 
A second study protocol will then be utilised to test the impact of caloric intake on systemic 
androgen metabolism, with participants receiving a standardized meal across the DHEA 
challenge. Patterns of fat distribution and visceral adiposity will be measured with DXA 
imaging and compared across the three study groups. 
 To study the effects of androgen exposure on adipose lipid metabolism and insulin 
sensitivity in realtime, levels of intra-adipose glycerol, pyruvate, lactate and glucose will be 
measured using microdialysis before and after oral DHEA (under fasted conditions). 
 
6.2.2 Subjects  
 Women with PCOS were recruited from outpatient clinics at the Queen Elizabeth 
Hospital Birmingham (QEHB) and Birmingham Women’s Hospital (BWH). This study 
received ethical approval from Edgbaston REC (Ref. 12/WM/0206) and all participants gave 
written informed consent. PCOS was diagnosed according to the Rotterdam ESHRE 2004 
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criteria, with the presence of two or more of the following: oligo-/anovulation, clinical signs 
of hyperandrogenism, and polycystic ovaries on ultrasound (Rotterdam, 2004b). Other causes 
of oligomenorrhoea and/or androgen excess were excluded by history, physical examination, 
biochemical assessment and, where appropriate, imaging. Healthy controls were recruited via 
local advertisement, with a diagnosis of PCOS excluded by clinical and biochemical 
parameters. Women with INSR mutations were recruited via the Severe Insulin Resistance 
(SIR) clinic at Addenbrooke’s Hospital, Cambridge. Exclusion criteria for all three groups 
were current or recent treatment with glucocorticoids, congenital adrenal hyperplasia, 
hyperprolactinemia, thyroid dysfunction, pregnancy, age <18 or >45 years, oral contraceptive 
or oral anti-androgen therapy within 3 months prior to recruitment, and diabetes mellitus.  
 
6.2.3 Clinical protocol 
 Participants attended the National Institute of Health Research/Wellcome Trust 
Clinical Research Facility at the Queen Elizabeth Hospital Birmingham at 08:00 after an 
overnight fast for a single day of integrated assessment (Figure 6-1). All patients provided a 
pre-collected 24-h urine sample for urinary steroid metabolite analysis by GC/MS. Baseline 
anthropometric assessment included height, weight and body mass index (BMI, kg/m2) and 
measurement. Dual-energy x-ray absorptiometry (DXA) was employed for body composition 
assessment using Hologic Discovery/W DXA as described in section 3.2.3. Fat phenotype 
was measured by assessment of android and gynaecoid fat distribution, with subsequent 
calculation of android:gynaecoid fat ratio. Estimated visceral adipose tissue was calculated as 
volume (cm3), mass (g) and  % of total fat mass.  Baseline bloods were drawn for fasting 
plasma glucose and insulin, as well as serum androgens and gonadotrophins. 
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 In Protocol A (Figure 6-1A), an adipose microdialysis catheter was inserted under 
local anaesthetic at 09.00. At 10.00, 100mg of the oral androgen precursor DHEA (25mg 
capsules, Olympian) was administered. Adipose microdialysis fluid and serum were sampled 
every 30 minutes for 4 hours for androgen quantification by LC-MS/MS. Participants 
remained fasted until the study visit conclusion. Participants in Protocol A also returned a 2nd 
24-hour urine sample to the Clinical Research Facility the following day so that the impact of 
DHEA on androgen excretion could be measured. In Protocol B (Figure 6-1B), a standardized 
mixed meal (carbohydrate 45g, protein 23g and fat 20g) was provided at 13.00. Adipose 
microdialysis was not performed in Protocol B due to the confounding effects of caloric 
intake on lipid metabolism. Study volunteers completed either Protocol A or Protocol B (no 
study crossover component), although INSR patients completed both.  
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Figure 6-1 Clinical protocol. (A) Patients fasted for the duration of the DHEA challenge and 
adipose microdialysis. In protocol A, patients also commenced a second 24 hour urine 
collection at the start of the DHEA challenge test, which was returned to the WTCRF the 
following day. (B) In protocol B, patients were given a standardised snack at 11.00 and a 
mixed meal at 13.00. 
 
6.2.4 Serum, urine and microdialysis steroid measurements 
 Serum androgens were measured by liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) as described in sections 2.5.1 and 3.2.4, employing a Waters Xevo 
mass spectrometer with Acquity uPLC system. Briefly, LC-MS/MS conditions consisted of 
an electrospray ionization source with capillary voltage 4.0kV, a source temperature of 
150°C, and a desolvation temperature of 500°C. Serum steroid oxime analysis was employed 
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for the measurement of T, A and DHEA and carried out in positive mode, whereas 
measurement of serum DHEAS was performed in negative mode. T, A and DHEA were 
extracted from serum via liquid-liquid extraction using tert-butyl-methyl-ether (MTBE), 
followed by derivatization into steroid oximes employing 100µl derivatization mixture. For 
protein precipitation and extraction of DHEAS, 20µl ZnSO4 0.1mM and 100µl acetonitrile 
were added to 20µl serum before evaporation under constant nitrogen flow (Chadwick et al., 
2005). All steroids were separated using an optimized gradient system consisting of methanol 
with 0.1% formic acid and quantified referring to a linear calibration series with appropriate 
internal standards. Each steroid was identified by matching retention times and two mass 
transitions in comparison to a deuterated reference compound.  
 Urinary steroid metabolite excretion analysis was carried out by GC/MS as described 
previously in sections 2.5.3 and 3.2.4 (Arlt et al., 2004). The sum of An and Et was 
considered representative of active androgen metabolite excretion (Silfen et al., 2002). Net 
systemic 5α-reductase activity was assessed by the ratios of An/Et and 5α-THF/THF. Total 
glucocorticoid metabolite excretion was assessed as the sum of 5α-THF + THF + THE + 
cortolones + cortols + cortisol + cortisone. 
 For steroid extraction from microdialysis fluid, vials containing 10-15µl of fluid were 
defrosted at room temperature. 50µl of LC-MS/MS grade water was added to each vial and 
gently spun at 12,000rpm for 5 minutes. Due to small sample volumes, it was necessary to 
combine samples from consecutive time-points as follows: (1) Pre-DHEA: time-points -15, 0 
and 30 minutes, (2) Post-DHEA (A): time points 60, 90, 120 and 150 minutes and (3) Post-
DHEA (B): time-points 180, 210 and 240 minutes, giving volumes of 150, 200 and 150µl 
respectively per combined sample in each patient. Samples were then added to sylinised tubes 
and reconstituted with water to give a final volume of 500µl. A calibration series was 
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prepared using serum steroid calibrants C0-C11 as described above. Internal standard 20µl 
was then added to each sample. MTBE 2.5ml was added to each sample, followed by 
vortexing and freezing for at least 60 minutes at -20°C. MTBE was then poured into next 
sylinised tubes and evaporated to dryness under nitrogen at 55°C, followed by reconstitution 
with 125µl methanol/water (50:50) and transfer to 96-well plates. Plates were stored at -20°C 
until LC-MS/MS analysis.  
 
6.2.5 Adipose microdialysis 
 Adipose microdialysis was carried out as described by Tomlinson, Figure 6-2 
(Tomlinson et al., 2007). A microdialysis catheter (CMA Microdialysis, Stockhold, Sweden) 
was inserted into the SC abdominal fat, approximately 10cm lateral to the umbilicus, under 
local anaesthetic and sterile technique. After an initial 5-10 minute flush sequence (15µl/min), 
microdialysis proceeded at a rate of 0.5µl/min; samples were collected at -15 and 0 minutes 
pre-DHEA administration, and subsequently every 30 minutes for 4 hours. Samples were 
analysed for metabolic markers of insulin action and lipid metabolism, and for adipose-
specific androgen levels. 
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Figure 6-2 Adipose microdialysis in SC abdominal adipose tissue (CMA Microdialysis, 
Sweden) (Tomlinson et al., 2007).  
 
6.2.6 Serum insulin and FFAs 
 Serum insulin was measured using a Human Insulin Elisa kit (Mercodia, Sweden) as 
described in section 2.6.1. Briefly, calibrators and samples (10µl each) in duplicate were 
transferred to a 96-well plate. Enzyme conjugate 1X solution was added to each well, and 
samples incubated on a plate shaker (700-900 rpm) for 2 hours at room temperature. The plate 
was then washed manually by adding 350µl wash buffer 1X solution to each well, followed 
by addition of Substrate TMB to each well. After incubation for 15 minutes at room 
temperature, Stop Solution was added and the plate placed on the shaker for 5 seconds to 
ensure mixing. Optical density of plates was measured at 450nm on spectrophotometer.  
Serum FFAs were measured as described in section 2.6.2, using a commercially available kit 
(ZenBio, NC, US).   
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6.2.7 Statistical analysis 
 Statistical Package for the Social Sciences (SPSS, Chicago, Il.) Version 21 was used 
for data analysis. All data is expressed as mean ± standard deviation (SD) unless otherwise 
stated. Data was log-transformed if necessary to normalize before using parametric tests. 
Independent samples t tests or Mann-Whitney were used as appropriate for comparison 
between two groups. One-way ANOVA with post hoc Tukey testing was used for multiple 
comparisons between different groups. Area-under-the-curve (AUC) across the DHEA 
challenge test was measured using the Trapezoidal Rule (Microsoft Excel). Categorical 
variables were compared using Pearson’s Chi-Square test. Correlation testing was performed 
on continuous variables using Pearson’s correlation co-efficient for normally distributed data 
or Spearman’s test for non-normally distributed data. Differences were considered statistically 
significant at p<0.05. 
 Consultation with a dedicated university statistician was necessary in order to obtain 
accurate power calculations for this clinical study. Based on estimated detectable differences 
and standard deviations in adipose microdialysis values, serum steroid levels and urinary 
metabolite excretion profiles, a sample size of 10 PCOS and 10 control patients was deemed 
sufficient to achieve 80% statistical power. This statistical powering could not be applied to 
the INSR cohort due to the small number of available study patients. 
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6.3 Results 
6.3.1 Serum androgens and urinary steroid excretion  
6.3.1.1 Baseline comparison 
 A total of 8 women with PCOS, 8 healthy controls and 2 INSR women completed 
Protocol A (fasted conditions). A further 10 PCOS, 10 healthy controls and 3 INSR women 
(two of whom also participated in Protocol A) took part in Protocol B (fed conditions). 
Patients attending for Protocols A and B were matched for age and BMI.  Baseline 
characteristics, baseline serum androgens and urinary steroid excretion of all study 
participants (Protocols A and B combined) are shown in Table 6-1.   
 All three participant groups were matched for age and BMI. Women with PCOS had 
higher serum levels of T, A and DHEA than healthy controls. Trends were observed towards 
higher urinary An/Et and 5α-THF/THF ratios (markers of 5α-reductase activity), and higher 
total urinary androgen and glucocorticoid metabolite excretion, in PCOS women compared to 
the other two groups, but these did not reach significance. HOMA-IR was significantly higher 
in INSR patients (p<0.0001); serum triglycerides were higher in PCOS women compared to 
controls (p=0.01).  
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Table 6-1 Baseline characteristics, serum androgens and urinary steroid profiles of healthy 
controls, PCOS and women with INSR mutations (both study protocols combined). Data 
expressed as mean±SD unless otherwise stated. 
a, p<0.05, b, p<0.01, c, p<0.001 as compared to BMI-matched healthy controls. d, p<0.05; 
e, p<0.01; f, <0.001 as compared to PCOS. 
Variable Healthy controls (n=18) PCOS (n=18) INSR mutations (n=3) 
Age (years) 
 
29.9±5.8 29.9±6.2 25.7±7.6 
BMI (kg/m2) 
 
27.2±5.1 31.9±7.5 29.1±2.6 
HOMA-IR 
 
1.3±1.3 4.8±4.4 44.9±41.5c, f 
Total cholesterol 
(mmol/l) 
3.7±1.2 4.3±1.3 5.3±0.9 
HDL cholesterol 
(mmol/l) 
1.5±0.3 1.5±0.6 2.1±0.5 
Triglcyerides 
(mmol/l) 
0.6±0.2 1.3±0.9a 1.0±0.4 
AST (U/L) 
 
16.2±3.2 25.5±18.9 13.7±2.0 
Testosterone (nmol/l) 
 
0.2±0.4 0.7±0.8a 0.1±0.2 
Androstenedione (nmol/l) 
 
3.9±3.2 6.9±3.8a 4.6±2.4 
DHEA (nmol/l) 
 
10.1±10.1 22.8±13.4b 14.3±11.6 
DHEAS (µmol/l) 
 
6.4±5.1 7.0±4.1 4.1±3.2 
FAI (T*100/SHBG) 
 
2.3±1.5 4.3±2.4 5.2±6.9 
An/Et ratio  
(5α-reductase activity) 
1.1±0.3 1.4±0.6 1.2±0.6 
5α-THF/THF  
(5α-reductase activity) 
0.8±0.3 1.1±0.6 1.0±0.7 
Total androgen 
metabolites (An+Et) 
3072±2447 4093±3623 3246±2162 
Total glucocorticoid 
metabolites 
4864±2757 6098±3535 3789±667 
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6.3.1.2 DHEA challenge test and serum androgens 
  Serum androgens across the DHEA challenge test for Protocol A and B are shown in 
Figure 6-3 and Figure 6-4 respectively. Baseline T levels did not differ significantly between 
PCOS women participating in the fasted and fed studies (p=0.70) or between the two 
corresponding healthy control groups (p=0.81). However, baseline A levels were higher in the 
PCOS women in Protocol B (fed) compared to those from Protocol A (9.3±3.3 v 
3.8±1.6nmol/l, p=0.001). The same observation was noted in healthy controls, with higher 
baseline A levels in the Protocol B (fed) group compared to those from Protocol A (5.6±3.4 v 
1.7±1.1, p=0.03).  Baseline DHEA and DHEAS levels did not differ significantly between the 
two PCOS groups (p=0.41 and p=0.99, respectively) or the two control groups (p=0.95 and 
p=0.98, respectively).  
 There was a trend towards higher AUC (mean±SEM nmol/l*min) values in PCOS 
compared to controls for T (156±43 [PCOS] v 78±27 [controls], p=0.15) and A (1065±245 
[PCOS] v 683±49, p=0.15) in the fasted protocol, but these did not reach statistical 
significance. AUC for T in INSR patients in the fasted protocol was significantly higher than 
in both PCOS and controls (731±46 [INSR] v 156±43 [PCOS], p<0.0001; v 78±27 [controls], 
p<0.0001). AUC for A was also higher in fasted INSR patients compared to PCOS and 
controls (4633±197 [INSR] v 1065±245 [PCOS], p<0.0001; v 683±49 [controls], p<0.0001). 
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Figure 6-3 Serum testosterone (A), androstenedione (B), DHEA (C) and DHEAS (D) across 
the DHEA challenge in Protocol A (fasted) in healthy controls (green line), PCOS (blue line) 
and INSR mutation women (red line). 
 
 In the fed state (Figure 6-4), AUC (mean±SEM nmol/l*min) for T and A was 
significantly higher in PCOS women compared to controls (258±65 v 63.3±25.1, p=0.01, and 
2507±237 v 1556±303, p=0.01, respectively). AUC for T did not differ significantly between 
INSR patients and controls (226±213 v 63±25, p=0.17); however AUC for A was 
significantly higher in INSR patients than in controls (2533±209 v 1556±303, p=0.02). AUC 
values for A and T did not differ significantly between INSR and PCOS (p=0.84 and p=0.96, 
respectively).  
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 AUC values (mean±SEM nmol/l*min) for T were similar across fed and fasted 
conditions in both PCOS women (p=0.23) and healthy controls (p=0.67); however AUC 
values for A were significantly higher in women participating in the fed protocol compared to 
their fasted counterparts, in both PCOS women (p=0.0007) and healthy controls (p=0.008).  
  
 
 
 
Figure 6-4 Serum testosterone (A), androstenedione (B), DHEA (C) and DHEAS (D) across 
the DHEA challenge in Protocol B (mixed meal) in healthy controls (green line), PCOS (blue 
line) and INSR mutation women (red line).  
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6.3.1.3 Urinary androgens androgen excretion after DHEA exposure 
 Urinary androgen excretion was measured before and after DHEA in PCOS, control 
and INSR women in Protocol B (Table 6-2). There were no significant differences in baseline 
urinary excretion of An, Et, total androgen metabolites (An+Et) or total glucocorticoid 
metabolites between the three groups, although PCOS had a trend towards higher values than 
controls. Urinary An, Et and total androgen metabolites (Figure 6-5) increased significantly in 
all three groups after DHEA. Excretion of An after oral DHEA was higher in INSR compared 
to controls (p=0.05), and there was a trend towards increased excretion compared to PCOS 
women (p=0.06). INSR women had higher urinary levels of Et post-DHEA compared to both 
PCOS and controls (p=0.001 and p=0.002, respectively). Urinary excretion of total androgen 
metabolites post-DHEA was also significantly higher in INSR women compared to both 
PCOS and controls (p=0.007 and p=0.009, respectively). Urinary markers of 5α-reductase 
activity (An/Et and 5α-THF/THF ratios) or total glucocorticoid metabolite excretion did not 
change significantly from baseline after DHEA in the three study groups (Table 6-2).   
 
 
 
 
 
 
 
 
 
 
Chapter 6                                                                                                                          The role of androgens in adipose tissue biology in vivo  
 
 202 
Table 6-2 Urinary androgen and glucocorticoid excretion after oral DHEA in controls, PCOS 
and INSR (Protocol A). Data expressed as mean±SD unless otherwise stated. 
a, p<0.05, b, p<0.01, c, p<0.001 as compared to BMI-matched healthy controls. d, p<0.05; 
e, p<0.01; f, <0.001 as compared to PCOS. 
Variable Control (n=8) PCOS (n=8) INSR mutations (n=2) 
An pre-DHEA 
(µg/24h)  
1468±977 2369±2375 1537±786 
An post-DHEA  
(µg/24h) 
4556±3111 4896±3379 12165±6477a 
Et pre-DHEA  
(µg/24h) 
1604±1528 1724±1402 1708±1505 
Et post-DHEA  
(µg/24h) 
5727±3372 4574±2464 15821±1680b, e 
Total androgen 
metabolites (An+Et) pre-
DHEA (µg/24h)  
3072±2447 4093±3623 3246±2162 
Total androgen 
metabolites post-DHEA 
(µg/24h)  
10283±6254 9471±5722 27986±8157b, e 
An/Et ratio pre-DHEA 
(5α-reductase activity) 
1.1±0.3 1.4±0.6 1.2±0.6 
An/Et ratio post-DHEA 
(5α-reductase activity) 
0.7±0.4 1.0±0.4 0.8±0.3 
5α-THF/THF pre-DHEA 
(5α-reductase activity) 
0.8±0.3 1.1±0.6 1.0±0.7 
5α-THF/THF post-DHEA 
(5α-reductase activity) 
0.8±0.2 0.9±0.8 0.9±0.8 
Total glucocorticoid 
metabolites pre-DHEA 
(µg/24h)  
4864±2757 6098±3535 3789±667 
Total glucocorticoid 
metabolites post-DHEA 
(µg/24h)  
3694±2225 5581±4742 6042±3264 
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Figure 6-5 Total urinary androgen metabolite (androsterone + etiocholanolone) excretion 
after oral DHEA in controls, PCOS and INSR women. Excretion increased significantly in all 
three groups. INSR women had higher post-DHEA levels compared to both controls and 
PCOS women. *p<0.05; **p<0.01. 
 
6.3.1.4 Adipose tissue interstitial fluid androgens pre- and post-DHEA exposure 
 T and DHT levels in adipose interstitial fluid before and after DHEA in the three study 
groups are shown in Figure 6-6. Adipose T levels (mean±SEM) were higher in PCOS women 
compared to controls, both at baseline (4.5±1.9 v 0.1±0.1nmol/l, p=0.03) and after DHEA 
(5.4±2.5 v 0.1±0.2, p=0.04). T was undetectable in adipose fluid pre- and post-DHEA in the 
INSR group. There was no significant increase in adipose fluid T after oral DHEA in either 
group (p=0.77 and p=0.63, respectively). DHT was detectable in adipose fluid in all three 
groups. PCOS women had a trend towards higher baseline DHT levels than controls (4.5±1.7 
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v 0.9±0.3nmol/l, p=0.06); post-DHEA levels in the PCOS group were significantly higher 
than those in controls (5.7±2.1 v 0.6±0.2nmol/l, p=0.03), but comparison of DHT levels pre- 
and post-DHEA in the PCOS group failed to reach statistical significance (p=0.68). DHT was 
detectable in INSR adipose fluid both pre- (1.8±0.1nmol/l) and post-DHEA (1.6±0.2nmol/l), 
with no significant difference between pre- and post-values (p=0.42). Baseline adipose T 
levels correlated with AUC for serum T (R=0.58, p<0.001) and A (R=0.44, p=0.005) across 
the DHEA challenge. Baseline adipose DHT levels correlated significantly with the urinary 
An/Et ratio (R=0.51, p=0.02, Figure 6-7). No association was observed between baseline 
DHT and the 5α-THF/THF ratio (R=0.33, p=0.15). 
 Adipose DHEA levels were higher in PCOS women compared to controls pre- 
(4.4±1.8 v 0.2±0.1nmol/l, p=0.03) and post-DHEA (5.1±2.3 v 0.1±0.1, p=0.04), with no 
significant differences observed between pre- and post-DHEA values in either group. 
Androstenedione was also higher in PCOS compared to controls, both before (3.7±1.5 v 
0.5±0.1nmol/l, p=0.04) and after (4.2±1.9 v 0.3±0.1, p=0.05) DHEA intake. 
 
Figure 6-6 T (A) and DHT (B) measured by LC-MS/MS in adipose interestitial fluid pre- and 
post-DHEA in the three study groups.   
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Figure 6-7 Positive relationship between adipose interstitial DHT levels and urinary An/Et 
ratio (marker of 5α-reductase activity) across all three groups. 
 
6.3.2 Metabolic consequences of DHEA exposure 
6.3.2.1 Adipose tissue metabolism in vivo 
 Realtime markers of adipose insulin sensitivity and lipid metabolism in the three 
groups (fasted studies only) during adipose microdialysis are highlighted in Figure 6-8. AUC 
values for pyruvate, lactate and glucose did not differ significantly between control, PCOS 
and INSR women. AUC for glycerol (mean±SEM µM*min) was significantly higher in INSR 
than in both PCOS and control patients (123922±31357 [INSR] v 50380±8910 [PCOS], 
p=0.01; v 70192±9403 [control], p=0.05). AUC for glycerol did not differ significantly 
between PCOS and controls. However, when analysed separately, AUC values for glycerol 
(mean±SEM µM*min) were significantly higher in controls compared to PCOS women at 
120-249 minutes (35347±4781 v 22310±3577, p=0.04). 
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Figure 6-8 Adipose fluid glycerol (A), pyruvate (B), lactate (C) and glucose (D) across the 
DHEA in healthy controls (n=8, green line), PCOS (n=8, blue line) and INSR mutation 
women (n=2, red line). Patients remained fasted for the duration of the challenge (Protocol 
A). Adipose glycerol levels in INSR women are signifcantly elevated compared to the other 
two groups, consistent with severe insulin resistance. Adipose glycerol AUC between 120 and 
240 minutes is significantly lower in PCOS women compared to controls (p=0.04), consistent 
with relative suppression of lipolysis in the PCOS group.  
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6.3.2.2 Serum metabolic markers after DHEA exposure 
 Serum insulin, glucose and FFAs across the DHEA challenge (fasted studies only) are 
shown in Figure 6-9. Fasting insulin levels were significantly higher in INSR women 
compared to both controls and PCOS women (1089.7±686.0 [INSR] v 45.1±45.9pmol/l 
[controls], p=0.005; v 79.8±23.4pmol/l [PCOS], p=0.006. There was no significant difference 
between fasting insulin levels between PCOS and control women (p=0.30). Serum insulin 
values did not change significantly over the course of the DHEA challenge in the three study 
groups. AUC for insulin (mean±SEM pmol/l*min) across the DHEA challenge was 
significantly higher in INSR women compared to both controls and PCOS women 
(200759±156888 [INSR] v 8043±2958 [controls], p=0.01; v 14672±4120 [PCOS], p=0.02. 
AUC for insulin did not differ significantly between PCOS and controls although there was a 
trend towards increased AUC in PCOS women (14672±4120 v 8043±2958, p=0.21).  
 Plasma glucose values remained consistent across the DHEA challenge in all three 
groups (fasted state only). AUC values for glucose (mean±SEM mmol/l*min) were similar in 
PCOS and control women (1169±30 [controls] v 1173±23 [PCOS], p=0.93). AUC for glucose 
in the INSR group (1105±4.2) did not differ significantly from PCOS (p=0.20) or controls 
(p=0.33). AUC for serum FFA (mean±SEM µM*min) after DHEA did not differ significantly 
between PCOS and controls (341515±76306 [PCOS] v 337401±94454, p=0.93).  Mean AUC 
for INSR patients was 333079±14917, and did not differ significantly from controls (p=0.95) 
or controls  (p=0.88).  
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Figure 6-9 Serum insulin (A), glucose (B) and free fatty acids (C) across the DHEA challenge 
test (fasted patients only, Protocol A) in healthy controls (n=8, green line), PCOS (n=8, blue 
line) and INSR mutations (n=2, red line). Fasting and AUC values for insulin are highest in 
INSR patients. 
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6.3.3 Body composition and androgen metabolism 
 Body composition results as measured by DXA are shown in Table 6-3. BMI did not 
differ significantly between the three study groups. No significant differences in android or 
gynecoid fat percentage, or in the android:gynaecoid ratio, were observed across the three 
groups, although PCOS women had a trend towards an increased android fat percentage and 
increased android:gynaecoid ratio compared to controls (p=0.12 and p=0.09, respectively). 
However, PCOS women had higher visceral fat volume (p=0.002), visceral fat mass 
(p=0.002) and percentage visceral fat mass (p=0.003) compared to healthy controls. No 
significant differences in visceral adiposity were detected in INSR women compared to the 
other two groups. Percentage visceral adiposity correlated positively with HOMA-IR 
(p=0.002), serum androstenedione (p=0.04), An/Et ratio (p=0.02) and the 5α-THF/THF ratio 
p=0.02), Table 6-4. 
 
Table 6-3 Markers of visceral adiposity on DXA imaging in all study patients (Protocol A and 
B). Data expressed as mean±SD unless otherwise stated. a, p<0.05, b, p<0.01, c, p<0.001 as 
compared to BMI-matched healthy controls.  
 Controls (n=18) PCOS (n=18) INSR (n=3) 
BMI (kg/m2) 
 
27.1±5.1 31.9±7.5 29.1±2.5 
Android fat (%) 
 
39.5±11.3 47.5±13.2 54.6±3.5 
Gynaecoid fat (%) 
 
43.9±5.6 45.6±9.4 53.1±7.6 
Android:Gynaecoid fat 
ratio 
0.88±0.20 1.02±0.19 1.10±0.13 
Visceral fat volume (cm3) 
 
413±396 1034±626b 841±268 
Visceral fat mass (g) 
 
389±374 976±591b 793±253 
% Visceral fat  
(of total fat mass) 
1.2±0.9 2.4±1.1b 2.2±1.0 
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Table 6-4 Association between visceral adiposity, insulin sensitivity and androgen 
metabolism (R-values) across all patients (n=39) using Spearman’s correlation testing. 
*p<0.05; **p<0.01; ***p<0.001.  
 Visceral 
fat 
volume 
Visceral 
fat mass 
% 
visceral 
fat 
HOMA-
IR 
Serum T Serum A An/Et 
ratio 
5α-
THF/THF 
ratio 
Total 
androgen 
metabolites 
Visceral 
fat volume 
- 0.99*** 0.94*** 0.45** 0.26 0.30 0.48** 0.45** 0.28 
Visceral 
fat mass 
0.99*** - 0.94*** 0.45** 0.26 0.31 0.48** 0.45** 0.29 
% visceral 
fat 
0.94*** 0.94*** - 0.49** 0.26 0.33* 0.38* 0.37* 0.28 
HOMA-IR 
 
0.45** 0.45** 0.49** - 0.28 0.41* 0.35* 0.33* 0.31 
Serum T 
 
0.26 0.26 0.26 0.28 - 0.43** 0.34* 0.29 0.33* 
Serum A 
 
0.30 0.31 0.33* 0.41* 0.43** - 0.48** 0.32* 0.21 
An/Et ratio 
 
0.48** 0.48** 0.38* 0.35* 0.34* 0.48** - 0.76*** 0.05 
5α-
THF/THF 
ratio 
0.45** 0.45** 0.37* 0.33* 0.29 0.32* 0.76*** - 0.12 
Total 
androgen 
metabolites 
0.28 0.29 0.28 0.31 0.33* 0.21 0.05 0.12 - 
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6.4 Discussion 
 The in vivo findings presented in this chapter highlight the role of adipose tissue as an 
important organ of peripheral androgen activation in PCOS, and support many of the in vitro 
data from chapter 4. Intra-adipose androgens were detectable in microdialysis fluid in a subset 
of women with PCOS, whilst present only in trivial amounts in the other two groups. DHT, 
the most potent androgen, was neither quantifiable nor detectable in the serum of study 
participants, even after DHEA, on our current LC-MS/MS assay, and therefore its detection in 
microdialysis fluid in SC fat robustly endorses a role for adipose tissue in androgen 
metabolism in PCOS. Adipose microdialysis has also facilitated the study of real-time effects 
of acute androgen exposure on lipid metabolism in vivo, with relative suppression of lipolysis 
demonstrated in PCOS women after DHEA compared to healthy controls. These data 
indirectly corroborate our de novo lipogenesis results from chapter 5, in which T and DHT 
promoted lipid accumulation in SC adipocytes. The utility of the DHEA challenge test in the 
investigation of in vivo androgen metabolism in humans is highlighted by the dramatic 
increases in serum and urinary androgen metabolites in study participants after DHEA 
administration, consistent with previous studies (Fassnacht et al., 2003). The observed 
changes in intra-adipose glycerol levels after DHEA also underpin its role as a tool for the 
study of acute androgen-mediated effects in human biology. 
 Evidence for intra-adipose androgen generation is convincing from multiple previous 
studies (Quinkler et al., 2004, Blouin et al., 2003). Local generation of androgens by 
adipocytes is particularly intriguing in the context of PCOS-related metabolic dysfunction. 
Adipose tissue plays an integral role in human energy homeostasis and metabolism 
(Tomlinson et al., 2008a), and recent studies, including our own data from chapter 5, have 
highlighted that androgens, acting via the AR, induce changes in adipocyte size and energy-
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storing capacity (Caldwell et al., 2015). We have previously discussed how chronic DHT 
exposure in female mice, whether in utero or at later developmental stages, induces adipocyte 
hypertrophy and metabolic derangements (Caldwell et al., 2014, Yan et al., 2013). Increased 
adipocyte size has been intimately linked to insulin resistance, dyslipidaemia and 
hypertension (Vazquez-Vela et al., 2008), and appears to be more metabolically deleterious 
than the fat expansion observed in hyperplasia (Villa and Pratley, 2011).  Cumulatively, these 
observations suggest that adipose-specific androgen generation may fuel an adverse metabolic 
phenotype in PCOS, creating a vicious circle which may be driven by hyperinsulinaemia. 
Unfortunately, the numbers in our study were too small to meaningfully correlate adipose 
DHT levels with markers of systemic insulin resistance or abdominal obesity in the PCOS 
group. To our knowledge, this is the first attempt to measure intra-adipose androgen 
concentration by LC-MS/MS in human microdialysis fluid. T generation was previously 
measured by thin layer chromatography (TLC) in differentiated SC and OM adipocytes in the 
study by Quinkler et al, who showed increased conversion of A to T in the SC samples. 
Glucocorticoids have been assayed using LC-MS/MS in adipose microdialysis fluid from 
both rats and monkeys (Huang et al., 2011, Sun et al., 2008), while E2 levels have been 
measured in SC and OM samples from severely obese patients (Wang et al., 2013). Detection 
of adipose androgens by LC-MS/MS now raises the exciting prospect of tissue-specific sex 
hormone estimation in future studies, including in androgen deficiency syndromes in men. 
 We demonstrated relative suppression of adipose lipolysis, as measured by 
microdialysis fluid glycerol concentrations, in PCOS women after DHEA, compared to 
healthy controls. This would appear to support our in vitro observations of upregulated ACC1 
expression and enhanced de novo lipogenesis in androgen-exposed SGBS cells (sections 
5.3.2.1 and 5.3.2.2). Recent studies have also demonstrated enhanced lipogenesis in response 
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to DHT in primary human female hepatocytes, a finding not observed in male tissue (Nasiri et 
al., 2015); Varlamov and colleagues also found attenuation of lipolysis, increased FAS 
mRNA expression and elevated FFA uptake in visceral WAT from females exposed to 
chronic androgen excess (Varlamov et al., 2013). Interestingly, one study suggested 
significant metabolic heterogeneity between obese and non-obese women with PCOS using a 
nontargeted GC/MS serum metabolomics approach, demonstrating increased lipolysis, likely 
secondary to insulin resistance, in obese women, and, conversely, suppression of lipolysis, 
likely secondary to significant androgen excess, in the non-obese cohort (Escobar-Morreale et 
al., 2012). Once again the small numbers in this study did not allow us to analyse obese and 
non-obese patients separately, as only 3 patients out of 8 had a BMI less than 30kg/m2 in the 
PCOS group.  
 A weight-loss intervention in PCOS women, who had similar age and weight 
parameters to those in the study above (mean BMI 32.0±1.6kg/m2), revealed reduced baseline 
catecholamine-stimulated lipolysis in SC fat in PCOS compared to controls using adipose 
microdialysis (Moro et al., 2009). This resistance of lipolysis to catecholamine stimulation 
subsequently improved after weight loss, despite the absence of changes in adipose insulin 
sensitivity. This suggests that the defects in lipolysis occur independent of insulin resistance. 
This is supported by our finding of constant serum insulin, glucose and FFA levels across the 
DHEA challenge in all groups, with no significant change in response to in vivo androgen 
exposure (in contrast to the in vitro observations in chapter 5). Androgen-mediated 
lipogenesis and adipocyte hypertrophy could represent a driving force for fat mass expansion 
and weight gain in PCOS. Reduction of androgen burden with pharmacotherapy, coupled with 
lifestyle intervention, may therefore represent the best strategy to enhance lipolysis and 
induce weight loss in PCOS.  
Chapter 6                                                                                                                          The role of androgens in adipose tissue biology in vivo  
 
 214 
 Comparison of serum androgens from the DHEA challenge test in the fed and fasted 
state does not suggest a major role for caloric intake in androgen metabolism in women. 
Interpretation of these results, however, is limited by the absence of a crossover component to 
the study (with the exception of the INSR women), whereby the same patients would have 
completed both protocols to allow direct comparison. AUC and baseline T values in the 
DHEA challenge were similar between fed and fasted PCOS women, and between fed and 
fasted controls. AUC for A was significantly higher in the fed PCOS and control groups 
compared to their fasted counterparts; however, higher baseline A levels in the fed study 
suggests that these were androgenically distinct from the fasted groups even before caloric 
intake. This baseline difference in the two PCOS groups underpins many of the difficulties 
with the interpretation of studies in this disorder, by highlighting the presence of significant 
biochemical and metabolic heterogeneity, despite methodical BMI matching of all study 
groups. Serum A and T in the hyperinsulinaemic INSR cohort after DHEA appear to be 
significantly higher than in the other two groups, suggesting a major role for insulin in 
androgen generation, although statistical analysis is not likely to be informative in view of the 
small numbers.  
 Our observation of increased markers of visceral adiposity in the PCOS group 
compared to BMI-matched controls is interesting, but these findings have not been replicated 
in all studies of fat distribution in PCOS. Discrepancies in results of studies on fat distribution 
in PCOS are often attributable to the use of distinct imaging modalities, or to heterogeneity in 
study groups as described above. Barber and colleagues found that PCOS and BMI-matched 
controls were indistinguishable in terms of visceral, abdominal, SC and gluteofemoral fat 
distribution on axial MRI imaging (Barber et al., 2008). A recent study employing ultrasound 
found that PCOS women had increased intra-abdominal and mesenteric fat thickness 
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compared to BMI-matched controls, representing an ‘intermediate’ phenotype between men 
and women (Borruel et al., 2013). PCOS women also had increased global adiposity 
compared to controls. Using a composite of anthropometric markers (waist circumference) 
and lipid biochemistry to calculate validated indices of adiposity, Tehrani and colleagues 
found no difference in the visceral adiposity index (VAI) between PCOS and controls, but 
noted significantly higher lipid accumulation product (LAP) values in PCOS women 
(Ramezani Tehrani et al., 2014). In the DXA data presented in this chapter, we found no 
significant differences in android or gynecoid fat distribution between PCOS and controls, but 
noted increased visceral fat mass and volume, and increased visceral fat percentage of total fat 
mass, in the PCOS group. Visceral adiposity was positively associated with serum androgens, 
systemic 5α-reductase activity, and markers of insulin resistance, suggesting that increased 
visceral fat in PCOS is a surrogate marker of circulating androgen burden and metabolic 
disease.  
 The clinical, biochemical and radiological data presented in this chapter support our 
overriding hypothesis of intra-adipose androgen generation, abdominal obesity and insulin 
resistance in PCOS. Using state-of-the-art in vivo research tools and biochemical analytical 
techniques, as well as diagnostic challenge test, we have identified key differences in serum, 
urinary and adipose androgen metabolism in PCOS, control and INSR mutation women, and 
have correlated these derangements with systemic insulin resistance and markers of adiposity. 
The summary and final conclusions of this thesis will consider all the data presented and set 
forth a clear strategy for future research directions in this field. 
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7.1 Final conclusions 
 PCOS is a complex, heterogeneous disorder, manifesting clinically with a series of 
diverse phenotypes. As our understanding of PCOS evolves, it is increasingly apparent that it 
represents the common clinical endpoint of a number of biologically distinct metabolic 
disturbances, and that current diagnostic and classification strategies, as discussed in section 
1.2.1, are largely inadequate. The notion that PCOS is a disorder of primary ovarian origin 
appears increasingly outdated. However, obesity, androgen excess and insulin resistance are 
highly prevalent in PCOS, are present in the majority of patients, and their respective 
phenotypic severities are closely correlated (O'Reilly et al., 2014a). This suggests that all 
three abnormalities are intimately linked, and play a causative role in the pathogenesis of 
PCOS, at least in the majority of patients. On the basis of the data presented in this thesis, we 
believe that adipose tissue is a crucial site of interaction between insulin signaling and 
androgen metabolism in women, functioning as an intracrine organ of androgen activation, as 
well as a target of androgen action. We have presented evidence for pro-lipogenic effects of 
androgens at cellular level, resulting in adipocyte hypertrophy, fat accumulation and insulin 
resistance. Secondary hyperinsulinaemia may fuel this vicious circle by further stimulating 
local adipose androgen generation through upregulation of AKR1C3 expression and activity 
(Figure 7-1). Further work is needed to understand if these mechanisms are only relevant in 
the context of PCOS-related obesity. Adipose androgens were detectable in only a subset of 
PCOS in the clinical study, although interestingly levels did not correlate with BMI or 
radiological indices of adiposity. 
 The rationale for our interest in adipose tissue as a key player in androgen metabolism 
is based upon the association of hyperandrogenism with adiposity in females (Mongraw-
Chaffin et al., 2015, Borruel et al., 2013). Intriguingly, this correlation appears to contrast 
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with that observed in men, where abdominal obesity and metabolic dysfunction are associated 
with low levels of circulating sex hormones. The role of peripheral tissue in androgen 
activation has been recognized for many years (Stewart et al., 1990, Fassnacht et al., 2003), 
and the persistence of hyperandrogenism after pharmacological suppression of ovarian and 
adrenal androgen output suggests that this phenomenon is very much physiologically relevant 
(Rosenfield et al., 2011).  Adipose tissue expresses a number of androgen-metabolising 
enzymes, and expression in women correlates with clinical markers of obesity such as BMI 
and waist circumference (Quinkler et al., 2004, Wake et al., 2007). As adipocytes possess the 
necessary cellular machinery for androgen activation and secretion (Blanchette et al., 2005, 
Blouin et al., 2009a), it seems very reasonable to hypothesise that obesity increases local and 
systemic androgen burden. AKR1C3, which converts the weak androgen precursor A into 
potent T, is highly expressed in adipose tissue, particularly in the SC fat depot. AKR1C3 
expression is higher in SC tissue from PCOS women compared to weight-matched controls 
(Wang et al., 2012). We found a strong correlation between expression and BMI in 38 
women. Interestingly, expression of the androgen-inactivating isoform, AKR1C2, also 
increased with obesity, suggesting the possibility of physiological equilibrium in adipose 
androgen metabolism in simple obesity. Insulin increased AKR1C3 expression and activity in 
both primary female SC adipocytes and SGBS cells in vitro, and although its effect on 
AKR1C2 was not explored, it is possible that hyperinsulinaemia, in the setting of systemic 
insulin resistance, is sufficient to tip the scales in favour of adipose androgen activation in 
PCOS.  
 In the clinical setting, the association of circulating androgens with insulin resistance 
has been explored in multiple studies, but none to our knowledge have attempted to delineate 
metabolic risk by simultaneous measurement of T and A using LC-MS/MS. In the study 
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presented in chapter 3, the utility of serum A as a marker of insulin resistance is demonstrated 
by its inverse relationship with the OGTT-derived ISI; furthermore, those PCOS women with 
co-elevation of both A and T above the normal reference range had the lowest ISI and highest 
HOMA-IR values, as well as an increased prevalence of dysglycaemia (O'Reilly et al., 
2014b). We believe that this strategy should be adapted into routine clinical practice in PCOS 
as it is a relatively straightforward screening tool to identify those at high risk of overt 
dysglycaemia and, by inference, future cardiovascular disease. These data notwithstanding, 
obesity remains the biggest risk factor for progression to frank hyperglycaemia in PCOS 
(Azziz et al., 2006), and obese PCOS women have an increased risk of progression to overt 
diabetes compared to control women with simple obesity (Jayasena and Franks, 2014). This 
suggests that obesity-related factors specific to PCOS may be responsible for β-cell 
decompensation and onset of hyperglycaemia. Adipose-specific androgen excess in obese 
PCOS women, fuelled by hyperinsulinaemia, may aggravate metabolic disturbances by 
impacting directly on local adipocyte function, and lead to acceleration of β-cell failure due to 
the insulinotropic effects of androgens, as highlighted in chapter 5. 
 Our in vivo and in vitro results support an emerging body of animal and human data 
on the role of androgens in adipose lipid accumulation. In SGBS cells, T and DHT 
upregulated ACC1 mRNA expression, and this correlated with increased rates of de novo 
lipogenesis as measured by uptake of 1-[14C]-acetate into the cellular component as lipid. 
Androgens also increased insulin-stimulated glucose uptake and suppressed β-oxidation, with 
a net effect of increased intracellular lipid accumulation. The use of primary fat culture for in 
vitro adipocyte studies, taken from distinct fat depots from both male and female patients, 
where available, is always preferable to the use of immortalized cell lines. However, SGBS 
cells have been characterised as a model for the study of human adipocyte biology (Wabitsch 
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et al., 2001), and we were able to validate their utility in the study of lipid metabolism by 
showing typical morphological changes and upregulation of lipogenic genes across 
differentiation. In our clinical study, PCOS women had relative suppression of lipolysis, 
measured indirectly by intra-adipose glycerol concentrations, compared to healthy controls 
after administration of the androgen precursor DHEA, and glycerol levels were inversely 
proportional to serum androgen generation at equivalent time points. This is compelling in 
vivo corroboration of our in vitro work showing enhanced adipose lipogenesis after androgen 
exposure. Androgens, acting via the AR, appear to induce lipogenesis by binding to the 
androgen response elements in the SREBP family of transcription factors (Zhou et al., 2012). 
SREBP-1 regulated genes in the fatty acid biosynthesis pathway, while SREBP-2 plays a role 
in cholesterol metabolism (Shimano et al., 1999). It is fascinating that androgen-mediated 
upregulation of SREBP-1a and SREBP-1c mRNA and protein expression drives excess lipid 
production and secretion in epidermal keratinocytes and sebaceous glands, contributing 
significantly to dermatological diseases such as acne vulgaris and seborrhoeic dermatitis 
(Rosignoli et al., 2003). The lipogenic actions of androgens also play a crucial role in growth 
and survival of prostate cancer cells (Huang et al., 2012). However, the contribution of pro-
lipogenic effects of androgens in adipose tissue to metabolic disease is an area which has until 
now been largely neglected. 
 Detection of significant concentrations of T and DHT in adipose microdialysis fluid 
emphasises the important of fat as an organ of androgen activation. It is also exciting to 
consider that measured T concentrations are likely to reflect free rather than ‘bound’ steroid 
levels. SHBG circulates as a homodimer, consisting of two monomers of 43.7kDa each 
(Grishkovskaya et al., 2000); the microdialysis membrane filtration cut-off for molecules is 
set at 20kDa or below. It is therefore highly likely that any T detectable in adipose fluid is 
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representative of unbound, physiologically active T. DHT was undetectable in serum, yet was 
quantifiable in adipose fluid, and correlated with systemic 5α-reductase activity. More 
sensitive LC-MS/MS assays for serum DHT measurement will be a crucial factor in our 
future studies on PCOS steroidomics, and its quantification in serum has already proved 
useful in predicting metabolic dysfunction (Munzker et al., 2015). In a subset of our PCOS 
patients, adipose DHT levels were as high as 20nmol/l, highlighting the significant 
steroidogenic and metabolic heterogeneity in this disorder. Small patient numbers rendered 
any further statistical correlation relatively meaningless, but it will be interesting in the future 
to examine potential associations with BMI, fat distribution and insulin resistance.  
  
  
 
Figure 7-1 The vicious circle of adipose androgen activation, adipocyte hypertrophy and 
insulin resistance in PCOS. 
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 In summary, we have described novel putative mechanisms by which androgens may 
regulate adipose tissue function, fat mass and lipid metabolism. A vicious of circle of adipose 
androgen activation, lipid accumulation and increased fat mass may drive systemic insulin 
resistance, with androgen generation in fat further exacerbated by hyperinsulinaemia (Figure 
7-1). Selective inhibition of androgen activation in fat may offer a novel therapeutic strategy 
to break this cycle and ameliorate the adverse effects of androgen exposure on metabolic 
phenotype in PCOS.   
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7.2 Future directions 
7.2.1 Depot-specific and gender-specific studies in primary human tissue culture 
 The work presented in this thesis has highlighted a role for insulin in the promotion of 
androgen generation in adipose tissue. This appears to be predominantly mediated through its 
stimulatory effects on AKR1C3 expression in human fat. Although our primary culture data 
suggest that this process occurs preferentially in SC adipose tissue, sample numbers were 
small, particularly when SC and OM cultures must be analysed separately. Our data on the 
effects of androgens on adipose lipid metabolism, whilst robust, are limited by the use of an 
immortalized cell line. Furthermore, any study on the influence of sex hormones on adipose 
tissue biology should consider the high likelihood of sexual dimorphism in any observed 
effects. In the future, therefore, in collaboration with the Tissue Biorepository at the 
University of Birmingham, we intend to examine the associations observed in this chapter in 
primary human adipose culture from SC and OM depots in both male and female (pre- and 
post-menopausal) patients. 
 
7.2.2 Selective inhibition of AKR1C3 activity in vivo 
 AKR1C3 has emerged as an exciting novel therapeutic target for androgen excess in 
PCOS. The association of adipose androgen activation with lipid accumulation and metabolic 
disturbance demonstrated in this thesis raises the possibility that selective modulation of 
AKR1C3 activity could improve both androgen burden and metabolic phenotype. To this end, 
we have designed a dedicated proof-of-concept clinical study, in which detailed metabolic 
phenotyping will be carried out in hyperandrogenic PCOS women before and after treatment 
with the NSAID indomethacin, which is known to have good selective activity against 
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AKR1C3.  Patients will undergo deep phenotyping with hyperinsulinaemic euglycaemic 
clamp for whole-body insulin sensitivity, as well as selective measurement of adipose vein 
free fatty acid and androgen levels after ultrasound-guided cannulation. 
 
7.2.3 Metabolomics and the transcriptome  
 The results presented in this PhD thesis have underscored the close association of 
hyperandrogenaemia with metabolic disease in women. However, most of the proposed 
mechanisms need to be examined at the level of the metabolome. With this in mind, we have 
recently submitted PCOS and control serum, urine and microdialysis fluid samples pre- and 
post-DHEA exposure for non-targeted metabolomics assessment by high-performance liquid-
chromatography/tandem mass spectrometry in the Birmingham MRC Phenome Centre. This 
will increase our understanding of enriched pathways and metabolite classes in response to an 
acute androgen load. To verify these data at the level of the adipose transcriptome, we will 
perform state of the art RNA-sequencing in the School of Biosciences on SC abdominal fat 
biopsies from PCOS and control women before and after DHEA exposure. 
 
 We believe that these proposed in-depth in vivo and ex vivo studies will increase our 
understanding of the role of androgens in PCOS-related metabolic dysfunction in the future. 
Deep phenotyping of PCOS women using in vivo metabolic testing, as well as identification 
of a unique metabolome and transcriptome in these patients, will help to unravel new 
mechanisms of disease and identify future therapeutic targets for amelioration of androgen 
burden and metabolic disturbance. 
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